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The Translocator Protein (18 kDa) (TSPO) resides mainly in microglia and is upregulated 
in response to neuronal injury and inflammation, rendering it an interesting target for 
imaging focal neuroinflammation in a range of diseases.  A library of TSPO ligands based 
on PK11195 with positions suitable for [11C]-, [18F]- and [123I]-labelling was prepared 
using three synthetic approaches.  Implementation of a 
physicochemical study enabled selection of compounds most likely 
to be brain penetrant, and biological evaluation identified those with 
high binding affinities for the TSPO.  From this, a lead candidate 
(compound 170) was identified.  Radiofluorination and in vitro 
autoradiography revealed the ability of this compound to image tumour tissue in a mouse 
model of glioblastoma.       
 
Poly(ADP-ribose) polymerase-1 (PARP-1) is an enzyme involved in the repair of DNA 
strand breaks, and widely regarded as a therapeutic 
target for cancer treatment.  Many inhibitors of PARP-
1 activity exist, e.g. olaparib.  A programme of 
research focussing on the preparation of a potential 
PET imaging agent for measurement of PARP-1 
activity, based on olaparib, was initiated.  An 
expeditious seven step synthetic route was used to 
prepare a small library of compounds.  Preliminary cell-free biological screening of these 
compounds indicated PARP-1 inhibitory potencies in the low nanomolar range 
demonstrating potential leads for development of a PET imaging agent, e.g. compound 
223. 
 
Extracts of Carduus crispus linn., traditionally used in Chinese folk medicine, yield a 
family of isoquinoline alkaloid natural products (Crispine A–E).  Upon commencement of 
this project no reported synthesis of Crispine C existed in the 
literature.  As such, a facile route utilising a key Pictet-Gams 
modification of the Bischler-Napieralski reaction for 
isoquinoline core formation was developed, enabling the first 
total synthesis of Crispine C to be achieved in seven steps and with an overall product 
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1.1 Molecular Imaging 
 
A recent definition of molecular imaging states that it is the real time characterisation and 
measurement of biological processes in vivo.1,2 Nuclear imaging, a technique that falls into 
the molecular imaging category, provides a visualisation of the in vivo distribution of an 
administered radiotracer via external detection of the high-energy photons emitted during 
radionuclide decay.  Adopting this method has enabled a continuously expanding range of 
molecular and cellular functions in both health and disease states to be studied 
non-invasively.  Two techniques that employ this fundamental basis are single photon 
emission computed tomography (SPECT) and positron emission tomography (PET).  
 
1.1.1 Single Photon Emission Computed Tomography (SPECT) 
 
SPECT is a nuclear imaging technique that utilises radioisotopes, which decay via the 
emission of "-radiation.  A few of the most commonly employed radionuclides for SPECT 
imaging are listed in Table 1.3 These radioisotopes display half-lives ranging from hours to 
days, and generally emit "-rays of lower energy (~70 keV to 360 keV) compared to PET 
radioisotopes.2  
 




123I Electron capture 0.16 13.2 
99mTc Isomeric transition 0.14 6 
111In Electron capture 0.17/0.25 67.9 
67Ga Electron capture 0.09/0.19/0.30 78.3 
 
Table 1. Radionuclides used for SPECT imaging  
 
Utilising a radiotracer with a longer half-life makes SPECT imaging a more accessible 
modality, from studying longer biological processes to allowing for a more practical 
radiosynthesis.  However, the compounding factor of this technique becomes apparent 
when considering the practical process of SPECT image acquisition.  A SPECT study is 
! "$!
initiated by a radiotracer administered to the patient, which travels to the site of interest 
and emits high-energy photons during the decay process.  Photon emission is directly 
detected using a gamma camera which rotates in a 360° revolution around the patient.4 
However, in order to obtain spatial resolution mechanical collimation is required.  A lead 
collimator is positioned in front of the detector allowing only incident photons of defined 
perpendicular angle to the axis of rotation, and not those of an oblique angle, to pass 
through.2 As a result, only 0.01% of signals are received by the detector and the necessary 
compromise between resolution and efficiency is a disadvantage of SPECT imaging.3,5 
Finally, a sodium iodide crystal within the detector then converts the photons to electrical 
signals which are used to create a 3D data set and subsequent image.4 
 
1.1.2 Positron Emission Tomography (PET) 
 
In contrast to SPECT, PET utilises radiotracers that are labeled with #+-emitters, and a few 
of the most commonly employed radioisotopes are listed in Table 2.3 These radionuclides 
have a considerably shorter half-life compared to those used for SPECT, and belong to 
elements more commonly found in nature.  Generally, production of these radioisotopes 
requires an on-site cyclotron, the necessity of which renders PET a more expensive 
medical imaging technique.  Furthermore, the significantly shorter half-life limits study 
length and applies greater pressure to the required radiosynthesis.   
 




11C #+ 0.97 20.3 
13N #+ 1.20 10 
15O #+ 1.74 2 
18F #+ 0.64 110 
 
Table 2. Radionuclides used for PET imaging  
 
During the decay process a nuclear proton is converted to a neutron, with subsequent 
emission of a positron and neutrino.  This positron travels a short distance within the test 
object and undergoes annihilation with a surrounding electron to form two photons with 
energies of 511 keV that are simultaneously emitted at 180° to each other (Figure 1).1,6 
Spatial distribution is determined by acquisition of a large number of decay events and 
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subsequent image reconstruction.3 This is referred to as electronic collimation and by 
removing the need for a lead collimator, it enables the collection of images of a much 




Figure 1. Positron decay and annihilation event6 
(Reprinted with permission from Angew. Chem. Int. Ed., 2008, 47, 8998. Copyright 2008 
John Wiley and Sons) 
 
1.1.3 Clinical Application of PET and SPECT 
 
An extensive range of diseases has been investigated using PET and SPECT imaging 
modalities.7,8 One such example of the clinical utility of PET imaging is use of the 
radioligand [18F]BAY-94-9172, which binds with high affinity to #-amyloid plaques.  
These plaques are known to accumulate in the brain of Alzheimer’s sufferers and are used 
as an indicator of the neurodegenerative disease.  The radiosynthesis of [18F]BAY-94-9172 
is illustrated in Scheme 1.9 Starting from mesylate precursor 1, a nucleophilic 
radiofluorination reaction in the presence of [18F]potassium fluoride and Kryptofix!, 
followed by N-Boc deprotection provided [18F]BAY-94-9172 (2) in a decay corrected 














i. [18F]F   , K222, K2CO3, 
   DMSO, 120 °C
ii. HCl (aq), 120 °C
Radiochemical Yield = 30% (DC)
Radiochemical Purity = >99%




Scheme 1. Radiosynthesis of [18F]BAY-94-9172 (2) 
   
Typical PET images obtained through administration of this radioligand are shown in 
Figure 2.1 The top row represents brain images obtained from a patient suffering from 
Alzheimer’s disease, and the bottom row are that of a healthy 75 years old control patient.  
It is apparent that an accumulation of the radiotracer has occurred within the brain of the 
Alzheimer’s patient, and much lower levels of radioactivity are detected in the brain of the 




Figure 2. PET images of [18F]BAY 94-9172 binding to #-amyloid plaques in an 
Alzheimer’s disease patient (top row) and healthy control (bottom row)1   
(Reprinted with permission from Chem. Rev., 2008, 108, 1501. Copyright 2008 American 
Chemical Society) 
 
Another clinical application involves the use of SPECT imaging for the diagnosis of 
Parkinson’s disease, a neurodegenerative condition that affects around 1 in 500 people in 
the UK.10 Parkinson’s disease is routinely diagnosed using [123I]FP-CIT (also commonly 
known as DATScan$), a SPECT radiotracer with high affinity for presynaptic dopamine 
transporters.  A typical radiosynthesis of this imaging agent is shown in Scheme 2.11 
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Starting from trimethylstannane precursor 3, an oxidative iododestannylation reaction in 
the presence of [123I]sodium iodide affords [123I]FP-CIT (4) in good radiochemical yield of 









Radiochemical Yield = 64%
Radiochemical Purity = 98%
3 [123I]FP-CIT (4)  
 
Scheme 2. Radiosynthesis of [123I]FP-CIT (4) 
 
Once radioiodination has been achieved, the radioligand is administered to the patient and 
scanning ensues.  A striking feature of Parkinson’s disease is a reduction in the number of 
dopamine transporters within the brain, and this change can be observed in images 
acquired from a SPECT scan.  Representative SPECT images obtained from a [123I]FP-CIT 
scan of a healthy patient (a) versus a Parkinson’s disease patient (b) is shown in Figure 3.3 
A comparison of the images highlights that a reduction in radioligand binding, correlating 
to a reduction in dopamine transporters is evident in the Parkinson’s disease patient.  This 





Figure 3. SPECT images of [123I]FP-CIT binding within an (a) normal and (b) Parkinson’s 
disease patient3 
(Reproduced from Ref. 3 with permission from The Royal Society of Chemistry) 
 
1.2 Translocator Protein (18 kDa) 
 
The Translocator protein (TSPO), formerly known as the peripheral benzodiazepine 
receptor (PBR), was discovered in 1977 by Braestrup and Squires while investigating 
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alternative binding sites for the benzodiazepine, diazepam.12 On discovering that in 
addition to rat brain membrane, [3H]diazepam bound to mitochondrial fractions from 
peripheral organs, the peripheral benzodiazepine receptor (PBR) was conceived.  This 
descriptor was coined to differentiate it from the central benzodiazepine receptor (CBR) 
site on the GABAA receptor complex within the central nervous system (CNS).
13 
 
Since its discovery, a great deal of research has gone into characterising the TSPO.  
Intensive genetic studies have shown that the gene encoding the TSPO, Bzrp,14 is a highly 
conserved primary coding sequence.  The receptor has been cloned from various species, 
such as rodents and humans,15,16 and the cDNA encoding this protein has shown to have up 
to 80% homology across different species.17 Functional inactivation experiments have 
shown that an early embryonic lethal phenotype is the result of this type of study and 
explains this high level of sequence homology conservation.18 The TSPO is evidently 
crucial for the development and functioning of an organism.   
 
1.2.1 TSPO Distribution, Structure and Function  
 
Anatomically the TSPO is widely expressed throughout the body and located within the 
peripheral organs.19 It is particularly prevalent at higher levels in tissues involved in the 
synthesis and distribution of steroids.20 In addition to the peripheral system, the TSPO can 
also be found in the CNS albeit at a much lower level of expression.  Within the CNS, 
however, expression is not widespread and generally restricted to ependymal and glial 
cells.21 
 
The TSPO is a tryptophan rich protein consisting of 169 amino acids.17,22 It exists as a 
multimeric 140–200 kDa complex that exists primarily on the outer mitochondrial 
membrane (Figure 4).14 The 18 kDa subunit has five transmembrane domains of %-helical 
secondary structure, which are connected by highly hydrophobic regions.22,23 It has been 
proposed that several TSPO molecules arrange themselves in such a way as to form what 
has been described as a pore.24 Protein density increases at contact sites between the inner 
and outer mitochondrial membrane and has therefore been classed as the mitochondrial 
permeability transition pore (MPTP).22 This, coupled with the name of the protein, 
indicates that its functional role is in the transport of chemicals into the mitochondria.  In 
addition to the 18 kDa subunit several other proteins are also associated with the TSPO at 
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these contact sites, including a 32 kDa voltage dependent anion channel (VDAC) and a 30 




Figure 4.  Structure of TSPO22 
(Reprinted with permission from J. Med. Chem., 2009, 52, 581.  Copyright 2009 American 
Chemical Society) 
 
Many functions have been attributed to the TSPO, with steroid biosynthesis being the most 
extensively investigated.14,18 In addition to steroidogenesis, the TSPO has also been 
associated with a wide range of cellular processes, e.g. oxygen sensing,  protein transport, 
porphyrin transport and heme biosynthesis, ion transport, immunomodulation, cellular 
respiration and apoptosis.17,25,26 However, as of yet, conclusive evidence for all proposed 
roles has not been presented.  The role of the TSPO within the CNS is much less clear than 
that of the peripheral nervous system.  One such proposal is that it contributes to three 
main functions: neurosteroid synthesis, regulation of the mitochondria and modulation of 
neuroinflammation in microglial cells.17,27,28  
 
1.2.2 TSPO in Neuroinflammation  
 
Within the CNS, the TSPO resides in glial cells including astrocytes and microglia.28 
Microglia are mesoderm-derived brain macrophages that represent the first-line of defense 
of the immune system, which predominantly exist in an inactive form but are activated in 
response to neuronal injury or inflammation.28,29 When in this activated form, they undergo 
a morphological change from a macrophage to a phagocyte eliciting an immunological 
response.30 Transformation into a phagocytic form is regarded as a protective role in the 
immunological response, however, it has also been proposed that activated microglia 
secrete neurotoxins such as nitric oxide and free radicals initiating a vicious cycle of 
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neuroinflammation.31,32 An illustration of microglia activation and its associated processes 




Figure 5.  Process of neuroinflammation and the dual role of activated microglia in 
ischemic stroke and multiple sclerosis (A), and neurodegenerative diseases (B).33 #-
Amyloid plaques synonymous with Alzheimer’s disease activate microglia triggering 
unselective neuronal death via secretion of inflammatory mediators.  Conversely, a 
protective role is also suggested whereby phagocytosis eliminates them.        
(Reprinted from A. H. Jacobs and B. Tavitian, J. Cereb. Blood Flow Metab., 2012, 32, 
1393 under a Creative Commons license) 
 
As previously mentioned, the TSPO resides in microglial cells and protein density is 
negligible in a healthy state.  However, when detrimental changes within the CNS occur, 
there is a marked upregulation in protein expression by means of a mechanism still not 
fully understood.28 The implication that the TSPO can be exploited as a sensitive 
biomarker for microglial activation has rendered it a very attractive diagnostic and 
therapeutic target for neuronal injury, neuroinflammation and neurodegenerative disorders 
such as Alzheimer’s disease,34 multiple sclerosis,35 Parkinson’s disease36 and 
Creutsfeldt-Jakob disease.37  
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Traditionally, activated microglia are detected postmortem and achieved using 
histopathological techniques to excise and study diseased tissue of the central nervous 
system.28 With recent advances in nuclear medicine and imaging modalities however, in 
vivo visualisation of activated microglia is now possible.  The ability to non-invasively 
detect microglial activation provides a very attractive tool for the diagnosis and 
progression monitoring of neuroinflammation and diseases of the CNS.  
 
1.2.3 TSPO Ligands and Radiotracers 
 
Several endogenous ligands have been shown to occupy binding sites on the TSPO, e.g. 
cholesterol, porphyrin, heme and endozepines.23 In addition, a substantial range of 
synthetic TSPO ligands with potential for PET and SPECT imaging applications have been 
developed.  These compounds can be divided into seven distinct structural classes: 
benzodiazepines, quinoline carboxamides, indoleacetamides and indolylglyoxylamides, 
vinca minor alkaloids, oxodihydropurines, imidazopyridines and bioisosteric structures 




In 1950, one of the most widely recognised classes of medicinal agents was discovered, the 
benzodiazepines (Figure 6).  1,4-Benzodiazepines are prescribed for their antianxiety, 
anticonvulsant and anaesthetic properties, and it was the discovery that [3H]diazepam 
bound to peripheral tissue that led to the generation of a series of analogues intended as 
TSPO ligands.  However, it became evident that the slightest of variations in structure 
affected selectivity, e.g. diazepam was equally potent for both the CBR and TSPO, while 
Ro5-4864 (an atypical benzodiazepine) and clonazepam was selective for the TSPO and 
CBR, respectively.13 Despite this, the ability of Ro5-4864 to preferentially bind to the 
TSPO with high affinity encouraged research groups to investigate its potential as an 






















Figure 6.  Benzodiazepines 
 
Wieland and co-workers reported the radioiodination of a Ro5-4864 analogue in 1988 
(Scheme 3).39 Treatment of 4-iodoaniline (5) with boron trichloride and subsequent 
condensation with 4-chlorobenzonitrile afforded intermediate ketimine 6, which was 
hydrolysed under acidic conditions affording 2-aminobenzophenone 7.  A cyclisation 
reaction with glycine ethyl ester hydrochloride generated the key 1,4-benzodiazepine core 
8, and a standard N-alkylation reaction using methyl iodide provided radiolabelling 
precursor 9.  Utilising an ammonium sulfate catalysed solid-phase halogen exchange 
reaction in the presence of [125I]sodium iodide, the synthesis of [125I]Ro5-4864 (10) was 









































95%Radiochemical Yield = 18"31%
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Scheme 3. Radiosynthesis of [125I]Ro5-4864 (10) 
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The [125I]Ro5-4864 analogue was then investigated for its potential to act as a SPECT 
imaging agent, and results from an ex vivo autoradiography study indicated an 
accumulation of the radiotracer within tumour cells of C6 glioma rats.39 [11C]-Labelling of 
the nor derivative of Ro5-4864 has also been achieved.40,41 A study by Young and co-
workers utilising [11C]Ro5-4864 concluded that, in contrast to the results of van Dort et al., 
no accumulation of the radioligand in tumorous tissue of a human glioma model was 
observed.41 This discrepancy in binding was subsequently reported by Krueger and co-
workers in the same year, with a high binding affinity for the TSPO in rat (KD = 1–9 nM) 
measured, but considerably lower affinity in humans (KD = 54 nM).
15 As this compound 
requires the presence of additional mitochondrial protein components for binding,23 and 
displays both temperature and species dependency,42 it was naturally rendered an 
unsuitable imaging agent for the TSPO. 
 
1.2.3.2 Quinoline Carboxamides 
 
In 1984, a new class of TSPO ligand was discovered (Figure 7).  The isoquinoline-3-
carboxamide PK11195, a pharmacological antagonist named by French company 
Pharmuka, was the first non-benzodiazepine to be synthesised with high binding affinity  
(Ki = 9.3 nM) and selectivity for the TSPO.
43 Advantageously, PK11195 did not require the 
interaction of additional mitrochondrial proteins for binding, nor did it display species 
variation making it a more suitable ligand compared to the benzodiazepines.42 Naturally, 
this led to the generation of large libraries of compounds bearing the key isoquinoline-3-
carboxamide core, e.g. PK14105, and later potent quinoline-2-carboxamide TSPO ligands 




















Figure 7. Quinoline carboxamide TSPO ligands 
 
Given that PK11195 has a nanomolar binding affinity with the TSPO, several facile 
synthetic routes for the preparation of this ligand and its synthetic intermediates have been 
! #$!
published in the literature.45,46,47 In addition, PK11195 has also been labeled with different 
radioisotopes, e.g. tritium for in vitro assays, carbon-11 and fluorine-18 for in vivo PET 
studies, and iodine-123/125 for SPECT studies. 
 
Camsonne et al. reported the first radiosynthesis of PK11195 by methylation of the the N-
desmethyl precursor using [11C]methyl iodide.48 In 1986, Charbonneau et al. demonstrated 
that [11C]PK11195 could be used to image TSPO binding sites within the heart and in 
doing so paved the way for it to be employed as a PET imaging agent.49  
 
It is known that enantiomers of a molecule often behave differently in biological systems. 
Radiolabelling of PK11195 and its use in biological studies are generally performed using 
the racemate, and in 1994 Shah et al. embarked on an investigation to determine the effect 
each individual enantiomer had on binding with the TSPO.50 The authors prepared (S)-
PK11195 and (R)-PK11195 according to Scheme 4.50 Starting from the carboxylic acid of 
1-(2-chlorophenyl)isoquinoline-3-carboxylic acid (11), reaction with ethyl chloroformate 
followed by addition of (S)- or (R)-sec-butylamine afforded (S)- and (R)-12, respectively.  
N-Alkylation using [11C]methyl iodide gave (S)- and (R)-PK11195 (13) in decay corrected 
radiochemical yields of 80%, within a reaction time of approximately 45 minutes.  Having 
synthesised both enantiomers, the authors examined the binding of these compounds 
within ischaemic-lesioned rat brains.  Preliminary results indicated that in healthy animals 
there was no apparent increase in uptake of one enantiomer over the other, however, in the 
disease model, a two-fold increase in uptake of the (R)-enantiomer was observed.  This 
was particularly so in regions of the brain known to express greater levels of the TSPO, 
e.g. olfactory bulbs.  The authors suggest that the slightly improved binding affinity of (R)-
PK11195 may be due to the sec-butylamine group of the stereogenic centre sitting in a 
more favourable conformation aiding interaction with the protein’s lipophilic binding 

























i. EtOCOCl, Et3N, CHCl3
ii. (S)-sec-butylamine
c. 50%





i. EtOCOCl, Et3N, CHCl3
ii. (R)-sec-butylamine
c. 50%
Radiochemical Yield = c. 80% (DC)
Radiochemical Purity = >99%







Scheme 4. Radiosynthesis of [11C]PK11195 (13) enantiomers 
 
In 2002, Rahman et al. reported a [11C]-radiolabelled synthesis of racemic PK11195 and 
related analogues using [11C]carbon monoxide and 1-(2-chlorophenyl)isoquinolin-3-yl 
triflate.51 The authors proposed that radiolabelling the molecule at the carbonyl position 
using [11C]carbon monoxide would yield a few key advantages over the conventional 
method of radioisotope incorporation using [11C]methyl iodide.  These advantages 
included, among others, a high specific activity due to reduction in isotopic dilution of the 
precursor compared to that for the N-alkylation method and a reduction in potential 
radiotracer metabolite interference. 
 
The radiosynthesis of [11C]PK11195 is illustrated in Scheme 5.51 Starting from 
2-chlorobenzophenone (14), reductive amination with ammonia gas followed by a sodium 
cyanoborohydride reduction of the resulting imine gave amine 15.  The amine was reacted 
with ethyl diethoxyacetate to give amide 16, which was cyclised in the presence of 
concentrated sulfuric acid to form the isoquinoline core.  The hydroxyl group of the 
isoquinoline core was then converted to the triflate, affording radiolabelling precursor 17.  
! #&!
A palladium-mediated carbonylation reaction in the presence of [11C]carbon monoxide and 
N-methyl-sec-butylamine afforded [11C]PK11195 (13) in a decay corrected radiochemical 
yield of 55 ±1%, and an overall synthesis time of 35 minutes.  
 
i. TiCl4, NH3 (gas)






















Radiochemical Yield  = 55 ± 1% (DC)
Specific Activity = 393 GBq/µmol
1. conc. H2SO4, 60%






Scheme 5. Radiosynthesis of [11C]PK11195 (13)    
 
Recently, Pimlott et al. reported the synthesis of an [123I]-labelled PK11195 analogue 
(Scheme 6).52 Synthesis of the bromide precursor utilised for the radiolabelling procedure 
was described by Stevenson et al.45 A palladium-catalysed coupling reaction of methyl 2-
iodobenzoate (18) and amidoacrylate (19), followed by cyclisation and loss of the acetyl 
group afforded isoquinoline 20.  Bromination of the hydroxyl group gave 21, and 
subsequent Suzuki-Miyaura cross-coupling reaction with 2-bromophenylboronic acid 
yielded biaryl 22.  Hydrolysis of the methyl ester group to give carboxylic acid 23 was 
achieved under basic conditions.  This intermediate acid was then converted to the acyl 
chloride in situ and coupled with N-sec-butylamine affording amide 24.  N-alkylation using 
methyl iodide formed tertiary amide 25, which was used to prepare the radiolabelling 
precursor.  Trimethylstannane precursor 26 was prepared by a palladium(0)-catalysed 
procedure utilising hexamethylditin.  Radioiodination was achieved by means of an 
electrophilic iododestannylation reaction in the presence of [123I]sodium iodide and 
chloramine-T as the oxidant.  Application of these reaction conditions afforded 
[123I]PK11195 analogue (27) in an 83.9 ± 4.1% radiochemical yield, with high specific 
activity (25.5 ± 7.4 Ci/µmol) and  radiochemical purity (>99%).  The high isolated 
! #'!
radiochemical yields and high specific activity in particular make this an attractive route 
for the synthesis of a radioiodinated PK11195 analogue for SPECT imaging of the TSPO.  
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[123I]NaI, NaOH (aq), HCl (aq),
EtOH, chloramine-T, r.t., 5 min
Radiochemical Yield = 83.9 ±4.1%
Radiochemical Purity = >99%




Scheme 6. Radiosynthesis of an [123I]PK11195 analogue 27 
 
An [18F]-analogue of PK11195 with potential for PET imaging was prepared and tested by 
Goodman and co-workers (Scheme 7).53 Coupling of norephedrine hydrochloride (28) with 
benzoyl chloride 29 provided amide 30.  Cyclisation using a modified Pictet-Gams 
reaction afforded substituted isoquinoline 31, which was converted to 32 under radical-
promoted bromination conditions.  The subsequent bromide was then used to prepare 
aldehyde 33 via an oxidative hydrolysis reaction using sodium periodate, which was 
further oxidised in the presence of silver nitrate to afford carboxylic acid 34.  Coupling of 
! #(!
the acid to methylamine gave secondary amide 35, which was reacted with 3-
triphenylmethoxypropylbromide to give 36.  Removal of the trityl group to give alcohol 
37, followed by treatment with p-toluenesulfonyl chloride afforded tosylate radiolabelling 
precursor 38.  An aliphatic radiofluorination reaction using [18F]potassium fluoride, 
Kryptofix! and potassium carbonate gave [18F]PK11195 analogue 39 in an 8% 
radiochemical yield (decay corrected) and 99% radiochemical purity.  The total reaction 
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DMSO, 120 °C, 10 min
Radiochemical Yield = 8% (DC)
Radiochemical Purity = 99%
ii. MeNH2, THF, 
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Scheme 7. Radiosynthesis of an [18F]PK11195 analogue 39 
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[11C]PK11195 has been extensively utilised as an imaging agent for the TSPO and a large 
volume of data focusing on animal models of health and disease is available in the 
literature.  The results of a recent microPET study of [11C]PK11195 binding in rats with 
temporal focal cerebral ischemia demonstrated an increase in binding potential of the 
radiotracer within the infarct at day 14, providing further validation of the radiotracer as an 
in vivo marker of activated microglia.54 In addition, a considerable number of studies have 
been performed in humans examining its potential as an imaging agent for multiple 
sclerosis, Alzheimer’s disease, ischemic stroke, Parkinson’s disease, schizophrenia, and 
many more diseases.42        
 
Despite the vast numbers of TSPO ligands and their radiolabelled versions that continue to 
be presented to literature, PK11195 is still widely regarded as the ‘gold-standard’ imaging 
agent and is routinely used in both research and clinical settings.  Regardless of its status 
however, it does exhibit several undesirable properties making it a less than ideal 
radiotracer.  The high lipophilicity of the compound results in substantial non-specific 
binding to additional fats and proteins.  For example, it has been shown to bind reversibly 
and with low µM affinity to acute phase1 alpha-1 acid glycoprotein (AGP), a plasma 
protein found in concentrations of up to 1 mg/mL.55 This reduces the concentration of free 
radiotracer available for blood brain barrier (BBB) penetration ultimately leading to poor 
signal to noise ratio. 
 
1.2.3.3 Indoleacetamides and Indolylglyoxylamides 
 
In the early nineties, Kozikowski and co-workers developed a new class of TSPO ligands 
that are now commonly referred to as the indoleacetamides.56 As part of their studies they 
investigated the effects of varying alkyl chain length, inclusion of a halogen substituent on 
the phenyl rings, substitution of the indole and replacement of the amide functionality on 
binding to the TSPO.  This intensive study provided FGIN-1-27 (Figure 8) with high 
binding affinity for the TSPO (Ki = 4.4 nM).  Furthermore, it showed no affinity for 
GABAA receptors and demonstrated an ability to stimulate pregnenolone synthesis.
13,57,58 
Tricyclic indoleacetamides have also demonstrated an affinity for the protein, e.g. 
SSR180575 (Figure 8) has a KD of 3.0 nM.  Similar to the FGIN-1 series this compound 
appears to have involvement in steroidogenesis.22,59 However, despite displaying potent in 
vitro binding affinities, the high lipophilicities of these compounds limits their potential for 




















Figure 8. Indoleacetamide TSPO ligands 
 
Analogues exhibiting a more appropriate lipophilicity were prepared by Tamagnan and co-
workers in 2006.60 Based on the indolylglyoxylamide core, the synthetic route depicted in 
Scheme 8 was used to generate a small library of TSPO ligands.  Compound 44 was 
prepared starting from phenylhydrazine (40) and 3-bromoacetophenone (41).  A Fisher 
indole synthesis afforded 2-(3’-bromophenyl)indole (42) which was converted to the 
corresponding iodo-compound 43 using a direct halogen exchange reaction.  Acylation in 
the presence of diethylamine then gave compound 44.  A radioligand binding assay with 
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Scheme 8. Synthesis of indolylglyoxylamide TSPO ligand 44 
 
The LogD value of 44 was measured at 2.18 and is within the acceptable range for 
successful blood brain barrier penetration, indicating a potential increase in uptake of the 
compound.  In addition, the presence of the meta-iodo substituent provides a labeling 




1.2.3.4 Vinca Minor Alkaloids 
 
Vinpocetine (eburanamenine-14-carboxic acid ethyl ester) is a vinca alkaloid presenting 
neuroprotective properties that has been used for the treatment of acute and chronic stroke 
patients.42,61 It is structurally related to the Vinca minor alkaloid, vincamine and has been 
radiolabelled by Farde and co-workers (Scheme 9).62 The carboxylic acid group of the 
labeling precursor, apovincaminic acid (45) was subjected to an esterification reaction 
using [11C]ethyl iodide to give [11C]vincamine (46) in a decay corrected radiochemical 














DMF, 100 °C, 10 min
Radiochemical Yield = ~20% (DC)
Specific Activity = 3.7 GBq/µmol (EOS)
apovincaminic acid (45) [11C]vincamine (46)  
 
Scheme 9. Radiosynthesis of [11C]vincamine (46) 
 
As a semi-synthetic ligand it has a particularly low binding affinity for the TSPO with an 
in vitro IC50 value of 0.2 µM.
61 However, it has been shown to block [3H]PK11195 
binding, demonstrating its potential as a TSPO ligand.  A drawback of utilising 
[11C]vinpocetine as an imaging agent for microglial activation is that in addition to 
occupying TSPO binding sites, it displays a similar binding affinity to other proteins, e.g. 
%2#-adrenergic receptors.
42 Despite the disadvantages associated with this radiotracer it has 
shown some success in a small clinical PET study of Multiple Sclerosis sufferers.63 
Preliminary findings indicated that uptake was greater for (46) compared to [11C]PK11195 
in all brain regions of interest.  
 
1.2.3.5 Oxodihydropurines  
  
TSPO ligands have also been modeled on purine, one of two nitrogenous bases that 
constitute the building blocks of nucleic acids.  AC-5216 is one such example and offers 
the therapeutic advantage of TSPO-mediated antianxiety and antidepressant-like effects.61  
 
The desmethyl precursor of [11C]AC-5216 was synthesised and labeled according to the 
procedure illustrated in Scheme 10.64 An amide coupling reaction between compound 47 
! $"!
and N-ethyl benzylamine in the presence of BOP gave amide 48.  Base hydrolysis of the 
ethyl ester functionality then afforded carboxylic acid 49, which was subjected to a Curtius 
rearrangement in the presence of diphenyl phosphorylazide to prepare the key dihydro-9H-
purineacetamide core of 50.  Finally, alkylation of the desmethyl precursor using 
[11C]methyl iodide produced [11C]AC-5216 (51) in radiochemical yields of 60 ± 26% 
(within 15–20 minutes from end of bombardment), and high radiochemical purity (!98%).  





































DMF, 30 °C, 3 min
Radiochemical Yield = 60±26% (mean ± SD, n = 25)
Radiochemical Purity = "98%














Scheme 10. Radiosynthesis of [11C]AC-5216 (51) 
 
This radiotracer has been extensively utilised, and successfully validated for use in PET 
imaging studies of both healthy and diseased animal models.  In 2004, Oka and co-workers 
demonstrated that [11C]AC-5216 bound with high affinity to rat C6 and human Hs683 
glioma derived mitochondrial fractions (IC50 3.04 nM and 2.73 nM, respectively).
64 In 
addition, an investigation by Yanamoto examining uptake of the radiotracer by kainic acid-
lesioned rats concluded that increased radioligand accumulation occurred, and that binding 





1.2.3.6 Imidazopyridines and Bioisosteric Structures 
 
The imidazopyridines and bioisosteric structures (imidazopyridazines and 
pyrazolopyrimidines) constitutes another class of TSPO ligands, some examples of which, 
followed by a selected radiosynthesis are illustrated below. 
 
Two examples of compounds representing the imidazopyridine are shown in Figure 9.  
Alpidem, the first ligand of this structural class of TSPO binders, binds to both the TSPO 
and CBR with high affinity (Ki = 0.5–0.7 nM and 1–28 nM, respectively), and in addition 
to stimulating steroid biosynthesis has anxiolytic and anticonvlusant properties.13,66 The 
fact that Alpidem presents a binding profile for two different sites led to the synthesis and 
testing of large compound libraries in search of a more appropriate ligand.  CLINME is 

















Figure 9. Imidazopyridine TSPO ligands 
 
In 2008, Katsifis and co-workers reported the synthesis of a tosylate precursor and 
radiofluorination reaction for the preparation of [18F]PBR111, a structural analogue of 
CLINME with high affinity for the TSPO (Scheme 11).68 The imidazo[1,2-a]pyridine 
scaffold of 52 was prepared by an initial condensation reaction between 2-amino-5-
chloropyridine and 2’-bromo-4-methoxyacetophenone.  Treatment of this starting material 
with dimethylamine and formaldehyde resulted in formation of compound 53 via a 
Mannich condensation.  Salt 54 was prepared by quaternisation of the tertiary amine using 
methyl iodide, which was converted to amide 55 via the nitrile intermediate.  
Demethylation of the methoxy group and amide hydrolysis in the presence of 48% 
hydrobromic acid afforded carboxylic acid 56, which was subsequently coupled to 
diethylamine under standard amide coupling conditions to give compound 57.  Phenol 57 
was then alkylated with 3-bromopropylacetate in the presence of the phase transfer catalyst 
tetrabutylammonium iodide to give phenol ether 58, which was treated with caesium 
! $$!
carbonate providing alcohol 59.  Finally, tosylation of the alchohol afforded 
radiofluorination precursor 60.  Incorporation of the radiolabel was then achieved under 
standard aliphatic radiofluorination conditions to afford [18F]PBR111 (61) in a decay 
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MeCN. 100 °C, 5 min
Radiochemical Yield = 56"75% (DC)
Radiochemical Purity = >95%





Scheme 11. Radiosynthesis of [18F]PBR111 (61) 
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[18F]PBR111 was then administered to rats and its biodistribution measured.  The authors 
reported an increased uptake within the olfactory bulbs of the brain, which was 
successfully blocked using PK11195 and Ro5-4864 indicating specific binding with the 
protein.  These results suggest that this radioligand has potential for imaging 
neuroinflammation.  
 
The 2-arylpyrazolo[1,5-a]pyrimidin-3-ylacetamides are a class of compounds displaying 
high affinity and selectivity for the TSPO (Figure 10).  Collectively they are bioisosteres of 
the imidazopyridines, but unlike Alpidem they exhibit much greater selectivity for the 
TSPO over the CBR.  Initial work on this class of TSPO ligand was performed by Selleri 
et al., whereby the authors investigated what effect varying the substituent at the 5- and 7-
position and the para-position of the phenyl ring of 62 had on selectivity and binding 
affinity with the TSPO.69 Focusing on the preparation of compounds where R represents a 
particular combination of H, Me, OMe, F and Cl substituents, DPA-713 was identified as a 
potent TSPO ligand.  This compound has a high binding affinity (Ki = 4.7 nM) and much 
greater selectivity for the TSPO over CBR.  A further study by the authors aimed at 
probing the size and linearity of the amide side chain generated a library of compounds 
with even greater potency for the protein.70 For example, a binding affinity of 0.8 nM was 
achieved when the p-OMe substituent and diethyl amide of DPA-713 was replaced for H 





















Figure 10. Pyrazolopyrimidine TSPO ligand DPA-713  
 
Kassiou and co-workers have achieved several radiosyntheses of the pyrazolopyrimidine 
class of compounds, focusing on the preparation of [11C]-labeled analogues through O-
methylation using [11C]methyl iodide and [11C]methyl triflate independently.71,72 In 
addition, a few analogues within this compound class contain a fluorine atom allowing for 
the genereation of [18F]-labeled PET agents.  One particular example is DPA-714, the 
radiolabelling precursor for which was synthesised as follows (Scheme 12).71 
! $&!
Starting from commercially available methyl-4-methoxy benzoate (63), reaction with 
acetonitrile gave aroylacetonitrile 64 which was subsequently reacted with N,N-
diethylchloroacetamide in the presence of sodium iodide to give 1,4-dione 65.  Pyrazole 66 
was then prepared by reaction of the dione with hydrazine hydrate under reflux conditions.  
A condensation reaction with the electrophilic reagent 2,4-pentadione led to formation of 
the pyrimidine ring of 67.  It is of interest to note that intermediate 67 is in fact the TSPO 
ligand DPA-713.  Finally, the preparation of a DPA-714 radiolabelling precursor was 
achieved by demethylation of 68 using 45% hydrobromic acid and tributyl hexadecyl 
phosphonium bromide (TBHDPB).   





















































Scheme 12. Synthesis of DPA-714 radiolabelling precursor 
 
Using phenolic pyrazolo[1,5-a]pyrimidine compound 68 the synthesis of [18F]DPA-714 
could now be achieved (Scheme 13).73 A Mitsunobu coupling reaction between 68 and 
toluene-4-sulfonic acid 2-hydroxy-ethyl ester in the presence of DIAD and 
! $'!
triphenylphosphine afforded tosylate precursor 69.  An aliphatic nucleophilic fluorination 
reaction using [18F]potassium fluoride and Kryptofix! gave [18F]DPA-714 (70) in an end 
of synthesis radiochemical yield of 16%.  The ability of this radioligand to image the 
TSPO was then examined through in vivo studies.  A dynamic PET scan of baboon brain 
after administration of [18F]DPA-714 (100 MBq, 270 GBq/µmol) showed uptake during 
the baseline study and specificity for the TSPO was demonstrated with a blockade study 
using unlabelled PK11195.      


























MeCN, 95 °C, 5 min
Radiochemical Yield = 16% (EOS)  
 
Scheme 13. Radiosynthesis of [18F]DPA-714 (70) 
 
In addition to in vivo animal studies, [18F]DPA-714 has been applied to the clinic.  Two 
separate studies have shown that this radioligand can be used to image gliomas and,74 that 




In 2004, Nakazato and co-workers developed a new potent class of TSPO ligands.76 Based 
on the ring-opening of the diazepine core of Ro 5-4864,13 the authors synthesised a large 
library of phenoxyarylacetamides and measured the binding affinity of this class of 
compounds with the TSPO.  From their extensive studies, two compounds in particular 
were shown to have potent binding with the TSPO, DAA1106 (IC50 = 0.28 nM) and 
! $(!
DAA1097 (IC50 = 0.92 nM) (Figure 11).  Both compounds have demonstrated anxiolytic 
properties within the laboratory,77 and DAA1097 has been shown to influence 
steroidogenesis.78 These preliminary results implicate a potential therapeutic application 
















Figure 11. Phenoxyarylacetamide TSPO ligands 
 
Many reported radiosyntheses of phenoxyarylacetamide TSPO ligands can be found in the 
literature along with their application in PET imaging studies.  [18F]PBR06, originally 
developed by Briard et al., is a potent TSPO radioligand with Ki values ranging from 
0.180–0.997 nM in rat, monkey and human brain.79,80 In 2011, Wang et al. developed a 
new and efficient synthesis of a tosylate labelling precursor and radiosynthesis of 
[18F]PBR06 (Scheme 14).81 In their publication the authors reported a facile synthesis 
starting from commercially available 2,5-dimethoxybenzaldehyde (72).  Following an 
initial condensation reaction between the aldehyde and 2-phenoxyaniline (71), reduction of 
the resulting imine using sodium borohydride formed phenoxyaniline intermediate 73.  
Intermediate 78 was then prepared in four steps from ethyl glycolate (74).  Treatment of 74 
with p-toluenesulfonyl chloride gave tosylate 75, the ethyl ester group of which was 
hydrolysed under basic conditions to afford carboxylic acid 76.  Conversion to acyl 
chloride 77 was then achieved using thionyl chloride.  Finally, an amide coupling reaction 
between these two fragments provided tertiary amide 78.  Radiofluorination of 78 using 
[18F]potassium fluoride and Kryptofix! in dimethylsulfoxide at 140 °C afforded 
[18F]PBR06 (79) in decay corrected radiochemical yields ranging from 30–60%, within a 
total synthesis time of 50–60 minutes.  Furthermore, the radiotracer was obtained in very 
high radiochemical purity (>99%) and specific activity (up to 222 GBq/µmol at the end of 
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Scheme 14. Radiosynthesis of [18F]PBR06 (79) 
 
In terms of clinical applicability, Fujita and co-workers have described a study whereby 
[18F]PBR06 was compared to [11C]PBR28 as a biomarker for TSPO expression in 
humans.82 The preliminary results of this study indicated that [18F]PBR06 has potential to 
be utilised as a PET imaging agent for TSPO expression and offers the advantage of a 
longer lived radioisotope (t1/2 = 110 minutes for 
18F versus 20.3 minutes for 11C).   
 
1.2.3.8 High, Low and Mixed Affinity Binders 
 
In 2010, Owen et al. performed an autoradiography study designed to compare the in vitro 
binding characteristics of the TSPO radioligand [3H]PBR28 with [3H]PK11195 within 
brain tissue.83 On conclusion of their investigation, the authors reported that approximately 
14% of the healthy volunteer cohort enlisted did not display specific binding for 
[3H]PBR28.  Instead, there existed three distinct classes of binders: high affinity binders 
(HABs, Ki = 3.4 ± 0.5 nM), low affinity binders (LABs, Ki = 188 ± 15.6 nM) and mixed 
affinity binders (MABs). 
 
! $*!
A further study by the same group later indicated that this occurrence was more prevalent 
than originally thought.  Through measurement of the binding affinities of TSPO 
radiotracers for PET currently being investigated for clinical applications, they discovered 
that all compounds tested recognised HABs, LABs and MABs.84 The ratios of high to low 
binding affinity measured for compounds tested are listed in Figure 12.  Interestingly, the 
prototypical ligand for the TSPO, PK11195 was the only compound not to demonstrate 


















































Figure 12. Binding ratios of TSPO ligands 
 
The differences in binding affinities experienced by the population was explained in 2012 
by Owen et al.85 A genetic study identified that the TSPO rs6971 polymorphism was 
responsible.  This polymorphism, occurring within exon 4 of the gene encoding the TSPO, 
results from substitution of alanine for threonine at position 147 of the fifth transmembrane 
spanning domain.  This amino acid substitution therefore presents an additional and 
unavoidable challenge in TSPO imaging.  Conscious efforts to take this polymorphism into 
account and identify appropriate binders will be required for future studies aimed at 
developing an imaging agent for the TSPO to be successful.  It has been proposed that 
suitable binders can be selected based on priori genetic testing or leukocyte binding 
assays.86     
 
! %+!
The challenge in development of new radiotracers for the TSPO has been compounded by 
the discovery of this genetic polymorphism.  As the isoquinoline-3-carboxamides are the 
only structural class of TSPO ligand not to display differences in binding affinity within 
the population, it was considered logical to attempt to address the problems described in 
section 1.2.3.2 associated with this compound.  
 
1.3 Proposed Research 
 
The primary aim of this research was to develop a new radiotracer for PET and SPECT 
imaging of the TSPO.  Based on the isoquinoline-3-carboxamide PK11195, a series of 
quinoline-2-carboxamide analogues would be prepared with two key objectives: to probe 
structure activity relationships and to reduce compound lipophilicity by variation of the X 
and R1–R4 groups (Figure 13).  It was proposed to incorporate groups containing carbon, 
fluorine or iodine that could be labeled at a later stage using carbon-11 and fluorine-18 for 













PK11195 Analogue  
 
Figure 13. PK11195 and quinoline-2-carboxamide analogue; potential imaging agent 
 
Upon completion of the synthesis of a small library of quinoline-2-carboxamides it was 
anticipated that the physicochemical properties of each analogue would be measured, 
providing an indication of their likelihood to successfully penetrate the blood brain barrier.  
It was determined that elimination of unsuitable compounds based on lipophilicity and 
plasma protein binding measurements would ensue, and only those displaying favourable 
characteristics progressed to the next stage of the study.  The in vitro binding affinity of 
selected analogues for the TSPO would then be measured using a competition binding 
assay.  If a lead candidate were identified, a suitable precursor would be radiolabelled and 
further in vitro and in vivo studies performed with the aim of developing a novel PET 
and/or SPECT imaging agent for the TSPO.    
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2 Development of Imaging Agents for the TSPO (18 kDa) 
 
2.1 Synthesis of PK11195 Analogues: Potential PET and 
SPECT Imaging Agents 
 
The first stage of this work required the synthesis of a small library of quinoline-2-
carboxamide TSPO ligands analogous with PK11195, the clinically utilised isoquinoline-
3-carboxamide PET ligand.  It was envisaged that the target compounds could be prepared 
in a timely and efficient manner, and moreover, that the synthetic routes employed would 
facilitate structural variation and confirmation of structure activity relationships.  
Following preparation of the target quinoline-2-carboxamides, assessment of 
physicochemical properties and measurement of binding affinity with the TSPO would 
determine potential for successful development into an imaging agent for the TSPO.  
 
2.1.1 Synthesis of Potential PET Imaging Agents 
 
In total, seven quinoline-2-carboxamides were initially identified as interesting targets with 
possible application as PET imaging agents (Figure 14).  Previous studies have shown that 
the more rigid the ligand, as exerted through restriction of amide bond rotation using 
strategically positioned substituents, the greater the binding affinity with the protein.22 It 
was therefore proposed that compounds 80 and 81 would probe the effect of a methyl 
group at the 3-position of the quinoline ring on protein binding.  Furthermore, compounds 
82 and 83 would indicate whether a substituent at this position was necessary, or if the 
presence of a large ortho-bromide substituent was sufficient for potent binding.  In 
addition, the effect of replacing the pendant phenyl ring with a heterocyclic ring system 
was identified as an area of interest.  As such, compounds 84–86, bearing a pyridin-4-yl, 
furan-2-yl and thiophen-3-yl substituent were also chosen as targets.  In all instances, 
selection of the amide side chain and heterocyclic system was done in anticipation of 
reducing compound lipophilicity and increasing bioavailability. 





































Figure 14. Potential PET imaging agents  
 
If any compound showed promise in terms of binding affinity and physicochemical 
properties, development of a synthetic route for the preparation of a [11C]-labeling 
precursor would ensue.  
 
2.1.1.1 Retrosynthetic Analysis of PK11195 Analogues 80–86 
 
A retrosynthetic analysis of the target PET compounds 80–86 is shown in Scheme 15.  It 
was proposed that a disconnection of the amide linkage would afford carboxylic acid 
intermediates 87–93, and that further disconnection of the aromatic or heteroaromatic 
moieties would lead to bromoquinolines 94 and 95.  Functional group interconversion of 
the halogen would then lead to hydroxyquinolines 96 and 97.  Finally, disconnection of the 
quinoline core would yield commercially available aniline (98) and either diethyl 
























80 R1 = H, R2 = Ph, R3, R4 = 4-Methylpiperazine
81 R1 = Me, R2 = Ph, R3, R4 = 4-Methylpiperazine
82 R1 = H, R2 = 2-BrPh, R3 = R4 = Me
83 R1 = Me, R2 = 2-BrPh, R3 = R4 = Me
84 R1 = H, R2 = Pyridin-4-yl, R3, R4 = 4-Methylpiperazine
85 R1 = H, R2 = Furan-2-yl, R3, R4 = 4-Methylpiperazine
86 R1 = H, R2 = Thiophen-3-yl, R3, R4 = 4-Methylpiperazine
87 R1 = H, R2 = Ph
88 R1 = Me, R2 = Ph
89 R1 = H, R2 = 2-BrPh
90 R1 = Me, R2 = 2-BrPh
91 R1 = H, R2 = Pyridin-4-yl
92 R1 = H, R2 = Furan-2-yl
93 R1 = H, R2 = Thiophen-3-yl
94 R1 = H
95 R1 = Me
96 R1 = H
97 R1 = Me
99 R1 = H




Scheme 15. Retrosynthetic analysis of PET compounds 80–86 
 
The synthetic strategy outlined highlights two molecular handles that will enable structural 
variation: bromoquinolines 94 and 95 can be subjected to a Suzuki-Miyaura cross-coupling 
with a range of commercially available boronic acids, and the penultimate carboxylic acids 
reacted with a variety of amines for final compound preparation.  
 
2.1.1.2 Synthesis of 4-Bromoquinolines 94 and 95 
 
The first step in the synthesis of the target quinoline-2-carboxamides was the preparation 
of the 2,4-disubstituted quinoline core, which was achieved in two steps using a procedure 
developed by Bradbury et al. (Scheme 16).87 Condensation of aniline (98) with either 
diethyl oxalacetate (99) or diethyl oxalpropionate (100) in the presence of para-
toluenesulfonic acid under Dean-Stark conditions, resulted in the formation of imines 101 
and 102.  Due to the instability of these imines on silica, they were applied immediately to 
the next step without prior purification.  Acid-mediated cyclisation of these intermediate 
imines in the presence of neat polyphosphoric acid at 120 °C afforded the desired 4-
hydroxyquinolines 96 and 97 in yields of 37% and 65%, respectively.  Construction of a 
quinoline ring under these conditions is referred to as the Combes quinoline synthesis (Cf. 














99 R = H
100 R = Me
101 R = H





96 R = H, 37% (2 steps)





Scheme 16. Synthesis of 4-hydroxyquinolines 96 and 97 
 
It was expected that a catalytic amount of para-toluenesulfonic acid would be sufficient for 
the preparation of the intermediate imines, and this was true for the preparation of 4-
hydroxyquinoline 97.  However, when a catalytic quantity of the acid was used for the 
preparation of hydroxyquinoline 96, inspection of the crude reaction mixture by 1H NMR 
spectroscopy indicated that only a negligible amount of product had formed.  In an attempt 
to increase the yield for this reaction, a stoichiometric amount of acid was employed and 
the desired 4-hydroxyquinoline was prepared in a low, but acceptable 37% yield. 
 
Having successfully formed the quinoline core structure, the next step required converting 
the hydroxyl group to the bromide.  This transformation was achieved via an SNAr 
reaction, whereby 4-hydroxyquinolines 96 and 97 were treated with phosphorus 
oxybromide to give 4-bromoquinolines 94 and 95 in excellent yields of 92% and 98%, 
respectively (Scheme 17).46,89 Preparation of the target PET compounds could now be 






96 R = H





94 R = H, 92%





Scheme 17. Synthesis of 4-bromoquinolines 94 and 95 
 
2.1.1.3 Synthesis of Potential PET Compounds 80 and 81 
 
In 1979, Suzuki and Miyaura reported the stereoselective synthesis of arylated (E)-alkenes 
by the palladium-catalysed reaction between 1-alkenylboranes and aryl halides.90 This 
seminal work paved the way for what is now commonly referred to as the Suzuki cross-
coupling reaction, and is defined as the palladium-catalysed cross-coupling reaction of an 
organoboron with an organic halide or triflate to form a new carbon-carbon bond.88 It is an 
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extremely powerful reaction with wide synthetic utility, and allows for the preparation of 
conjugated olefins, styrenes and biaryls.  There are many advantages associated with this 
reaction; a few of which include mild reaction conditions, tolerance of a wide range of 
functional groups, stability under aqueous conditions and wide range of commercially 
available starting materials.91   
 
Biaryl compounds 103 and 104 were prepared via a palladium(0)-catalysed Suzuki cross-
coupling reaction between benzeneboronic acid and either 4-bromoquinoline 94 or 95 
(Scheme 18).  A wide range of reagents and reaction conditions have been developed for 
the Suzuki reaction, and in this case tetrakis(triphenylphosphine)palladium(0) and 
potassium phosphate in DMF were sufficient for the preparation of compounds 103 and 






94 R = H
95 R = Me
103 R = H, 81%









Scheme 18. Synthesis of 4-phenylquinolines 103 and 104 
 
The Suzuki cross-coupling reaction is a palladium(0) to palladium(II)-catalytic cycle 
(Figure 15).92 Oxidative addition of the aryl halide bond of 94 to palladium(0) generates a 
palladium(II) species, and a cis complex that rapidly isomerises to trans complex 105.93 It 
has been proposed that the role of the base in the reaction is to facilitate the quaternisation 
of the boron,94 resulting in the formation of the boronate 106, which undergoes 
transmetallation with the palladium(II)-complex.  Isomerisation of this newly formed 
trans-palladium(II) intermediate to the corresponding cis-palladium(II) complex 107 then 
allows for the final step of the catalytic cycle to be achieved.  Reductive elimination 
produces the desired biaryl compound 103, whilst regenerating the palladium(0) species 












































Figure 15. Suzuki-Miyaura cross-coupling reaction mechanism 
 
The synthesis of quinoline-2-carboxamides 80 and 81 could now be completed in just a 
few short steps (Scheme 19).  Hydrolysis of the ethyl ester group of 103 and 104, under 
basic conditions, resulted in the formation of quinoline-2-carboxylic acids 87 and 88 in an 
89% and 82% yield, respectively.  The resulting carboxylic acids were then converted to 
their corresponding acyl chlorides by reaction with oxalyl chloride and a catalytic quantity 
of DMF.  The acyl chloride intermediates were not isolated, and treated immediately with 
1-methylpiperazine in situ to form the target compounds 80 and 81 in a moderate yield of 
59% and 43%, respectively over 2 steps.   
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87 R = H, 89%









80 R = H, 59% (2 steps)
81 R = Me, 43% (2 steps)
103 R = H




NaOH, aq. EtOH, !
(COCl)2, DMF, CH2Cl2,




108 R = H
109 R = Me




Scheme 19. Synthesis of potential PET compounds 80 and 81 
 
2.1.1.4 Synthesis of Potential PET Compounds 82 and 83 
 
Quinoline-2-carboxamides 82 and 83 were prepared using the same synthetic route 
described for 80 and 81 (Scheme 20).  Briefly, 4-bromoquinolines 94 and 95 were 
employed in a palladium(0)-catalysed cross-coupling reaction with 2-bromophenylboronic 
acid to give biaryl compounds 110 and 111 in 69% and 32% yield, respectively.  
Hydrolysis of the ethyl ester using sodium hydroxide gave carboxylic acids 89 and 90 in an 
excellent quantitative yield for 89, and 89% yield for 90.  In situ formation of acyl 
chlorides 112 and 113, and subsequent treatment with dimethylamine afforded quinoline-
2-carboxamides 82 and 83 in low yields of 26% and 38%, respectively.  In terms of 
biological testing, milligram quantities of a compound are required for performing the 
assay in triplicate, and so despite the low isolated product yields, a sufficient mass was 
obtained for ensuing biological investigations. 






89 R = H, 100%








94 R = H
95 R = Me
82 R = H, 26% (2 steps)
83 R = Me, 38% (2 steps)
110 R = H, 69%
















112 R = H
113 R = Me







Scheme 20. Synthesis of potential PET compounds 82 and 83 
 
Despite variations in temperature and reagent equivalents employed, the reaction of 
compound 95 tended to produce either trace amounts, or very low isolated product yields 
of 111 (24–32%).  Inspection of the crude reaction mixture by 1H NMR spectroscopy 
indicated that at most, a 2:1 mixture of 4-bromoquinoline starting material to desired 
product was forming.  As such, alternative reagents and reaction conditions were 
investigated in an attempt to improve the yield of this reaction (Scheme 21, Table 3).  
 
Janin and Guillou reported that by replacing tetrakis(triphenylphosphine)palladium(0) with 
[1,1’-bis(diphenylphosphino)ferrocene]dichloropalladium(II) as the catalyst employed for 
Suzuki cross-coupling reactions, they could achieve the synthesis of their target 1-
arylisoquinoline-3-carboxylates in much greater yields.95 As such, these optimised reaction 
conditions were applied to substrate 95 (Entry 1).  However, inspection of the crude 
reaction mixture using 1H NMR spectroscopy highlighted the presence of starting material 
and an aromatic by-product only, and the decision to return to 
tetrakis(triphenylphosphine)palladium(0) was taken.  In this instance, an alternative base 
and reaction conditions were employed, but again only unreacted starting material and 
aromatic by-products resulted from this reaction (Entry 2).  Isolation and identification of 








95 111  
 
Scheme 21. Suzuki coupling reaction 
 
Entry Reagents Conditions Outcome 
1 
PdCl2(dppf) (0.05 mol%), 
CsCO3 (2.1 eq) 
1,4-dioxane/H2O, 
85 °C 
SM (+ aromatic  
by-product) 
2 
Pd(PPh3)4 (10 mol%), 
Na2CO3 (3.0 eq) 
Toluene/H2O/EtOH, 
90 °C 
SM (+ aromatic  
by-products) 
 
Table 3. Alternative Suzuki-Miyaura cross-coupling conditions   
 
On the whole, the product yield for the Suzuki coupling reaction between 4-
bromoquinoline 95 and 2-bromophenylboronic acid was not improved beyond 32%.  The 
reasons for the low yield of this transformation may be due to interference resulting from a 
combination of steric and electronic factors.  In terms of steric obstruction, the presence of 
the methyl substituent in the 3-position of the quinoline ring, coupled with the presence of 
the ortho-bromide substituent of the boronic acid, could be hindering the already slow 
transmetallation step.  As well as potentially imparting a steric barrier to the reaction, the 
inductive effect of the methyl group may also be slowing down the initial oxidative 
addition step of the aromatic halide bond to the palladium(0) species.  Furthermore, it has 
been reported that under aqueous conditions, reduction of the C-Br bond can occur,96 and 
phenylboronic acids with an electron withdrawing substitutent at the ortho-position can 
increase the rate of hydrolytic deboronation.91  
 
2.1.1.5 Synthesis of Potential PET Compounds 84, 85 and 86 
 
TSPO ligands 84, 85 and 86, bearing a heterocycle in place of the pendant phenyl ring, 
were prepared in four overall steps (Scheme 22).  Again, 4-bromoquinoline 94 was 
employed in a Suzuki cross-coupling reaction with pyridin-4-ylboronic acid, furan-2-
ylboronic acid and thiophen-3-ylboronic acid, under standard coupling conditions, to give 
biaryl compounds 114, 115, and 116 in good yields of 94%, 85% and 76%, respectively.  
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Subsequent base hydrolysis of the ethyl ester afforded carboxylic acids 91, 92 and 93 in 
yields ranging from 79–93%.  Finally, conversion of the carboxylic acids to the 
corresponding acyl chlorides 117, 118 and 119, and subsequent reaction with 1-
methylpiperazine resulted in the successful completion of the synthesis of target quinoline-
2-carboxamides 84, 85 and 86.  Compounds 84, 85 and 86 were obtained in a low to 





















CH2Cl2, 0 °C then !
94 114 R = Pyridin-4-yl, 94%
115 R = Furan-2-yl, 85%
116 R = Thiophen-3-yl, 76%
91 R = Pyridin-4-yl, 93%
92 R = Furan-2-yl, 79%
93 R = Thiophen-3-yl, 80%
84 R = Pyridin-4-yl, 53% (2 steps)
85 R = Furan-2-yl, 56% (2 steps)
86 R = Thiophen-3-yl, 32% (2 steps)
117 R = Pyridin-4-yl
118 R = Furan-2-yl






Scheme 22. Synthesis of potential PET compounds 84, 85 and 86 
 
Having completed the synthesis of quinoline-2-carboxamides 84–86, attention now turned 
to preparation of TSPO ligands with potential application in SPECT imaging. 
 
2.1.2 Synthesis of Potential SPECT Imaging Agents 
 
As mentioned previously, increased binding affinity of a ligand with the TSPO can be 
achieved by restricting rotation of the amide bond.  In doing so, the molecule increases in 
rigidity and consequently finds favourable interactions within the binding pocket of the 
protein.  It was therefore proposed, that quinoline-2-carboxamides 120 and 121 (Figure 16) 
were suitable targets, and anticipated that the large ortho-iodide substituent would obstruct 













Figure 16. Potential SPECT imaging agents 
 
Following this, synthesis of a labeling precursor for [123I]-incorporation and development 
as a potential SPECT imaging agent for the TSPO would commence if preliminary in vitro 
investigations yielded promising results.     
 
2.1.2.1 Proposed Synthetic Route for SPECT Compounds 120 and 121 
 
It was originally proposed that compounds 120 and 121 could be prepared using the same 
synthetic route as that for PET compounds 80–86, with the addition of a key synthetic step 
(Scheme 23).  Carboxylic acid 89, the preparation for which was described previously, 
could be converted to amides 122 and 123 via the acid chloride.  Finally, a halogen 
exchange reaction could then be employed for inclusion of the iodide, providing quinoline-















122 R1 = R2 = Et
123 R1, R2 = Morpholine
120 R1 = R2 = Et





Scheme 23. Proposed synthetic route for quinoline-2-carboxamides 120 and 121 
 
2.1.2.2 Synthesis of SPECT Compounds 120 and 121 
 
Oxalyl chloride and a catalytic amount of DMF was used to convert carboxylic acid 89 to 
the corresponding acid chloride intermediate 124, which was in turn treated immediately 
with diethylamine to give bromide precursor 122.  This sequence of transformations 









         0 °C then !
46% (2 steps)
N COCl







Scheme 24. Synthesis of bromide precursor 122 
 
In order to complete the synthesis of the first target SPECT compound, conversion of the 
aryl bromide to an aryl iodide was required (Scheme 25).  It was envisaged that this 
transformation could be achieved directly by means of a metal-mediated halogen exchange 
reaction.  Several methods have been developed for the preparation of aryl iodides from 
aryl bromides, which involve nickel- and copper-mediated reactions.97 However, the 
disadvantages associated with such procedures, e.g. requiring stoichiometric amounts of 
nickel(0) powder, limits their synthetic and economic utility.98  
 
At this point in time, a research project within the group, was aimed at developing a new 
nickel-mediated halogen exchange reaction for the generation of aryl iodides from aryl 
bromides.99 This methodology was therefore used as a starting point.  An initial attempt to 
prepare the iodinated compound employed 10 mol% of nickel(II) bromide, an excess of 
sodium iodide and 10 mol% of tri-n-butylphosphine as the ligand (Table 4, Entry 1).  After 
stirring in NMP for 18 hours at 180 °C, analysis of the 1H MMR spectrum of the crude 
reaction mixture indicated that complete consumption of the bromide starting material 122 
had occurred, however, evidence of the desired iodide product 120 was absent.  Instead, it 
appeared that reduction of the C-Br bond leading to dehalogenated product 125 had 
occurred.  This is a known side reaction of metal mediated halogen exchange reactions.100 
In an attempt to overcome reduction of the starting material, the reaction was carried out 
using the same reagents, but in the presence of 4Å molecular sieves and at a lower 
temperature of 150 °C (Table 4, Entry 2).  Unfortunately, these reaction conditions also 
resulted in the formation of the reduced by-product 125.   
 
The unsuccessful attempts to prepare the target quinoline-2-carboxamide using a nickel-
mediated halogen exchange reaction led to the investigation of a different catalytic system.  
Klapars and Buchwald have reported a highly efficient method for the preparation of a 
range of aromatic and heteroaromatic iodides from the analogous bromides via a copper-
catalysed aromatic Finkelstein reaction.101 Under the reported optimised reaction 
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conditions, which utilised copper(I) iodide in the presence of a diamine ligand, it was 
anticipated that the desired iodide could be prepared without formation of the 
dehalogenated by-product.  A first attempt at using this methodology employed 5 mol% 
copper(I) iodide, an excess of sodium iodide and 10 mol% of N,N-
dimethylethylenediamine (DMEN) as the diamine ligand (Table 4, Entry 3).  The starting 
material and reagents were dissolved in n-butanol and stirred for 18 hours at 180 °C.  
Analysis of the crude reaction mixture by 1H MNR spectroscopy indicated that a 2:1 
mixture of dehalogenated by-product and starting material was present. 
 
A final attempt to exchange the bromide for the iodide using 5 mol% copper(I) iodide, an 
excess of sodium iodide and 10 mol% of DMEN, and executing the reaction in a 
microwave was performed (Table 4, Entry 4).  After stirring for 1 hour at 200 °C, the 
reaction mixture was again inspected.  From the 1H NMR spectrum, it appeared that a 2:1 
mixture of dehalogenated by-product 125 and iodinated product 120 was present.  
However, despite several attempts to isolate the final compound using flash column 
chromatography, it could not be achieved due to close running impurities on the silica 
column.  Despite the inability to isolate compound 120, formation of the small amount of 
product offered encouragement to pursue an alternative synthetic strategy.  



























Entry Reagents Conditions Outcome 
1 
NiBr2 (10 mol%), NaI (6.0 eq), 
P(n-Bu)3 (10 mol%) 




NiBr2 (10 mol%), NaI (6.0 eq), 
P(n-Bu)3 (25 mol%) 
NMP, 4Å MS, 
150 °C, 18 h 
Dehalogenation 
3 
CuI (5 mol%), NaI (2.0 eq), 
DMEN (10 mol%) 





CuI (5 mol%), NaI (2.0 eq), 
DMEN (10 mol%) 
n-BuOH, µW 
(200 °C), 1 h 
Dehalogenation/Product 
2:1*   
* Determined by measurement of integrals in 1H NMR spectrum of crude reaction mixture. 
 
Table 4. Conditions trialed for direct halogen exchange reaction 
 
Previous work in the group has shown that the copper(I)-catalysed aromatic Finkelstein 
reaction can be successfully applied to isoquinolines bearing an ester group in place of the 
amide side chain.  As such, quinoline-2-carboxylate 110 was identified as a potential 
precursor for the halogen exchange reaction (Scheme 26).  The conditions trialed for this 
reaction are listed in Table 5.  Briefly, a nickel-catalysed halogen exchange reaction was 
initially employed for the synthesis of 126, but resulted in formation of a complex mixture 
of dehalogenated and unidentified by-products only (Entry 1).  Application of the Klapars 
and Buchwald conditions was then attempted, but again afforded complex mixtures from 
which compound identification was difficult (Entries 2 and 3).  It should be noted that 
under the reaction conditions employed, a transesterification reaction occurs forming 127.  
In addition to the use of a metal-catalysed halogen exchange reaction, a lithium-halogen 
exchange reaction was considered for the preparation of 126,102,103 however treatment of 
110 with n-butyllithium followed by molecular iodine yielded another complex mixture 














Scheme 26. Attempted halogen exchange reaction of quinoline-2-carboxylate 110 
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Entry Reagents Conditions Outcome 
1 
NiBr2 (5 mol%), NaI (6.0 eq),  
P(n-Bu)3 (10 mol%) 




CuI (5 mol%), NaI (2.0 eq),  
DMEN (10 mol%) 




CuI (5 mol%), NaI (2.0 eq),  
DMEN (10 mol%) 
n-BuOH, 130 °C, 
4 days 
Complex Mixture 
4 n-BuLi (1.1 eq) then I2 (1.4 eq) 




Table 5. Conditions trialed for halogen exchange reaction on quinoline-2-carboxylate  
 
In order to show that the reagents employed for the copper(I)-catalysed aromatic 
Finkelstein reaction were of sufficient enough quality, and that there were no practical 
issues surrounding the handling and setting up of this experiment, a model substrate was 
investigated.  5-Bromoindole was chosen to replicate the experiment carried out by 
Klapars and Buchwald who had also selected this compound as a substrate.  Treatment of 
5-bromoindole (128) with 5 mol% copper(I) iodide, an excess of sodium iodide and 
DMEN as the ligand in 1,4-dioxane at 110 °C proceeded to give 5-iodoindole (129) in a 
63% yield (Scheme 27).  This reaction was replicated to ensure reproducibility.  These 
results, therefore, indicate that the attempts to convert the aryl bromide 122 into aryl iodide 
120 using the copper(I)-mediated approach, most likely failed due to steric hinderance 
















Scheme 27. Synthesis of 5-iodoindole (129) via a halogen exchange reaction 
 
Unsuccessful attempts to directly convert the aryl bromide to the aryl iodide required an 
alternative synthetic route to be devised.  One such approach involves electrophilic iodo-
demetallation.104 Various metals have been effectively employed for the iodo-
demetallation transformation including, but not limited to, silicon, boron and tin.105 At 
present, the most commonly used metal is tin, and the reaction proceeds via a two-step 
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process involving an initial palladium(0)-catalysed stannylation of the halogenated arene 
followed by iodo-destannylation under oxidative conditions.106 Unfortunately, the reaction 
of bromide 122 with 10 mol% tetrakis(triphenylphosphine)palladium(0) and 
hexamethylditin affording organostannane 130 was unsuccessful (Scheme 28).  As such, 























Scheme 28. Attempted synthesis of 120 via a stannylation iodo-destannylation sequence 
 
A procedure reported by Lunazzi et al. indicated that the more sterically encumbered 
ortho-bromide substituent of a biaryl system could be converted to the trimethylstannane 
using tert-butyllithium and trimethyltin chloride.107 However, the use of these more forcing 
reaction conditions would not be compatible with the functionalities of this molecule, as 
has been previously indicated.    
 
2.1.2.3 New Synthetic Route for the Preparation of SPECT Compounds 
120 and 121 
 
Despite several attempts using different approaches, incorporation of the iodide substituent 
into the quinoline core could not be achieved.  An alternate synthetic route, circumventing 
this troublesome step was therefore necessary.  The synthetic utility of aromatic iodides as 
building blocks for organic chemists in combination with their biological activity,108 has 
resulted in an increasing interest in methodology enabling efficient generation of this 
motif.  In 1884, T. Sandmeyer discovered that while attempting to prepare phenylacetylene 
from benzenediazonium chloride and copper(I) acetylide, he had in fact, synthesised 
chlorobenzene in good isolated yield with no evidence of the desired product.88,109 This 
serendipitous discovery of the ability to substitute an aryldiazonium salt with a halide or 
pseudo-halide is now refered to as the Sandmeyer reaction, and is a powerful tool for the 
regioselective preparation of aromatic iodides, bromides and chlorides for example. 
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It was, therefore, anticipated that the preparation of an aryldiazonium salt followed by a 
Sandmeyer reaction with an iodine source could be exploited to synthesise the target 
SPECT compounds.  Utilisation of this synthetic transformation would first require 
generation of the primary aromatic amine starting material, which could be formed from 
the corresponding nitro functional group.   
 
An initial Suzuki cross-coupling reaction of 4-bromoquinoline 94 and 2-
nitrobenzeneboronic acid under standard conditions afforded biaryl compound 131 in an 
excellent 91% yield (Scheme 29).  The success of this coupling reaction provided a 
chemical handle in the form of the nitro group, allowing for insertion of the iodine atom.  
Reduction of the nitro group was achieved using conditions reported by Bellamy and 
Ou,110 whereby the aromatic nitro group of 131 was converted to the corresponding amine 
132 in an excellent 99% yield using tin(II) chloride. Formation of the aromatic amine 
enabled the key transformation to be investigated.  Krasnokutskaya et al., reported the 
preparation of aromatic and heterocyclic iodides via a one-pot diazotisation/iodination 
sequence using a mixture of para-toluenesulfonic acid, sodium nitrite and potassium 
iodide.111 Initial treatment of aromatic amine 132 with para-toluenesulfonic acid in 
acetonitrile at ambient temperature, followed by the dropwise addition of an aqueous 
sodium nitrite and potassium iodide solution at 0 °C, resulted in the formation of the 
intermediate aryldiazonium which reacts immediately to form the desired iodoarene 126.  
This key transformation proceeded in very good yield of 83%.  Having successfully 
incorporated the iodine substituent into the molecule over three steps, completion of the 
target compounds 120 and 121 could now be achieved.  Firstly, hydrolysis of ethyl ester 
126 under basic conditions resulted in the formation of carboxylic acid 133 in quantitative 
yield, which was subsequently converted to acid chloride 134.  Treatment with the 
appropriate amine completed the target compound synthesis.  Reaction with diethylamine 
and morpholine afforded target SPECT compounds 120 and 121 in a moderate 51% and 












K3PO4, DMF, 120 °C
(COCl)2, DMF, CH2Cl2,














i) p-TsOH, MeCN, r.t.










0 °C then !
120 R1 = R2 = Et, 51% (2 steps)




Scheme 29. Synthesis of potential SPECT compounds 120 and 121 
 
In addition to conferring high binding affinity to its biological target and displaying the 
appropriate physicochemical properties, the development of a compound as a potential 
imaging agent relies heavily on the ability to radiolabel a suitable precursor.  Regrettably, 
attempts to incorporate the iodine atom into the quinoline core via the more traditional 
methods of direct halogen exchange and sequential stannylation/iodo-destannylation, both 
of which have been adapted for radiolabelling procedures, had failed.112,52 Nevertheless, 
Pasternak and co-workers have reported conditions for the radioiodination of fully 
deprotected peptides, which proceed via a diazotisation/Sandmeyer sequence.113 Therefore, 
if either target compound shows potential as a SPECT imaging agent for the TSPO, the 
conditions described in the literature could be trialed as a means of incorporating 
radioactive iodine into the appropriate molecule. 
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2.1.2.4 Attempted Synthesis of an Additional SPECT Compound 
 
In addition to analogues 120 and 121, quinoline-2-carboxamide 135 (Figure 17) was also 
identified as a compound of interest.  Prior investigations within the Sutherland group had 
shown that the presence of a substituent para-to the quinoline ring had a detrimental effect 
on the compounds ability to successfully bind to the TSPO.  It was therefore of interest to 
investigate the effect a large substituent such as iodine at the meta- position would have on 
TSPO binding. 








Figure 17. Potential SPECT imaging agent 
 
Synthesis of the bromide precursor of 135 was achieved in four steps (Scheme 30), 
utilising the synthetic chemistry described for previous analogs.  4-Bromoquinoline 94 was 
coupled to 3-bromophenylboronic acid under standard Suzuki cross-coupling conditions to 
give biaryl compound 136 in a good 78% yield.  Hydrolysis of the ethyl ester group 
afforded carboxylic acid 137 in an excellent 94% yield.  Finally, conversion of the 
carboxylic acid to diethyl amide 139, by reaction of acid chloride 138 with diethylamine, 
was achieved in a moderate yield of 57% over two steps. 















         0 °C then !
57% (2 steps)
N COCl











Scheme 30. Synthesis of bromide precursor 139 
 
In order to complete the synthesis of potential SPECT compound 135, replacement of the 
bromine atom for iodine was imperative.  Previous attempts at performing a copper(I)-
catalysed direct halogen exchange reaction on bromide 122 had shown limited success 
when applied to a microwave reaction (Scheme 25, Table 4; Entry 4).  However, when 
these conditions were applied to bromide 139, analysis of the crude reaction mixture by 1H 



















Scheme 31. Attempted halogen exchange on bromide precursor 139 
 
As the direct halogen exchange approach had once again failed to provide the target 
compound, the two-step process of stannane formation followed by iodo-destannylation 
was revisited (Scheme 32).  Inspection of the crude reaction mixture by 1H NMR 
spectroscopy and mass spectrometry indicated the presence of the target iodinated 
! '"!
compound 135.  However, a large proportion of the crude reaction mixture consisted of 
unreacted bromide starting material 139.  Unfortunately, stringent attempts to isolate the 
iodinated product from the bromide starting material by flash column chromatography 






















Scheme 32. Attempted synthesis of compound 135 via stannane 140 
 
In the interest of time, the synthesis of this additional target compound was not pursued 
further.  Should it be revisited as part of a future research initiative, focus should center on 
ensuring the complete conversion of the bromide starting material 139 to the stannane 140.   
 
The synthesis of potential PET and SPECT imaging agents 80–86 and 120–121 was 
achieved through application of a well developed route utilising two key steps for 
diversification: the Suzuki-Miyaura cross-coupling reaction and amide formation using 
different secondary amines.  Attention now turned to a new shorter synthetic route for the 
preparation of iodinated and fluorinated quinoline-2-carboxamides that could have 
potential as molecular imaging agents.     
 
2.1.3 Multicomponent Reactions: Synthesis of Potential SPECT 
and PET Compounds 
 
Despite a great deal of research centred on development of a novel TSPO imaging agent, 
incorporation of a radioisotope on the phenyl ring of the quinoline core has never been 
considered.  To account for this, we aimed to prepare a series of ligands bearing a fluoride 
or iodide atom in the 6-position of the quinoline ring (Figure 18).  In essence, 
incorporation of the halogens would allow us to probe the effect a substituent at this 
position has on binding affinity with the protein, and provide an easily accessible 
radiolabelling position for [123I]- or [18F]-incorporation if development into a PET and/or 

































144 145 146  
 
Figure 18. Potential SPECT and PET imaging agents 
 
2.1.3.1 Retrosynthetic Analysis of PK11195 Analogues 141–146 
 
The retrosynthetic analysis of the target SPECT and PET compounds 141–146 is shown 
(Scheme 33).  Disconnection of the amide bond gives carboxylic acid intermediates 147 
and 148, which can in turn be prepared via a functional group interconversion from the 
ethyl esters 149 and 150.  A further disconnection of the quinoline ring gives commercially 
available phenylacetylene (151) and imines 152 and 153, which are prepared in situ from 
commercially available ethyl glyoxalate solution, 4-iodoaniline (155) and 4-fluoroaniline 















141 X = I, R1, R2 = Morpholine
142 X = I, R1, R2 = 4-Methylpiperazine
143 X = I, R1 = R2 = Et
144 X = F, R1, R2 = Morpholine
145 X = F, R1, R2 = 4-Methylpiperazine
146 X = F, R1 = R2 = Et
152 X = I
153 X = F
147 X = I
148 X = F
155 X = I




149 X = I
150 X = F
 
 
Scheme 33. Retrosynthetic analysis of PET and SPECT compounds 140–146 
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The proposed synthetic route will utilise a key molecular iodine-catalysed three-
component, one-pot process for the synthesis of the desired quinoline-2-carboxylate 
intermediates 149 and 150.  The advantages of utilising this chemistry are that it enables 
the efficient preparation of the substituted quinoline core structure in one step, and also 
allows for the incorporation of an iodide and fluoride in the 6-position of the quinoline 
ring.  Furthermore, this route could be used for synthesis of a radiolabelling precursor by 
utilising bromo- or nitroaniline starting materials for [123I]- and [18F]-incorporation, 
respectively.   
 
2.1.3.2 Synthesis of Potential SPECT and PET Compounds 141–146 
 
In 2011, Li et al., reported the synthesis of substituted quinoline-2-carboxylates using a 
molecular iodine-catalysed multicomponent reaction.114 These conditions were utilised to 
rapidly assemble quinoline-2-carboxylates 149 and 150 in yields of 50% and 57%, from 
reaction of 4-iodoaniline (155) or 4-fluoroaniline (156) with ethyl glyoxalate (154) and 










155 X = I
156 X = F
149 X = I, 50%
150 X = F, 57%
154 151





Scheme 34. Three-component synthesis of quinoline-2-carboxylates 149 and 150 
 
A proposed reaction sequence for this one-pot, three component process is illustrated in 
Scheme 35.114 Initially, a condensation reaction between 4-iodoaniline and ethyl glyoxalate 
gives imine 157, which undergoes an iodine-catalysed imino-Diels-Alder reaction with 
phenylacetylene (151).  Isomerisation of intermediate 158, and subsequent oxidation of the 

































Scheme 35. Proposed reaction sequence for synthesis of 6-iodoquinoline 149 
 
Preparation of the target compounds was then achieved using the standard synthetic route 
(Scheme 36).  Hydrolysis of the ethyl ester under basic conditions gave carboxylic acids 
147 and 148 in yields of 70% and 82%, respectively.  6-Iodoquinolines 141, 142 and 143 
were then prepared in yields of 92%, 46% and 31% by reaction of acid chloride 160 with 
morpholine, 1-methylpiperazine and diethylamine, respectively.  Similarly, 6-
fluoroquinolines 144, 145 and 146 were prepared in yields of 61%, 56% and 28% from the 












149 X = I
150 X = F
147 X = I, 70%
148 X = F, 82%
160 X = I
161 X = F
141 X = I, R1, R2 = Morpholine, 92% (2 steps)
142 X = I, R1, R2 = 4-Methylpiperazine, 46% (2 steps)
143 X = I, R1 = R2 = Et, 31% (2 steps)
144 X = F, R1, R2 = Morpholine, 61% (2 steps)
145 X = F, R1, R2 = 4-Methylpiperazine, 56% (2 steps)
146 X = F, R1 = R2 = Et, 28% (2 steps)
NaOH, aq. EtOH, !
(COCl)2, DMF, CH2Cl2










CH2Cl2, 0 °C then !
 
 
Scheme 36. Synthesis of potential SPECT and PET compounds 141–146 
 
2.1.3.3 Synthesis of an Additional SPECT Compound 
 
8-Iodoquinoline 162 (Figure 19) was also identified as a potential TSPO imaging agent, 
and it was anticipated that the same synthetic approach used for compounds 141–146 could 










Figure 19. Potential SPECT imaging agent 
 
Initial attempts to prepare quinoline-2-carboxylate 164 utilising the molecular iodine-
catalysed method were unsuccessful, with complex mixtures containing starting material 
forming (Scheme 37).  A subsequent search of the literature provided an alternative 
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procedure by Huang et al., employing a catalytic quantity of copper(II) triflate, for the one-
pot tandem synthesis of 164.115 This method however also proved ineffective for the 
preparation of the 8-iodoquinoline core.  Monitoring the progress of the reaction using 
TLC indicated slow consumption of the 2-iodoaniline starting material, and again 





















Scheme 37. Attempted one-pot multicomponent synthesis of quinoline-2-carboxylate 164 
 
A slight modification to the synthetic route proved successful for the preparation of the 
target compound (Scheme 38).  Condensation of 2-iodoaniline (163) and ethyl glyoxalate 
(154) separately at ambient temperature, using magnesium sulfate as the dehydrating 
agent, afforded imine 165.  This intermediate was then reacted with phenylacetylene (151) 
in the presence of catalytic copper(II) triflate to give 2-iodoquinoline 164 in a 22% yield, 
which was sufficient for completion of the synthetic route.  Hydrolysis of the ester group, 
followed by conversion to the acid chloride and treatment with morpholine gave the 8-





































Scheme 38. Synthesis of potential SPECT compound 162 
 
The low yields obtained for the two-step synthesis of the 2-iodoquinoline core resulted 
from difficulties separating the desired compound from an unidentified side-product.  Chan 
and co-workers have reported that the copper-catalysed Grignard-type addition of an 
acetylene to imine forms a propargylic amine.116 It is proposed that this intermediate then 
undergoes Friedel-Crafts alkenylation affording the target quinoline core.115 However, 
oxidation of the propargylic amine to the corresponding imine prevents this final step 
occurring.  Inspection of the 1H NMR spectrum of the crude reaction mixture indicates that 
this may be the unidentified side-product, however, isolation and full characterisation is 
necessary to confirm this.   
 
With a library of sixteen potential TSPO imaging agents in hand, attention now turned to 




2.1.4 Investigation of Physicochemical Properties 
 
A defining feature of higher organisms is the existence of a central nervous system (CNS), 
which comprises the brain and spinal chord.  Despite the substantial blood flow serving the 
brain, seminal work by Ehrlich and Goldmann proved that the brain and its blood supply 
were in fact separate.117 Numerous studies performed since then have shown that the 
separation of the blood from the CNS is achieved by the presence of two key physiological 
barriers:  the blood brain barrier (BBB) and the blood-cerebrospinal fluid barrier 
(BCSFB).118   
 
2.1.4.1 Blood Brain Barrier  
 
The BBB is formed by a monolayer of cerebrovascular endothelial cells connected by 
complex tight junctions, with enhanced structural and functional support contributed from 




Figure 20. Structure of BBB117 
(Reprinted from A. M. Palmer, Neurobiol. Dis., 2010, 37, 3. Copyright 2010, with 
permission from Elsevier) 
 
Separation of the brain from its blood supply, and the extremely constrained movement of 
molecules across the BBB result almost entirely from the junctions between adjacent 
endothelial cells: tight junctions and adherens junctions (Figure 21).119 Adherens junctions 
are responsible for maintaining the structural integrity of the BBB by ensuring that 
adjacent cells are held together and accomplish this role by the interaction of cadherin and 
catenin proteins through the intercellular cleft.119 Adherens junctions are crucial for tight 
junction formation.  Tight junctions are composed of three integral proteins: occludin, the 
claudins and junctional adhesion molecules.  These proteins form complexes, which are 
linked to the cytoskeleton of adjacent cells by interaction with additional cyctoplasmic 
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proteins such as the zonula occludens.119,120 The presence of these tight junctions force the 
majority of molecules to traverse the BBB in a transcellular rather than paracellular 




Figure 21. BBB tight junctions119 
(Reprinted from N. J. Abbot, A. A. K. Patabendige, D. E. M. Dolman, S. R. Yusof and D. 
J. Begley, Neurobiol. Dis., 2010, 37, 13. Copyright 2010, with permission from Elsevier) 
 
Several functions are associated with the BBB including being concerned with the supply 
of essential nutrients to the brain, removal of metabolites through efflux mechanisms, 
separation of CNS neurotransmitters from the peripheral system and vice versa, and the 
prevention of toxic and infective agents entering the brain.120,122  
 
2.1.4.2 Partition Coefficient 
 
The lipophilicity of a compound is determined experimentally as the partition coefficient, 
and defined as the ratio of concentrations of a compound in a mixture of two immiscible 
layers at equilibrium.123 It is usually displayed as the logarithmic form of the octanol-water 
partition coefficient, LogP (Figure 22), and plays a crucial role in the absorption, 
distribution, metabolism and elimination characteristics of a compound.124 Measurement of 
a compound’s LogP is therefore the most widely used indicator for predicting its ability to 





   [Compound]octanol
[Compound]water
LogP   =   Log
 
 
Figure 22. Equation for calculating LogP of a compound 
 
The partition coefficient of a molecule is traditionally measured using the flask method, 
however, there are some disadvantages associated with this technique; it is time 
consuming, not suitable for all compounds, and influenced by the presence of impurities.  
Other, more modern methods, circumventing these problems include in silico and HPLC 
methods.125,126 In particular, HPLC confers the ability to screen large numbers of 
compounds, and as a technique, it is fast, reliable and reproducible.  It does however, have 
its own limitations, and the most poignant being that it is only able to model hydrophobic 
compound-membrane interactions.127 
 
2.1.4.3 Membrane Partition Coefficient and Permeability 
 
Development of a compound intended for the CNS must take into consideration its ability 
to cross brain capillary endothelial cells.  Penetration of the BBB can therefore be greatly 
affected by solute-membrane interactions.  A characteristic equilibrium constant for 
partitioning into a compound-lipid membrane mixture can be derived for every compound 
and, is defined as the membrane partition coefficient (Km).  This physicochemical 
measurement can be estimated using immobilised artificial membrane (IAM) 
chromatography as it can model hydrophobic and electrostatic interactions.  IAM columns 
are designed to mimic the lipid surface of fluid cell membranes, and are prepared by 




Figure 23. Solute binding to fluid membranes 
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However, it is important to bear in mind that Km cannot be used to directly predict 
membrane transport, as cellular membranes consist of a lipid bilayer.  When a compound 
enters the cytosol it does so by passing through the first lipid membrane.  In order to exit, it 
must then penetrate a second lipid membrane meaning that equilibrium partitioning occurs 
four times overall.  To account for this, an additional measurement is required: 
permeability (Pm).  Permeation of a molecule is directly proportional to Km (Figure 24a), 
where Dm is the membrane diffusion coefficient and L is the membrane thickness.  
Furthermore, Dm is inversely proportional to molecular size, and assuming that molecular 
weight (MW) is proportional to molecular size and membrane thickness remains constant, 
Pm can be calculated from Km (Figure 24b).
128,129  
 
Pm  =  DmKm
L





Figure 24. Equations relating Km and Pm  
 
Limitations to this methodology do exist, including the assumption of passive diffusion 
across the BBB.  It is well known that other forms of active transport mechanisms and 
efflux pumps are utilised by the BBB,118 and that this should be considered when applying 
IAM chromatography for compound selection. 
 
2.1.4.4 Plasma Protein Binding 
 
When a compound intended for the CNS enters the blood stream, in addition to the 
challenge of crossing the BBB, it also faces potential binding to proteins present in blood 
serum.  Many plasma proteins exist with human serum albumin (HSA) and %1-acid 
glycoprotein (AGP) being the two most abundant.130 If a compound exerts high plasma 
protein binding, this can have several implications for drug and radiotracer development, 
including low brain penetration and low blood clearance.131 A low level of brain 
penetration results from a reduction in the fraction of unbound compound available to 
cross the BBB, and is attributed to high lipophilicity.  Consequently, deposition of the 
radiotracer within peripheral organs is often observed.132 Overall, these notable problems 
can have a considerable effect on the quality and accuracy of image and data acquisition.          
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Valko et al., have developed a fast and simple HPLC method, utilising a HSA modified 
chromatographic material to determine plasma protein binding associated with a particular 
compound.131     
 
2.1.4.5 HPLC Measurement of Physicochemical Properties 
 
Tavares et al., have indicated that a compounds physicochemical properties can be used to 
predict its ability to penetrate the BBB.133 Correlations between HPLC derived 
measurements and in vivo data were established and parameters set to aid lead compound 
selection (Table 6).  However, it should be emphasised that these parameters are for 
compound ranking and guidance purposes only.  The overriding advantages of this method 
are that it is quick, reproducible and enables the rapid elimination of unsuitable analogues.  
Percentage injected dose (% ID) and binding potential (BPND) are commonly used 
indicators of radiotracer performance,134 and will facilitate compound selection for 
radiotracer development.    
 
Parameter HPLC Measurement Predicted in vivo Measurement 
Pm  < 0.5  ID > 4.0% 
Km  < 250  BPND > 2.0
* 
%PPB  < 95%  ID > 2.0% 
* BPND defined at equilibrium as the ratio of specifically bound to non-displaceable 
radiotracer 
 
Table 6. Proposed selection criteria for aiding lead compound identification 
 
The library of quinoline-2-carboxamides was subject to the HPLC methods described, and 
the physicochemical properties of each compound measured (Table 7).  PK11195 was 
included as the standard enabling direct comparison.   
 
An initial observation highlights that the HPLC measured cLogP values are generally 
greater than the recommended 1–3.5 for CNS compounds,132 with the exception of 
analogues 84 and 86.  The cLogP values obtained from ChemDraw Ultra 9.0.1 are also 
included, and a striking lack of consistency amongst the two methods is evident.  For some 
analogues, there is very little difference between the two measurements.  However, an 
obvious discrepancy for others exists, e.g. a difference of 2.89 versus 4.37 for in silico and 
! ($!
HPLC values, respectively are observed for 85.  This lack of method uniformity has been 
observed by others,133 and is why additional physicochemical measurements for Pm, Km 
and %PPB are obtained. 
 
Based on these additional HPLC measurements, ten compounds in total were selected as 
displaying physicochemical properties within (blue), or only marginally outside of (red), 
defined parameters.  Inclusion of an iodine atom has a noticeable effect on a compound’s 
lipophilicity, with the majority eliminated from future studies.  Ideally, all compounds 
would be subject to biological investigation, but due to limited resources only those with 
the correct physicochemical profile or ability to contribute to the SAR were selected.  This 
reasoning forms the basis for selection of iodoquinoline 120 and exclusion of 81.  
 




























3.35 4.11 0.29 103.02 91.87 
* Taken from literature.133 Physicochemical properties determined using a ChemDraw Ultra 
9.0.1, b C18 column (mean ± SD, n = 3), 
c IAM column, and d HSA column (mean ± SD, 
n=3) 
 
Table 7. In silico and HPLC determined physicochemical properties 
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4.09 5.19 0.55 244.35 95.38 
Physicochemical properties determined using a ChemDraw Ultra 9.0.1, b C18 column 
(mean ± SD, n = 3), c IAM column, and d HSA column (mean ± SD, n = 3) 
 
Table 7 (cont.). In silico and HPLC determined physicochemical properties 
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4.09 5.69 0.41 182.15 98.19 
Physicochemical properties determined using a ChemDraw Ultra 9.0.1, b C18 column 
(mean ± SD, n = 3), c IAM column, and d HSA column (mean ± SD, n = 3) 
 
Table 7 (cont.). In silico and HPLC determined physicochemical properties 
 
In addition to BBB penetration, a high binding affinity with the molecular target is 
essential for an imaging agent targeting the brain.  Having selected eleven analogues for 
progression, the next stage of the project involved biological investigation. 
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2.1.5 Biological Evaluation 
 
Quantification of the in vitro binding interactions of each compound for the TSPO was 
determined using a competitive binding assay with whole rat brain homogenate.  The 
inhibition constant (Ki) of a ligand denotes affinity of a ligand for a receptor and is defined 
as the concentration of unlabelled competing ligand that occupies 50% of binding sites in 
the presence of radioligand at equilibrium.135 Generation of a sigmoidal dose response 
curve by plotting radioligand binding (disintegrations per minute) versus log[unlabelled 
ligand], provides a means from which the Ki value of a compound can be calculated.  A 
representative competition binding curve for PK11195 is illustrated (Figure 25a). 
 
Two important features of a competition binding experiment must be taken into 
consideration: total binding and non-specific binding.  Total binding refers to the binding 
of a radiolabelled ligand in the absence of a competitor and is represented by the top 
plateau of the binding curve.  In addition, ligands have a tendency to bind to components 
other than the sites of interest, e.g. membranes and other protein receptors, and are referred 
to as non-specific binding.  This characteristic can be measured by exploiting the 
saturability of the protein target, and is achieved experimentally by addition of a large 
excess of the unlabelled ligand in the presence of a much lower concentration of 
isotopically labelled ligand.  The bottom plateau of the curve represents non-specific 
binding.  The specific binding of a ligand is therefore calculated by subtracting 
non-specific binding from total binding.   
 
The Ki of a compound is the equilibrium point in the curve, and is calculated from the IC50 
value using the Cheng-Prusoff equation (Figure 25b),136 where IC50 is the half maximal 
inhibitory concentration, [L] is the concentration of free radioligand, and Kd is the 
equilibrium dissociation constant for radioligand binding to the receptor.  This calculation 
was performed by non-linear regression analysis using GraphPad Prism 4.0 (GraphPad 
Software Inc).   
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Figure 25. a) Representative PK11195 sigmoidal dose response curve, and b) Cheng-
Prusoff equation 
 
The binding affinities of the quinoline-2-carboxamides selected are listed (Table 8).  From 
the results obtained it is evident that replacement of the pendant phenyl ring of the ligand 
has a negative impact on binding affinity with the TSPO.  Compared to 80, with a low Ki 
value of 1524 nM, substitution of the phenyl for a heterocyclic moiety further reduces 
binding affinity, as illustrated by quinoline-carboxamides 84–86.  The Ki values obtained 
for these analogues ranged from approximately 5000–100000 nM.  It has been proposed 
that the pendant phenyl provides a dispersive, space filling role enabling binding within the 
hydrophobic binding pocket of the TSPO.137 A reasonable conclusion may therefore be 
that despite imparting more favourable physicochemical properties on the molecule, 
replacement of the phenyl ring with an alternative heterocycle greatly diminishes binding 
affinity with the TSPO. 
 
It was anticipated that the presence of the ortho-bromide substituent on the phenyl ring of 
82 would generate a more rigid molecule, resulting in an increase binding affinity with the 
protein, but the Ki value of this compound was found to be in the low micromolar range 
(3600 nM).  It is probable that the dimethyl amide side chain is too small for effective 
restricted rotation of the amide bond, resulting in low binding affinity with the TSPO.  
Incorporation of a 3-methyl group in the quinoline ring of 83, however, results in a 
substantial increase in potency by affording a Ki value of 103 nM.  The proximity of the 
methyl group at the C-3 position to the dimethyl amide may provide enough steric 
interference to restrict rotation of this bond, encouraging a greater H-bonding interaction 
with a carboxylic acid side chain within the lipophilic binding pocket of the protein.138 
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Morpholine amide 121 was shown to have a relatively low binding affinity for the protein 
with a Ki value of 929 nM.  This was a somewhat surprising outcome, and may be due to 
the inability of the ligand to adopt the optimum binding conformation, resulting from the 
presence of the large ortho-iodine atom and the relatively large amide side chain.  
However, a more favourable binding affinity for TSPO was found with diethyl amide 
compound 120.  The Ki value of this compound was measured at 5.01 nM, which when 
compared to the PK11195 standard, shown to be twice as potent.  This result shows that 
the large ortho-iodine atom provides enough steric bulk to restrict rotation of the diethyl 
amide effectively, advantageously allowing greater electrostatic interactions with the 
protein.  
 
Compounds 141 and 162 were found to have a particularly low binding affinity for the 
TSPO, with Ki values of 29890 and 76100 nM, respectively.  It is evident from these 
results that the inclusion of an iodine atom at both the 6- and 8-position of the benzene ring 
of the quinoline moiety has a very negative effect on binding to the target protein.  
Furthermore, compound 144 bearing a fluorine atom at the 6-position of the quinoline was 
deemed to have greater than 5-fold increase in binding affinity with the TSPO compared to 
the analogous iodide compound.  Overall, these results demonstrate that the presence of a 
much larger substituent on the phenyl ring of the quinoline impedes binding to the protein.  
An unsubstituted phenyl ring appears to be required for molecular recognition of the 
quinoline pharamcophore.        
                   
Structure Ki (nM)




























18722 ± 228 
a 
Ki values determined from independent experiments (mean ± SD, n = 3), except for those 
marked * (mean ± SD, n = 2) 
!
Table 8. Binding affinity of quinoline-2-carboxamides with the TSPO 
! (*!
Structure Ki (nM)



























































76100 ± 6550* 
a 
Ki values determined from independent experiments (mean ± SD, n = 3), except for those 
marked * (mean ± SD, n = 2) 
 




In total, sixteen PK11195 analogues with the potential for molecular imaging applications 
have been prepared.  A combination of routine synthetic transformations in conjunction 
with relatively novel one-pot multicomponent reactions has enabled preparation of a small 
library of structurally diverse compounds.  Despite repeated attempts to effect a key 
halogen exchange reaction for the generation of potential SPECT imaging agent for the 
TSPO, the ortho-position of the pendant phenyl ring was deemed too inaccessible.  
Nevertheless, an alternative diazotisation-Sandmeyer sequence was successfully employed 
for the preparation of these targets. 
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An effort to eliminate unsuitable compounds from the study, based on their lipophilicity, 
was achieved utilising HPLC methodologies.  The behavior of each compound in vivo was 
predicted using a series of physicochemical parameters (LogP, Km, Pm and %PPB) with 
defined limits.  This enabled ranking of the compounds relative to PK11195, and those 
with improved properties were selected for progression to the next stage of the project.  As 
these limits are used for guidance purposes only, certain compounds were progressed 
despite displaying high lipophilicity in some respects.   
 
Having selected eleven analogues based on their physicochemical properties or interesting 
structure, the binding affinity of each compound with the TSPO was measured by means of 
a competitive binding assay.  The majority of the compounds were shown to have low 
binding affinities with the protein with Ki values in the micromolar range.  However, two 
novel TSPO ligands displayed nanomolar affinity with the most potent having a Ki value of 
5.01 nM.   
 
Overall, an attempt to lower compound lipophilicity with the ultimate aim of reducing non-
specific binding and improving biodistribution was achieved.  However, this was not 
achieved in conjunction with maintaining high binding affinity for the protein target.  
 
2.2 Development of [18F]AB5186; A Potential PET Imaging 
Agent for the TSPO 
 
Results obtained from the previous study, in conjunction with information available in the 
literature, highlighted that a pendant phenyl ring and restricted rotation of the amide bond 
of the TSPO ligand was imperative for potent binding affinities.  A study published by 
Stevenson et al., focusing on the development of quinoline-2-carboxamides as potential 
SPECT imaging agents for the TSPO reported the synthesis of compounds 168 and 169 
(Figure 26) both of which displayed nanomolar affinity with the protein.89 However, the 
lipophilic nature of the iodine atom creates unfavourable physicochemical properties, and 
renders such compounds unsuitable for targeting the brain.  In an effort to overcome these 
problems, it was anticipated that retention of key structural features in combination with 
the presence of the less lipophilic fluorine atom of 170 would generate a potential PET 
imaging agent for the TSPO (Figure 26).  Additionally, quinoline-2-carboxamide 171 has 
been utilised previously as a [11C]-labeled TSPO ligand, and was identified as a potential 




















169 Ki = 26.1 ± 4.7 nM  
 
Figure 26. Potential PET Imaging agents 170 and 171 
 
2.2.1 Retrosynthetic Analysis of PK11195 Analogues 170 and 
171 
 
The retrosynthetic analysis of the target PET compounds 170 and 171 is shown in Scheme 
39.  The proposed synthetic route requires an initial functional group interconversion of the 
aliphatic fluoride 170 and 171 to the primary alcohol 172 and 173.  A subsequent 
disconnection of the amide bond results in lactone 174, which is further disconnected at the 
C-O bond resulting in intermediate diol 175.  This diol can be prepared from lactone 176, 
which is generated via intramolecular cyclisation of quinoline 177.  Finally, disconnection 
of the quinoline moiety of 177 affords commercially available 2-aminobenzophenone 





























170 R1 = R2 = Et
171 R1 = Me, R2 = Bn
172 R1 = R2 = Et







Scheme 39. Retrosynthetic analysis of PET compounds 170 and 171 
 
The key step in the preparation of compounds 170 and 171 is the ability to convert the 
primary alcohol 172 and 173 to the target 3-fluoromethyl analogues 170 and 171.  
Additionally, these hydroxyl-containing compounds will also act as the radiolabelling 
precursors for in vitro and in vivo imaging studies.  
 
2.2.2. Synthesis of Potential PET Compounds 170 and 171 
 
The acid- or base-catalysed condensation reaction between an aromatic 2-amino 
substituted carbonyl compound and a ketone bearing a reactive %-methylene group, 
followed by a cyclodehydration reaction is known as the Friedländer synthesis.139 This 
transformation is employed for the synthesis of substituted quinoline rings, and was used 
as the starting point for the synthesis of target compounds 170 and 171.  As such, quinoline 
177 was prepared in an excellent 98% yield via a trimethylsilyl chloride-mediated 
Friedländer condensation between 2-aminobenzophenone (178) and ethyl 4-
















Scheme 40. Synthesis of quinoline 177 
 
The second step of the synthesis required formation of lactone 176 (Scheme 41).  Initially, 
this reaction was performed under acidic conditions using a 6 M aqueous hydrochloric acid 
solution, and the desired product 176 was obtained in a 73% yield (Table 9, Entry 1).  
However, the drawback of this reaction was that it required stirring under reflux conditions 
for 4 days, to obtain acceptable quantities of product.  This was deemed too inefficient for 
an early step in the synthesis, and so alternative reagents for the transformation were 
investigated (Table 9).  Briefly, when trifluoroacetic acid and caesium carbonate were 
employed, no desired product was formed (Entries 2 and 3).  A subsequent attempt using 
silver nitrate proved more successful,141 with a 58% yield of lactone 176 being obtained 
(Entry 4).  Still, a greater isolated yield was sought and a procedure by Goto and co-
workers utilising dimethylsulfoxide was employed.142 In this instance, the cyclised product 
176 was obtained in a 63% yield (Entry 5), with only a 5% improvement in yield over the 
use of silver nitrate.  Granted that the latter two reaction conditions afforded the desired 
product, the use of silver nitrate and dimethylsulfoxide offered lower product yields 



















Entry Reagents Conditions Yield 176 (%) 
1 6 M HCl EtOH, ' , 4 days 73 
2 TFA r.t, 24 h - 
3 Cs2CO3 H2O/MeOH, ', 24 h - 
4 AgNO3 H2O/1,4-dioxane, 90 °C, 72 h 58 
5 DMSO 120 °C, 18 h 63 
 
Table 9. Conditions trialed for lactonisation 
 
The wish to avoid the use of these reagents and improve the overall synthesis of the target 
carboxamides meant that an alternative synthetic route was sought.  One such route 
involved preparation of quinoline dicarboxylate 181 (Scheme 42).  Addition of diethyl 
acetylenedicarboxylate (180) to 2-aminobenzophenone (178) and subsequent quinoline 
synthesis was initially attempted using triphenylphosphine to effect an intramolecular 
Wittig reaction.143 However, only trace amounts of product were formed while trialing 
these conditions.   On the other hand, when indium(III) chloride was employed for this 
reaction under solvent free conditions (Scheme 42), quinoline 181 was obtained in 
quantitative yield and a very short reaction time.144 This reaction presumably proceeds via 















Scheme 42. Synthesis of quinoline dicarboxylate 181 
 
Reduction of the ethyl ester groups of 181 to diol 175 was then necessary for continuation 
of the synthetic route (Scheme 43).  A number of reducing agents were investigated for 
this transformation including diisobutylaluminium hydride, lithium aluminium hydride, 
lithium borohydride and sodium borohydride.  Surprisingly, the majority of the reaction 
conditions employed did not yield the intended product, nor did the reactions progress 
cleanly.  The main product identified from reduction of 181 with sodium borohydride was 
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lactol 182 (Scheme 43), and so the reaction was optimised to afford this unexpected 




















Scheme 43. Synthesis of lactol intermediate 182 
 
Next, oxidation of lactol 182 to lactone 176 was achieved in 83% yield using 
manganese(IV) oxide, and from this point, the original synthetic route could be pursued 
(Scheme 44).  Introduction of the appropriate amide side chain within the molecule 
required switching the lactone from the C-3 to C-2 position, and was achieved in two steps.  
Firstly, reduction of the lactone to diol 175 was achieved in 77% yield using lithium 
aluminium hydride.145 Small quantities of dihydroquinoline are formed during this 
reaction, and 10% Pd/C is added to reform the quinoline core.  Subsequent regioselective 
oxidation, in the presence of manganese(IV) oxide converted diol 175 to the desired 
lactone 174 in a high 92% yield.  Repositioning of the lactone functionality lends the 
molecule to inclusion of the appropriate amide side chains under aminolysis conditions.138 
As such, lactone 174 was reacted with diethylamine and N-benzylmethylamine in the 
presence of a trimethylaluminium solution, affording quinoline-2-carboxamides 172 and 






















172 R1 = R2 = Et, 61%





1. LiAlH4, THF, 0 °C









Scheme 44. Synthesis of quinoline-2-carboxamides 172 and 173 
 
Efforts to convert the hydroxyl group of compound 172 to an effective leaving group failed 
under standard conditions.  Generally, a tosylate or mesylate is the leaving group of choice 
for substitution reactions in mainstream organic synthesis, and this is also true of 
radiochemistry.146,147 As such, incorporation of these leaving groups into the benzylic 
position of 172 was attempted, but unfortunately both transformations were unsuccessful 
(Scheme 45).  Analysis of the crude reaction mixtures by 1H NMR spectroscopy indicated 
that in both cases, only starting material remained.  It can therefore be reasonably assumed 
that the failure of these reactions is the result of inaccessibility of the di-ortho substituted 



























Scheme 45. Attempted tosylation and mesylation of quinoline-2-carboxamide 172 
 
An alternative and smaller leaving group was therefore required for this transformation and 
halogenation of the benzylic position of 172 and 173 was considered (Scheme 46).  
Chlorination of hydroxyl compounds 172 and 173 using thionyl chloride gave chloro-
! )(!
precursors 185 and 186 in quantitative yields (Scheme 46).  Finally, substitution of the 
chloride for fluoride utilising potassium fluoride in the presence of 18-crown-6,148 afforded 






172 R1 = R2 = Et
173 R1 = Me, R2 = Bn
185 R1 = R2 = Et, 100%
186 R1 = Me, R2 = Bn, 100%
170 R1 = R2 = Et, 60%















Scheme 46. Synthesis of potential PET compounds 170 and 171 
 
Investigation of the physicochemical properties and biological binding affinity of 
quinoline-2-carboxamides 170 and 171 with the TSPO was required for the next stage of 
this project. 
 
2.2.3 Measurement of Physicochemical Properties and 
Biological Evaluation 
 
The partition coefficient (cLogP), and other key physicochemical properties including 
permeability (Pm), membrane partition coefficient (Km) and plasma protein binding (PPB), 
associated with compounds 170 and 171 were measured by HPLC methods (Table 10).  
Again, using established limits of these parameters (Pm<0.5, Km<250, %PPB<95), this 
would allow the prediction of in vivo performance.  From Table 10, it is evident that both 
compounds display very high cLogP values compared to PK11195, but the necessity of 
additional lipophilicity measurements has been discussed previously.  Compared to 
PK11195, both compounds display better permeability and lower membrane partition 
coefficient, implying that they will exhibit better BBB penetration and reduced non-
specific binding characteristics in vivo.  In addition, compound 170 shows reduced binding 
to plasma protein compared to PK11195.  Next, the binding affinities of ligands 170 and 
171 with the TSPO were evaluated using a competition binding assay.  Both were shown 
to have nanomolar affinity for the protein, with compound 170 displaying the greatest 
potency. Similar to PK11195, the diethyl amide has a Ki value of 2.79 nM, and is likely 
! ))!
due to the 3-fluoromethyl group restricting rotation of the amide bond within the H-



























5.95 0.28 108.90 95.67 11.96 ± 3.33 
* Taken from literature.133 Physicochemical properties determined using a C18 column 
(mean ± SD, n = 3), b IAM column, c HSA column (mean ± SD, n = 3), and d Ki values 
determined from independent experiments (mean ± SD, n = 3) 
 
Table 10. HPLC measured physicochemical properties and biological evaluation of 
quinoline-2-carboxamides 170 and 171 
 
From the results obtained, compound 170 was selected for having improved 
physicochemical properties over PK11195, and similar binding potency with the TSPO.  It 
was therefore determined that this compound should be progressed to the next stages of 
radiotracer development.  Quinoline-2-carboxamide 170 is referred to as AB5186 from this 
point onwards. 
 
2.2.4 Stability Testing 
 
As AB5186 170 bears a fluoroalkyl substituent, a potential alkylating agent, in vitro 
stability of the compound under physiological conditions was investigated.  A solution of 
the unlabelled compound in a 1:1 mixture of acetonitrile/phosphate buffered saline was 
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maintained at 37 °C for 24 hours, and sampled at the times specified (Table 11).  From the 
results obtained it is evident that after an incubation period of 6 hours, only minimal 
decomposition (0.03%) of the compound has occurred (Table 11, Entry 5 and Figure 27).  
The presence of the bulky di-ortho-substituents in combination with the relatively strong 
C-F bond (approx. BDE 413 kJ/mol) imparts stability on the compound.149,150   
 
This study indicated that AB5186 170 could be progressed, as toxicity issues arising from 
alkylation were not apparent at this stage.  Furthermore, a patient is normally scanned 2–4 
hours after administration of a radiotracer, and it doesn’t appear that rapid defluorination at 
the aliphatic position will be problematic.  However, a more robust and detailed in vivo 
investigation will be required at a later date to confirm these preliminary findings. 
 
Entry Time (h) Compound Purity (%) 
1 0 98.81 
2 1 98.75 
3 2 98.76 
4 4 98.80 
5 6 98.78 
6 24 91.94 
 




Figure 27. Representative analytical HPLC trace of unlabelled AB5186 170 stability test 
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2.2.5 Synthesis of [18F]AB5186 
 
Previous attempts to generate a tosylate or mesylate precursor for the cold fluorination 
reactions failed, and so a halogen exchange reaction was revisited for the preparation of an 
[18F]-labelled version of AB5186.  A key factor in the development of any radiolabelling 
procedure is the ability to isolate with ease, precursor from unlabelled standard and/or 
radiotracer.  In this instance, a semi-preparative HPLC system was employed for 
separation of the chloride precursor (tr = 11.841 minutes) and AB5186 standard (tr = 7.803 




Figure 28. UV chromatogram showing chloride precursor 185 and cold AB5186 standard 
170 co-injection on semi-preparative HPLC system 
 
Having found a suitable mobile phase enabling efficient separation of precursor and 
standard on both semi-preparative and analytical HPLC systems, the synthesis of 
[18F]AB5186 was investigated.  Chloride 185, the penultimate compound in the synthesis 
of cold AB5186, was subject to standard aliphatic radiofluorination conditions, utilising 
[18F]potassium fluoride, Kryptofix® and potassium carbonate at 100 °C for 12 minutes 
(Scheme 47).  Application of these conditions afforded [18F]AB5186 170 with a percentage 
incorporation of 66.1 ± 10.7% (n = 3), and radiochemical yield of 35 ± 9% (DC) in 118 ± 
24 minutes (n = 3).  The specific activity of [18F]AB5186 was determined using a 
concentration response curve and measured at 0.6 ± 0.2 Ci/µmol (n = 2).  A typical 














MeCN, 100 °C, 12 min
185
Radiochemical Yield = 35 ± 9% (DC)
Radiochemical Purity = >99%
Specific Activity = 0.6 ± 0.2 Ci/µmol
[18F]AB5186 170  
 




Figure 29. Representative radio-HPLC trace for [18F]AB5186 synthesis  
 
Quality control was performed on a semi-preparative HPLC system to ensure that the 
radiochemical purity after formulation was of a high enough standard.  The radiochemical 
purity of the final radiofluorinated compound (tr = 5.591 minutes) was determined by 
integration of the peaks present in the radiotrace (Figure 30) and found to be >99% (n = 3). 
The identity of the radiolabelled compound was confirmed by co-injection of the QC 





Figure 30. UV chromatogram overlay of AB5186 standard (blue trace) and QC sample 
(black trace) co-injection 
 
Having successfully radiolabelled the lead candidate, the next stage of this research 
programme required provision of an initial proof of concept study, whereby, a 
demonstration that [18F]AB5186 could, in fact, be utilised to image the TSPO. 
 
2.2.6 In vitro Autoradiography Study of a Human Glioblastoma 
Mouse Model using [3H]PK11195 and [18F]AB5186   
 
Autoradiography is an imaging technique used to detect and visualise the distribution of a 
radiolabelled compound bound to a solid biological section, and relies on the use of a 
radiation-sensitive film.151 As an imaging technique it offers a few advantages: rapid, 
simple in practice, and can offer quantitative information.  In vitro autoradiography is a 
particularly useful autoradiographic technique that can be employed to investigate the 
distribution and localisation of receptors within the central nervous system, and do so with 
sensitivity at a relatively inexpensive cost.152 
 
The TSPO has been for some time, a target of interest for studying patients affected by a 
range of pathological conditions including, but not limited to neurodegenerative disorders, 
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stroke and brain injury.21 More recently, the implication of TSPO upregulation in tumours 
has garnered considerable interest.  A number of studies have shown that this protein plays 
a significant role in the development and maintenance of a plethora of different cancers 
including cancers of the breast, colon, prostate, mouth and brain.153,154,155 Furthermore, 
studies have revealed that there is a remarkable increase in TSPO expression within cancer 
cells of aggressive tumours,156 and radioligands targeting this protein can therefore be 
exploited as a prognostic biomarker for metastasis and cancer imaging.  
 
As such, we sought to determine whether our candidate tracer, [18F]AB5186 could be 
utilised as a radioligand for TSPO in brain tumours, and more importantly, whether our 
radioligand provided superior binding characteristics compared to the ‘gold standard’, 
PK11195.  The potential of [18F]AB5186 binding to TSPO expressed in brain tumours was 
therefore investigated using an orthotopic mouse model of human glioblastoma prepared 
and provided by colleagues from The Beatson Institute for Cancer Research.  Preparation 
of the disease model was achieved by injection of 105 cultured G7 glioblastoma cells 
directly into the caudate nucleus of a CD1 nude mouse.157 Prior to commencement of the 
autoradiography study, location of the tumour within the mouse brain was determined 
using a haematoxylin and eosin stain.  Haematoxylin and eosin staining is a histological 
stain that is routinely used in clinical settings,158 and comprises two different dyes: 
haematoxylin and eosin.  Haematoxylin stains nucleic acids a dark purple colour, and can 
be used to visualise rapidly replicating cells, whereas eosin stains proteins and other 
cellular components a pink colour.  Consideration of the stained brain section (Figure 31) 
revealed the presence of a large and locally invasive tumour of unilateral expression.  
Despite the distorted morphology of the contralateral hemisphere, there was no evidence 
that tumour infiltration or inflammation had occured. 
     
 
 
Figure 31. Haemotoxylin and eosin stained section of a mouse intracranial xenograft 






The in vitro autoradiography study showed that the total binding of [3H]PK11195 was 
greater within the tumour tissue compared to that of the contralateral tissue (Figure 32a).  
Furthermore, a remarkably similar pattern of total radioligand binding was observed for 
[18F]AB5186, with greater binding evident in the tumour tissue compared to the 
contralateral hemisphere (Figure 32b).  
 
In addition to poor brain penetration, the utilisation of PK11195 as a TSPO ligand for brain 
imaging studies confers the further limitation of significant levels of non-specific binding 
to plasma proteins, resulting in a low signal to noise ratio.  The levels of non-specific 
binding associated with PK11195 and AB5186, in both the tumour and unaffected tissue of 
the disease model, was determined by incubation of the brain sections with either 
[3H]PK11195 or [18F]AB5186 in the presence of excess unlabelled PK11195.  Non-
specific binding of the radioligand was defined as the optical density signal derived from 
the resulting autoradiogram and measured using MCID basic 7.0 software.  The results are 
shown in Figure 32 and Table 12.  In the presence of excess unlabelled PK11195, 55% of 
[3H]PK11195 was displaced from the tumour tissue, and 25% from the contralateral tissue 
(Figure 32c, Table 12).  It would be expected that 100% displacement of [3]PK11195 
would occur in the presence of an excess of unlabelled PK11195, however, this was not the 
case.  This isoquinoline has been described as “sticky”, which appears to be an appropriate 
description in this instance, and serves to highlight the limitations of using PK11195 as an 
imaging agent for the brain.  In addition to total binding and non-specific binding 
displayed by the radioligands, the level of specific binding of these compounds within the 
glioblastoma mouse model was also determined, the results of which are listed in Table 12.  
Specific binding (defined as optical density in the absence of unlabelled ligand minus 
optical density in the presence of unlabelled ligand) for [3H]PK11195 was measured to be 
four times greater in the tumour tissue than the contralateral tissue.   
 
In the presence of excess unlabelled PK11195, 76% of [18F]AB5186 was displaced from 
the tumour tissue, and 23% from the contralateral tissue (Figure 32d, Table 12).  
Furthermore, the specific binding of [18F]AB5186 was measured to be eleven times greater 
in the diseased compared to unaffected tissue (Table 12).  These preliminary findings 
indicate that this lead candidate tracer has the potential to act as a PET radioligand for 
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Figure 32. Representative autoradiograms showing total binding: a) [3H]PK11195 and b) 
[18F]AB5186 and, non-specific binding in the presence of excess cold PK11195: c) 














[3H]PK11195 55% 25% 4:1 
[18F]AB5186 76% 23% 11:1 
 
Table 12. Measurement of radioligand displacement by cold PK11195 and ratio of specific 
binding (tumour:contralateral tissue) 
 
Information obtained from in vitro studies is beneficial as it provides an indication as to 
whether a compound should be progressed for development.  However, this information is 
limited and only in vivo investigations can provide an accurate insight into the behavior of 






Initial attempts to prepare the quinoline-2-carboxamide targets focused on a Friedlander 
reaction followed by lactonisation of the resulting product.  This latter step, however, 
proved very time consuming, and several attempts to improve this transformation were 
trialed but deemed unsatisfactory.  As such, an alternative synthetic strategy was sought.  
Preparation of the PK11195 analogues was subsequently achieved via an expeditious 
eight-step synthesis.  This route proved to be quick to execute and efficient, with a key 
one-pot two component indium(III)-catalysed cyclocondensation reaction utilised for the 
synthesis of the quinoline core.  
 
Both analogues displayed good physicochemical properties and their binding affinity with 
the TSPO shown to be in the nanomolar range.  In particular, quinoline-2-carboxamide 
170, subsequently named AB5186, was deemed to have lower binding to plasma protein 
and improved permeability compared to PK11195.  Furthermore, the Ki value of this 
compound (2.79 nM) was comparable to that of PK11195 (3.10 nM).  
 
Synthesis of an [18F]-labelled version of AB5186 was achieved via an SN2 reaction under 
standard aliphatic radiofluorination conditions, affording the radiotracer in good 
radiochemical yield and high radiochemical purity.  An in vitro autoradiography study with 
a mouse intracranial G7 human glioblastoma xenograft has revealed that [18F]AB5186 has 
potential application as an imaging agent for neuroinflammation associated with focal 
neurological disease.   
 
2.2.8 Future Work 
 
Future work centered on the development of [18F]AB5186 as a PET imaging agent for the 
TSPO is currently underway. An intensive in vivo PET study comprising two stages has 
been initiated; the first is designed to measure the kinetic profile of the radiotracer and the 
second, to perform a pre-blocking study with unlabelled PK11195.  Both studies will 
utilise a characterised U87 luciferase glioblastoma mouse model.  The kinetic profiling 
study aims to determine the time required for maximal [18F]AB5186 uptake within the 
target to occur, which can then be applied to the pre-blocking study.  This latter study will 
examine the specificity of radiotracer binding, i.e. whether or not AB5186 and PK11195 
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compete for the same TSPO binding sites.  In addition, the metabolic profile of 
[18F]AB5186 will be examined through blood sampling and subsequent HPLC analysis.   
 
If these preliminary results are encouraging additional in vivo studies, e.g. measurement of 
the binding profile within human tissue, will be initiated with the ultimate aim of 
progressing [18F]AB5186 to the clinic.   
! *)!




Deoxyribonucleic acid (DNA), the molecule from which our genetic material is composed, 
contains the instructions necessary for creating and maintaining life.  As such, the human 
genome is a vastly complex system that is continuously sustaining high levels of damage 
originating from both endogenous and exogenous sources.  Endogenous sources include 
biological processes, e.g. DNA replication and repair, and exposure to genotoxic agents, 
such as reactive oxygen species formed during metabolism.159,160 Damage resulting from 
exogenous sources, on the other hand, arise from exposure to external radiation and 
chemical agents.161 The consequence on the structural integrity of DNA are, therefore, 
wide and varied, and classified according to the type of changes inflicted.  Furthermore, in 
an effort to rectify these abberations and minimise the probability of a genetic mutation 
occuring, a range of extensive repair mechanisms has evolved.  
 
DNA lesions in the form of single-strand breaks (SSBs) and double-strand breaks (DSBs) 
are just two examples of the types of damage routinely caused.  DSBs involve both strands 
of the double helix, and are remedied by non-homologous end joining (NHEJ) and 
homologous recombination (HR), whereas SSBs affect just one strand of the DNA duplex, 
and are rectified by base excision repair (BER).162  SSBs and the BER pathway form the 
premise for this research program.            
 
3.1.1 PARP-1: Structure and Function 
 
Poly(ADP-ribose) polymerases (PARP) are a family of proteins found in eukaryotic cells 
responsible for the regulation of a variety of nuclear signal transduction pathways.163 When 
activated, they are responsible for catalysing the addition of long linear or branched 
poly(ADP-ribose) chains to target proteins.164 At present, this superfamily comprises 18 
members, but despite all bearing the strictly conserved catalytic domain,165 only six 
(PARP-1 to 4, and tankyrases 1 and 2) exhibit the poly(ADP-ribosylation) activity 
charactersitic of this family of proteins.166  
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PARP-1 is an abundant, chromatin bound protein that constitutes approximately >90% of 
total cellular PARP activity, and partners with closely related PARP-2 to function as a 
DNA damage sensor and ensuing response enzyme.167,168 This 113 kDa protein consists of 
three distinct domains that allow it to perform this function: the DNA-binding domain, the 
automodification domain, and the catalytic domain.160 As its name suggests, the N-
terminal DNA-binding domain is responsible for recognition and binding to SSBs 
primarily, but includes DSBs, and does so using two highly conserved zinc fingers.169 A 
third zinc finger also exists, however, it is not thought to partake in DNA binding.170 
PARP-1 is constitutively expressed in a basally active form, but on binding to transient and 
localised DNA strand breaks, the C-terminal catalytic domain is activated.171 When this 
occurs, the protein rapidly catalyses the cleavage of nicotinamide adenine dinucleotide 
(NAD+) forming nicotinamide and ADP-ribose moeities, and subsequently transfers the 
resulting ADP-ribose units to various target proteins (Figure 33).164 This results in the 
formation of the long poly(ADP-ribose) (PAR) chains mentioned previously.  Finally, the 
automodification domain, covering the central portion of the protein, displays glutamate 
and lysine residues required to accept the ADP-ribose moieties, essentially allowing the 




Figure 33. Formation of poly(ADP-ribose) chains173  
(Reprinted with permission from J. Med. Chem., 2010, 53, 4561.  Copyright 2010 
American Chemical Society.) 
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Implementation of SSB repair by PARP-1 occurs in the following manner: a DNA lesion is 
recognised and bound to, which signals the relevant repair proteins, and the enzymatic 
function of PARP-1 is then activated.  Histone proteins, and PARP-1 itself, are 
subsequently poly(ADP-ribosyl)ated, resulting in the generation of large PAR chains 
bearing a substantial negative charge.174  The resulting charge repulsion experienced by the 
DNA and modified proteins, leads to relaxation of the chromosomes, and following 
poly(ADP-ribose)glycohydrolase (PARG) cleavage of the PAR chains, PARP-1 is 
subsequently inactivated and disassociates from the DNA.173 This enables proteins 
associated with the BER pathway, including XRCC1, DNA Polymerase # and LIG-III%, 
greater access to the damaged DNA.173,175 Repair of the DNA strand break can now take 




Figure 34. Function of PARP-1 in single-stranded DNA break repair162  
(Reprinted with permission from Brit. Med. Bull., 2009, 89, 23.  Copyright 2009 Oxford 
University Press.) 
 
3.1.2 PARP-1 Inhibitors and Application in Cancer Therapy 
 
In 1971, it was shown that nicotinamide could weakly inhibit PARP-1 activity (Ki = 20 
µM).176 Since then, PARP-1 inhibitors of varying structural classes have been developed, 
including benzimides, isoquinolinones, dihydroisoquinolinones, benzimidazoles, indoles, 
isoindolinones, phenanthridinones, phthalazinones and quinazolinones.160 A few select 









































Figure 35. PARP-1 inhibitors 
 
Inhibitors of PARP-1 activity fall into one of two classes: competitive or non-competitive 
inhibitors.  Those that act in a competitive manner, which account for the majority of 
inhibitors known, are designed to mimic nicotinamide.165 By imitating the natural 
substrate, these compounds compete for binding to the catalytic site and, subsequently 
restrict the enzymatic property of the protein. Rational for compound design is attributed to 
crystallographic and computational studies that have shown the binding interactions 
between PD128763, a PARP-1 inhibitor, and the catalytic fragment of chicken PARP-
1.177,178 Generally, inhibitors of PARP-1 tend to be large hydrophilic compounds that bind 
to a polar site at the entrance to the proteins catalytic binding pocket.179 
 
Given that PARP-1 functions to repair DNA, it is unsurprising that it has received a great 
deal of interest as a potential therapeutic target.  In particular, it has been a key focus of 
those seeking to treat certain cancers.180 Application of a PARP-1 inhibitor can be effective 
in one of two ways, either as a chemopotentiator or a single agent.  In the first instance, a 
large number of anticancer drugs aim to bind to DNA and inflict damage on the rapidly 
dividing tumour cells, ultimately resulting in genome instability and cell death.  As such, 
exploitation of the PARP-1 mediated DNA repair pathway can lead to continued growth of 
the tumour, and an increase in resistance to chemotherapy.181 Administration of a PARP-1 
inhibitor, however, in combination with chemotherapy or radiation, would impede DNA 
repair in cancer cells, obstruct continued division and ultimately enhance therapeutic 
intervention.182 Even more interestingly, research has shown that tumours lacking breast 
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cancer susceptibility protein 1 (BRCA1) and 2 (BRCA2) function, which depletes the cells 
ability to repair damaged DNA via the HR pathway, are particularly susceptible to the 
effects of PARP-1 inhibitors.183,184 This leads to what is termed ‘synthetic lethality’, i.e. a 
mutated BRCA1/2 and PARP-1 gene leads to cell death, but a mutation in either one does 
not.185 It may, therefore, be possible to treat certain tumours with such compounds, 
negating the need for additional courses of chemo- and/or radiotherapy.     
 
3.1.3 PET Imaging of PARP-1 Activity 
 
Despite the fact that several PARP-1 inhibitors, including olaparib,186 rucaparib,187 and 
veliparib,188 are currently undergoing clinical evaluation for the treatment of certain 
cancers, a few key areas still need to be addressed.  For instance, the inability to monitor 
the action of these drugs at the molecular level non-invasively, providing evidence of a 
specific drug-target site interaction, is proving problematic.  Furthermore, as 
chemopotentiation requires dual administration, detailed studies that aim to determine both 
optimal PARP inhibitor-chemotherapy drug combination, and establish dosing regimes, are 
imperative for advancement of this type of therapy.189 These issues can be addressed using 
molecular imaging tools that enable quantification, and as such, the potential application of 
a PET imaging agent for PARP-1 activity is being realised. 
 
In 2005, Tu et al. prepared [11C]PJ34, a potential radiotracer for the in vivo imaging of 
PARP-1 activity during cellular necrosis.190 Starting from phenanthridin-6(5H)-one (187), 
the authors prepared the des-methyl labeling precursor 188 in three steps.  Incorporation of 
the radiolabel was then achieved using [11C]methyl iodide, giving [11C]PJ34 (189) in both 
a high radiochemical yield and specific activity (Scheme 48).  The radiotracer was then 
administered to a Type 1 diabetes rat model and, following in vivo PET imaging 
biodistribution studies, shown to accumulate in the pancreas and liver, where levels of 






















Radiochemical Yield = ~60%
Radiochemical Purity = >99%




Scheme 48. Radiosynthesis of [11C]PJ34 (189) 
 
Based on an initial screen of NU1085 and AG14361 analogues (Figure 35), Chen and co-
workers identified compound 192 as a potent PARP-1 inhibitor (Scheme 49).191 As part of 
their study, the authors investigated the potential for this compound to act as a PET 
imaging agent for PARP-1 activity, the preparation of which is illustrated in Scheme 49.  
Mesylate precursor 191, prepared from amine intermediate 190, was subject to 
radiofluorination using [18F]potassium fluoride and Kryptofix( under standard reaction 
conditions to give [18F]-labeled benzimidazole carboxamide 192 in high radiochemical 
yield, purity, and specific activity.  Total radiosynthesis time was 90 minutes.  
 
Having prepared [18F]192, an initial in vivo study using an MDA-MB-436 human breast 
cancer xenograft mouse model to determine radiotracer uptake within the tumour was 
performed.  The preliminary results of the microPET study indicated that there was 
increased uptake within the tumour and that this uptake was specific, as determined by the 
use of olaparib and cold 192 in blocking studies.  
  
191 [18F]192
[18F]KF, K222, K2CO3, 
DMF, 105 °C, 10 min
Radiochemical Yield = 40!50% (DC)
Radiochemical Purity = 100%























Scheme 49. Radiosynthesis of [18F]benzimidazole carboxamide 192  
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In addition to the application of PARP-1 inhibitors as imaging agents, there has also been 
interest in the development of novel radiolabeling procedures.  A highly efficient method 
for the preparation of an [18F]-labeled PARP-1 inhibitor, based on AZD2281 (olaparib), 
which utilises a chemically orthogonal scavenger was recently reported by Reiner et al.192 
Based on initial studies, whereby the authors used fluorophores to visualise PARP-1 
activity at the cellular level and in real-time,193,194 a technique exploiting the fast reaction 
time between trans-cyclooctene (TCO) and tetrazine was extrapolated for incorporation of 
an 18F-radiolabel.  The reaction sequence of this technique is illustrated in Scheme 50, and 
proceeds as follows: [18F]-labeled trans-cyclooctene 196 is prepared by nucleophilic 
substitution of the tosylate group of 195.195 The resulting intermediate is then reacted with 
the tetrazine-conjugated analogue of AZD2281 193 via an [4+2] inverse-electron-demand 
Diels-Alder cycloaddition to give [18F]-labeled compound 194 in very high radiochemical 
yield.  Finally, unreacted tetrazine precursor is removed using a magnetic TCO-decorated 
scavenger resin.  The advantages of this procedure include fast reaction and purification 
times, the ability to perform the reaction at ambient temperature, and more importantly, 
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[18F]F   (n.c.a)
195 196
Radiochemical Yield = 92.1 ± 0.4% (DC)  
 
Scheme 50. Radiosynthesis of [18F]194, an AZD2281 analogue 
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The authors also noted successful application of this radiotracer to a PET/CT study using 
an MDA-MB-436 tumour-bearing mouse, with encouraging results.  Accumulation of the 
radiotracer within the tumour, and specific binding was confirmed.  Moreover, uptake of 
the radiotracer could also be quantified in vivo.   
 
This latter study has shown that the development of a PET imaging agent targeting 
PARP-1 activity has scope and promise.   
 
3.1.4 Proposed Research 
 
The aim of this project was to generate a small library of novel PARP-1 inhibitors based 
on olaparib (Figure 36), which have the potential to be labeled with either [18F]potassium 
fluoride or [11C]methyl iodide for PET imaging applications.  It was anticipated that 
analogues of 197 (Figure 36) could be prepared via an expeditious route, enabling late 
structure variation and radiolabelling.  Coupling of an appropriate precursor with a range 
of commercially available carboxylic acids and benzyl halides, bearing either a fluoro- or 



















Olaparib 197  
 
Figure 36. PARP-1 inhibitor Olaparib and structure of potential PET imaging agent 
 
Following optimisation of the synthetic route and completion of the target compound 
library, the PARP-1 inhibitory potency and pharmacological profile of each compound 
would be measured and assessed by collaborators.  Furthermore, if any of the compounds 
displayed the appropriate characteristics, development into a potential PET imaging agent 
that could be used to assess PARP-1 activity in glioblastomas and PARP-1 inhibitor 
treatments, would be investigated.  
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In terms of structure-activity relationship, there are particular structural features of olaparib 
that account for its high binding affinity to PARP-1 protein (Figure 37).  The amide 
functionality of the phthalazinone core provides scope for three key hydrogen-bonding 
interactions: the carbonyl acts as a H-bond acceptor from Ser-904, and a bidentate 
interaction is formed with the backbone of Gly-863.160,165  A hydrophobic )-) stacking 
interaction between the aromatic rings of the phthalazinone core and Tyr-907 also occurs.  
In addition, it has been suggested that the m-carbonyl group of the benzyl ring accepts a H-
bond from Met-890, resulting in the displacement of a conserved water molecule.196 
Extensive studies have shown that the 4-NH-piperazine moiety of olaparib can 
accommodate a very diverse range of capping groups with no discernable effect on binding 
affinity,197,198 and can be rationalised by the discovery of a large hydrophobic pocket that 
sits adjacent to the nicotinamide binding site.199 More recently, this has been substantiated 
by Reiner et al., who have studied the inclusion of very large functionalised capping 
groups and observed no detrimental effect on binding potential.193 Given that these key 
binding interfaces remain present and unchanged in the target PET compounds, it is 

























Figure 37.  Key Olaparib-PARP-1 binding interactions 
 
3.2 Results and Discussion 
 
3.2.1 Retrosynthetic Analysis of Olaparib Analogues 
 
A proposed retrosynthetic analysis of the target analogues of olaparib is illustrated below 
in Scheme 51.  An initial disconnection of the N-R of 198 bond provides the corresponding 
commercially available acid or acyl derivative and secondary amine 199, which can in turn 
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be prepared by deprotection of Boc-amine 200.  Further disconnection of the amide 
linkage of 200 affords carboxylic acid 201 and Boc-protected piperazine 205.  Amine 
fragment 205 can be prepared in a single step from commercially available piperazine.  A 
functional group interconversion of the carboxylic acid yields the corresponding nitrile 
group, and disconnection of the phthalazinone core of 201 leads to benzofuran-1-one 202.  
Disconnection of the double bond then affords commercially available phosphonate ester 
203 and 2-fluoro-5-formylbenzaldehyde (207).  A final functional group interconversion of 
the phosphonate ester group gives 2-carboxybenzaldehde (204) and dimethylphosphite, 
both of which are commercially available. 






























































Scheme 51. Retrosynthetic analysis of olaparib analogues 
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The successful synthesis of a small library of novel PARP-1 inhibitors based on olaparib 
relies upon the ability to prepare the key phthalazinone core rapidly and with efficiency.  
Procedures for the preparation of penultimate compound 199 are documented in the 
literature, and this, coupled with the wide availability of both carboxylic acid and benzyl 
coupling partners, should enable the rapid synthesis of a range of compounds bearing 
fluoro- and methoxy-substituents.           
 
3.2.2 Synthesis of Potential PET Imaging Agents for PARP-1  
 
Preparation of olaparib analogues with the potential to be used as PET imaging agents for 
PARP-1 activity was achieved using synthetic procedures reported by Menear et al.200,201 
 
The first step towards the preparation of a small library of novel PARP-1 inhibitors 
required the synthesis of benzofuran-1-one 203.  Starting from commercially available 2-
carboxybenzaldehyde (204), a coupling reaction with dimethylphosphite in the presence of 
sodium methoxide gave benzofuran-1-one 203 in an excellent 96% yield (Scheme 52).200 
The phosphonate ester functionality of 203 could then be exploited for the preparation of 
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Scheme 52. Benzofuran-1-one 203 synthesis 
 
Originally reported in 1958 by Horner,202 and subsequently in 1961 by Wadsworth and 
Emmons,203 this chemical transformation utilises a phosphoryl-stabilised carbanion for the 
stereoselective olefination of both aldehydes and ketones.  The stereochemical outcome of 
this olefination reaction is predominantly the (E)-alkene, and is probably a consequence of 
the reversibility of the initial C-C bond forming step and oxaphosphetane formation.204 
However, under certain reaction conditions, formation of the (Z)-isomer can be 
achieved.205 As such, the modern organic chemist can tailor the reaction conditions to 
influence formation of one isomer over the other, therefore, enhancing selectivity of the 
product formed.  In this instance, however, the geometry of the resulting double bond is 
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irrelevant, as conversion to the phthalazinone core structure in the proceeding step will 
result in removal of the alkene, and so steps to exert control over the selectivity of the 
reaction are unnecessary.    
 
As such, compound 203 was reacted with commercially available 2-fluoro-5-
formylbenzonitrile in the presence of triethylamine, forming alkene 202 in very high yield 
of 95% (Scheme 53).  Inspection of the 1H NMR spectrum of the isolated product 
indicated a 75:25 mixture of E- and Z-isomers respectively, which were not separated.  
Identification and measurement of the isomeric ratio of alkene products was based on data 
presented in the literature for this compound.201 It is noteworthy that mixtures are often 






















Scheme 53. Synthesis of 202 via the Horner-Wadsworth-Emmons reaction 
 
A two-step, one-pot procedure was then employed for the preparation of substituted 
phthalazinone 201 (Scheme 54).  Initial hydrolysis of the pendant nitrile group of 
benzofuran-1-one 202 to the corresponding carboxylic acid was achieved using a 13 N 
aqueous sodium hydroxide solution.  Following this step, addition of hydrazine 
monohydrate to the reaction flask at a lower reaction temperature of 70 °C, resulted in the 
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Scheme 54. Synthesis of the phthalazinone core 
 
! ""+!
Having successfully prepared the key phthalazinone core of the olaparib analogues, 
progression to the next step of the synthetic route was feasible.  This next step involved an 
amide bond coupling reaction between the carboxylic acid of the phthalazinone core and 
the piperazine fragment.  However, before this transformation could be considered, the 
mono-protection of commercially available piperazine was necessary to prevent 
polymerization of the phthalazinone unit.  In this instance, the Boc-protecting group was 
selected for the amine as the conditions needed for its inclusion and subsequent removal 
will not affect the more sensitive functionalities present within the molecule.  As such, N-
Boc protected piperazine 205 was prepared in a high yield of 88%, by the slow addition of 
a solution of di-tert-butyl dicarbonate (209) in dichloromethane to commercially available 
















Scheme 55. Mono-N-Boc protection 
 
With the mono-N-Boc protected piperazine now in hand, attention was turned to the amide 
coupling reaction with the phthalazinone core (Scheme 56).  A few different amide 
coupling reagents and conditions were trialled for this transformation, and are listed in 
Table 13.  Briefly, the use of EDCI (Entry 1) was inconclusive, as it was not apparent from 
inspection of the crude reaction mixture by 1H NMR spectroscopy whether any reaction 
had taken place.  Utilisation of HOBt resulted in a 44% yield of the desired amide product 
(Entry 2).  HOBt is known to form diazetidine by-products on reaction with diimides,209 
and due to the potentially explosive nature of this reagent reluctance to increase the 
reaction temperature in an attempt to improve product yield lead to consideration of 
another reagent.  In keeping with the benzotriazole coupling agents, HBTU was 
considered, but only starting material remained after an initial attempt (Entry 3).  By 
substituting Hünigs base and DMA for triethylamine and DMF, respectively amide 200 
was obtained in a 27% yield (Entry 4).  Precipitation of the desired product occurs on 
addition of water, aiding isolation.  Efforts to increase isolated product yield was attempted 
by raising both reaction and work-up temperature (Entries 5 to 7).  In doing so, an 
optimum product yield of 68% for compound 200 was obtained when the reaction was 
performed initially at ambient temperature before increasing to 50 °C, and after addition of 




















Scheme 56. Amide coupling reaction 
 
Entry Reagents Conditions Work-Up* Yield 200 (%) 
1 EDCI, DMAP DMF, r.t. to 0 °C - & 
2 HOBt, EDCI CH2Cl2, 0 °C to r.t. - 44 
3 HBTU, DIPEA DMA, 0 °C to r.t. - & 
4 HBTU, Et3N DMF, r.t. H2O, 0 °C 27 
5 HBTU, Et3N DMF, r.t.  H2O, 60 °C 42 
6 HBTU, Et3N DMF, r.t. to 50 °C H2O, 50 to 0 °C 68 
7 HBTU, Et3N DMF, 70 °C - 64 
* Addition of H2O to HBTU reactions only 
 
Table 13. Amide coupling conditions trialed  
 
Precipitation of the product was desirable, as it circumvented the need for silica column 
chromatography as a means of purification.  The reason for this was that previous attempts 
to purify the product using chromatography, proved problematic.  In particular, the urea 
by-product, formed when HBTU is employed as the coupling agent, was difficult to 
remove.     
 
The proposed mechanism for the HBTU coupling of phthalazinone 201 and N-Boc 
piperazine is illustrated in Scheme 57.209 Deprotonation of carboxylic acid 201 in the 
presence of base generates carboxylate anion 210, which undergoes nucleophilic 
substitution with the uronium moiety of HBTU 213 to give intermediate 211.  The oxygen 
anion of benzotriazole 214 then participates in a second SN2 reaction with 211, generating 
the OBt active ester 212 and a urea by-product 215.  The activated ester subsequently 









































































Scheme 57. HBTU amide coupling mechanism 
 
Subsequent removal of the N-Boc protecting group under acidic conditions afforded 
penultimate compound 199 in a 70% yield (Scheme 58).  Addition of a linking group to the 
4-NH position of the piperazine ring would complete the synthesis of a small library of 

























Scheme 58. N-Boc protecting group removal  
 
N-Alkylation of the piperazine unit of 199 using either 4-fluoro- or 4-methoxybenzyl 
chloride in the presence of base (Reaction Conditions A), resulted in the formation of 
analogues 216 and 222 in a moderate yield of 38% and 42%, respectively (Scheme 59). 
The remaining final compounds were prepared via an amide coupling reaction between 
phthalazinone 199 and the appropriate carboxylic acid, the conditions for which are listed 
below in Scheme 59.  Target compounds 217, 218, 220, 223 and 224 were prepared using 
HBTU and Hünigs base (Reaction Conditions B and D) in yields ranging from 40–75%, 
and EDCI in the presence of catalytic DMAP (Reaction Conditions C) was used to prepare 
analogues 219 and 221 in yields of 31% and 34%, respectively.   
 
The primary reaction conditions employed for the amide coupling reflected a slightly 
modified version of that of Menear et al.200 HBTU and Hünigs base was initially trialled in 
dichloromethane at ambient temperature, but reaction progression proved slow.  Stirring 
the mixture under reflux conditions (Reaction Conditions B) on the other hand, was more 
constructive and applied to the synthesis of 217 and 218.  Unfortunately, as previously 
experienced for the synthesis of amide 200, the high polarity of the amide products lead to 
purification difficulties, and repetitive rounds of silica column chromatography were 
required to remove the 1,1,3,3-tetramethylurea (215) by-product, which was evident from 
1H NMR spectroscopy.  In an effort to avoid further use of HBTU, EDCI and DMAP 
(Reaction Conditions C) was utilised for the preparation of compounds 219 and 221.  
However, this coupling agent could not be widely applied, and the synthesis of several of 
the analogues failed under these conditions.  As such, the use of HBTU was once again 
revisited.  In this instance, DMF was employed as the reaction solvent, and after stirring 
for an initial period of 1 hour at ambient temperature, the reaction temperature was 
increased to 50 °C and the phthalazinone substrate added.  Again, purification of the 



















(A) DIPEA, CH2Cl2, r.t.
(B) HBTU, DIPEA, CH2Cl2, !
(C) EDCI, DMAP, CH2Cl2, r.t. then !


















216 38% (A) 217 75% (B) 218 53% (B)
219 31% (C) 220 46% (D) 221 34% (C)




Scheme 59. Synthesis of potential PET imaging agents for PARP-1 activity 
 
Product yields for the final compounds are not optimised, and further work regarding 
reaction conditions is required to aid purification and develop a more universal method for 
the amide bond formation.  
 
In an effort to overcome the purification difficulties encountered, a slight modification of 
the synthetic route was considered.  To avoid the use of an amide coupling reagent, 
formation of an additional target, compound 225, was achieved via the acid chloride 
(Scheme 60).  4-Methoxyphenylacetic acid (226) was treated with thionyl chloride to give 
acid chloride 227 in a very high 90% yield,210 which was immediately coupled with 
phthalazinone 199 in the presence of Hünigs base at ambient temperature.  The resulting 
product 225 was obtained with greater ease of purification in an unoptimised yield of 53%.  
An advantage of using the coupling reagent is that it reduces the number of overall 
chemical transformations required to develop the compound library.  However, if the use 
of an acid chloride is advantageous in terms of final product purification, this route may 
































Scheme 60. Synthesis of PARP-1 compound 225 via the acyl chloride 
 
3.2.3 Cell-Free PARP-1 Inhibition Study 
 
Following the synthesis of the novel PARP-1 inhibitors, Filip Zmuda, a PhD student 
within the Sutherland group, performed an initial biological screen of the compound 
library.  This was achieved using the Trevigen( PARP-1 colourimetric assay, which is an 
in vitro assay designed to measure the PARP-1 IC50 value associated with each analogue 
under cell-free conditions.  Performing a rudimentary screen of this sort offers two key 
advantages: it is a rapid procedure, and allows for the swift elimination of those 
compounds lacking PARP-1 inhibitory potency.   
 
To ensure that the assay was functioning correctly, and to allow for direct comparison with 
compounds 216–225, the IC50 value of olaparib was measured as the reference standard.  
The preliminary IC50 values obtained for all compounds are listed below in Tables 14.  
Consideration of the IC50 values obtained indicates that under the assay conditions 
employed, all analogues confer greater PARP-1 inhibitory potency than that of olaparib, 
which had an IC50 value of 11.9 nM.  The most potent compound is methoxy-compound 
223 with an IC50 of 1.1 nM.  A couple of approximate observations can be made at this 
point.  Firstly, as the compounds are all very close in range of IC50 values, it would appear 
that the presence of an electron withdrawing or an electron donating substituent on the 
aromatic ring has minimal effect on binding potential, and secondly, that the presence of 
an amide linkage on the terminal benzene moiety provides greater inhibitory potency.  The 
carbonyl group may offer an additional hydrogen bond acceptor site, and thus prevent 
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unrestricted rotation around the amide bond leading to an increased binding affinity.  
However, it should be noted that the differences in inhibitory potency in the presence of an 
amide bond is not of great magnitude, and that further investigation is required to confirm 






































































































































Table 14 (cont.). Cell-Free IC50 PARP-1 potency of olaparib and compounds 216–225 
 
Preliminary results from the biological screening of analogues 216–225 are encouraging, 
and at this point in time no compound should be eliminated from the study.  However, a 
more detailed investigation is required to determine the actions of these compounds within 




A research project, which aims to develop a potential PET imaging agent for PARP-1 
activity has been initiated.  Based on the PARP-1 inhibitor, olaparib, a small library of ten 
analogues bearing either an aromatic fluoro- or methoxy-substituent has been prepared via 
a rapid seven-step synthesis allowing for late stage structural variation.  Furthermore, the 
route employed allows for the preparation of a suitable radiolabeling precursor, averting 
the need for an alternative synthetic route.  A preliminary biological screen of the 
compound library has determined cell-free PARP-1 inhibitory potencies ranging from 






3.4 Future Work 
 
Further work on this project has been initiated and aims to gain further insight into the 
behavior of these compounds within the cellular environment.  This will be achieved by 
determining the following molecular characteristics: physicochemical properties 
(lipophilicity and % plasma protein binding), and cellular IC50 values.  The previously 
described HPLC methodology will be used to determine physicochemical properties, 
providing an indication of each compounds ability to penetrate the blood brain barrier.  
These results, in conjunction with the initial cell-free IC50 values, will enable selection of 
the most appropriate compounds for further studies.  A biological screen employing human 
G7 and T98G glioblastoma cell lines will then be performed, which aims to measure the 
cellular IC50 values of the compounds chosen, and establish whether they target the 
nucleus.  If upon conclusion of this secondary study, any of the analogues are deemed 
suitable, they will be further developed as potential PET imaging agents for PARP-1 
activity.  
 
Additionally, the synthesis and biological evaluation of PARP-1 analogues are ongoing in 
the Sutherland research group.  Variants of olaparib bearing an aliphatic moiety in place of 
an aromatic fluoride substituent have been identified as interesting targets.  Work in this 
area has already commenced with the attempted synthesis of fluoro-analogue 228 (Scheme 
61).  Commercially available 3-fluoropropan-1-ol (229) was converted to the tosylate 230 
in a high yield of 82%,211 and then subjected to a coupling reaction with phthalazinone 199 
to give the N-alkylated product 228.  Inspection of the crude reaction mixture by 1H NMR 
spectroscopy and mass spectrometry indicated the presence of product 228, but due to time 
constraints the pure compound was not isolated to a satisfactory standard.  Optimisation of 
reaction conditions and identification of a suitable purification system will enable 





























Scheme 61. Attempted synthesis of a potential fluoropropyl PARP-1 inhibitor 
 
! "#"!




Carduus crispus linn., also known as welted thistle, is a flowering biennial plant that 
belongs to the asteraceae family (Figure 38).212 It is native to both Europe and Asia, and 
has been introduced to North America where it is broadly regarded as an invasive weed.  In 
nature, the principle role of C. crispus is sustaining the insect population, e.g. it is regarded 
as the food of choice for the Painted Lady Butterfly and is utilised by bees for the 
production of honey.212,213 In addition to its role in wildlife, C. crispus is also believed to 
impart medicinal properties.  Extracts of the plant have been utilised in Chinese folk 
medicine to alleviate the symptoms of common cold, stomachache and rheumatism,214 and 
the root has been implicated in the provision of alterative and anodyne properties.215 
Furthermore, in vitro screening of the effects of C. crispus extracts on cellular growth has 
shown that the plant confers significant cytotoxic activity against several human cancer 




Figure 38. Carduus crispus linn.  
(Reprinted from www.seasonalwildflowers.com with kind permission of Dr. Keith 
Jones)216 
 
In 2002, Zhang et al. reported the isolation and subsequent identification of five natural 
products from C. crispuus (Figure 39).214 This small library of compounds consisted of two 
pyrrolo-[2,1-a]isoquinoline alkaloids (Crispine A and B) and three bicyclic isoquinoline 










































Figure 39. Crispines A–E 
 
Naturally, the interesting chemical structures and pharmacological potential of these five 
natural alkaloids has led to an increase in the research and development of synthetic routes 
for the provision of these products.  To date, the synthesis of Crispine A, B and E have 
been reported in the literature, and example syntheses of the pyrrolo-[2,1-a]isoquinoline 
alkaloids (Cripsine A) and bicyclic isoquinoline alkaloids (Crispine E) are described 
below. 
 
A review of the current literature highlights the diverse range of key chemical 
transformations that have been successfully employed in the preparation of Crispine A.  
These reaction sequences have been both racemic and asymmetric,217,218,219 and have 
utilised chemistry ranging from a one-pot tandem cyclisation via a Bischler-Napieralski 
reaction followed by cyclopropylimine rearrangement,220 to a highly diastereoselective N-
acyliminium cyclisation reaction.221 More recently, Ruano and co-workers published a 
very short and highly stereoselective synthesis of (R)-(+)-Crispine A (Scheme 62), utilising 
the p-tolylsulfinyl group as a chiral auxiliary.222 Treatment of 3,4-
dimethoxyphenylethylamine (231) with strong base, and subsequent reaction with (S)-
menthyl p-toluenesulfinate resulted in the enantioselective preparation of N-sulfinyl amine 
232 (94.5% e.e.).  Reaction of this precursor with 4-chlorobutanal in the presence of boron 
trifluoride as the Lewis acid catalyst gave the desired Pictet-Spengler product 233 in both 
high diastereo- and enantioselectivities (>98% d.e., 94.8% e.e.).  Removal of the chiral 
auxiliary by acidic cleavage of the N-S bond, followed by in situ cyclisation of 
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Scheme 62. Synthesis of (R)-(+)-Crispine A by Ruano and co-workers222 
 
In 2008, Czarnocki et al. reported the enantioselective synthesis of (R)-(+)-Crispine E 
(Scheme 63).223 Commercially available "-phthalimidobutyric acid was initially converted 
to acid chloride 236, and coupled to homoveratrylamine (231) to form amide 237.  
Treatment of this amide with phosphorus(V) oxychloride gave the Bischler-Napieralski 
product, imine 238, which was subsequently reduced using (S,S,)-242 to afford 
intermediate 239 in high enantioselectivity (e.e. 89%).  Deprotection of the phthalyl group 
using hydrazine, followed by immediate reaction with N,N’-bis(Boc)-S-methylisothiourea 
to introduce the guanidine unit, resulted in the formation of precursor 240.  A final Boc 
group deprotection of the guanidyl moiety of 240 under acidic conditions afforded the 
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Scheme 63. Synthesis of (R)-(+)-Crispine E by Czarnoki et al.223 
 
4.2 Proposed Research 
 
Owing to the interesting chemical structure of this class of natural products and their 
potential application in medicine, the synthesis of Crispine A, B and E has thus far been 
achieved and reported in the literature.  To date, there has been no reported synthesis of 
Crispine C (243) (Figure 40), and so the aim of this project was to develop a short and 









Crispine C (243)  
 
Figure 40. Crispine C 
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4.3 Retrosynthetic Analysis of Crispine C 
 
A proposed retrosynthetic analysis of Crispine C is detailed below in Scheme 64.  An 
initial disconnection of the guanidine unit of 243 gives amine 244.  Further disconnection 
of the core isoquinoline ring then affords amide 245, which can in turn be prepared from 
amine 246 and Cbz protected "-aminobutyric acid (250).  "-aminobutyric acid is a 
commercially available starting material that can be protected in a single step.  Functional 
group interconversion of amine 246 to the nitro group of compound 247, followed by 
disconnection of the methoxy substituent provides, %,#-unsaturated nitro compound 248.  
Finally, this nitroalkene can be prepared from commercially available 3,4-








































Scheme 64. Retrosynthetic analysis of Crispine C (249) 
 
Formation of the isoquinoline core from the corresponding amide 245 via the Pictet-Gams 
modification of the Bischler-Napieralski reaction, will be the key step in this sequence of 





4.4 Steps Towards the First Total Synthesis of Crispine C 
 
4.4.1 Synthesis of Amine 246 
 
The first step towards the total synthesis of Crispine C required the preparation of amine 
intermediate 246, which was achieved in three steps starting from commercially available 
3,4-dimethoxybenzaldehyde (Scheme 65).  Firstly, reaction of aldehyde 249 with 
nitromethane in the presence of ammonium acetate under reflux conditions gave (E)-
nitroalkene 248 exclusively in quantitative yield.224 Inspection of the 1H NMR spectrum of 
the crude product indicated that no side products or starting material were present, and the 
compound was applied to the next synthetic step without prior purification.   
 
Formation of a #-nitro alcohol by reaction of a carbonyl containing compound and 
nitroalkane under basic conditions is referred to as the Henry or nitro-aldol reaction, and is 
a completely reversible reaction.88 In principal, a base is initially used to generate a 
resonance-stabilised anion of the nitroalkane, which then undergoes an aldol reaction with 
the carbonyl carbon forming a #-nitro alcohol after protonation.  Under the reaction 
conditions detailed in step one of Scheme 65, dehydration of the #-nitro alcohol forming 
nitroalkene 248 occurs.  The synthesis of this %,#-unsaturated nitro compound prevents the 
retro-Henry reaction from occurring, and furthermore, can act as a Michael acceptor in the 
next step.      
 
Next, conjugate addition of the methoxide ion to nitroalkene 248 using a 25% sodium 
methoxide in methanol solution, gave #-nitro alkoxide 247 in a moderate 50% yield.224 In 
addition to compound 247, unidentified side-products were an observed consequence of 
this transformation, making purification troublesome.  At times, repetitive cycles of silica 
column chromatography to remove close running impurities, followed by recrystallisation, 
was required for purification, and this stringent purification process greatly affected 
product yield.   
 
Reduction of the nitro group to the corresponding amine was then necessary to complete 
the synthesis of amine fragment 246, and this step was initially performed using a lithium 
aluminium hydride solution in diethyl ether under reflux conditions.  Despite several 
attempts at this reaction, only a low yield of 30% was obtained for compound 246.  
Termination of the reaction by addition of water to quench excess reducing agent generates 
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lithium salts.  It is, therefore, possible that the product is becoming trapped in the salts 





























Scheme 65. Synthesis of amine fragment 246 
 
Aliphatic nitro groups are generally reduced to the corresponding amine using relatively 
harsh reducing agents and conditions, e.g. high-pressure catalytic hydrogenation and 
lithium aluminium hydride.225,226 As such, an effort to improve the reduction of compound 
247 to amine 246 through application of milder reducing conditions was investigated 
(Table 15).  A procedure developed by Osby and Ganem, utilising an excess of sodium 
borohydride and a catalytic quantity of nickel(II) chloride to form the active catalyst was 
trialed for the reduction of compound 247 (Entry 1).227 Unfortunately, analysis of the crude 
reaction mixture indicated that these conditions were ineffective, and only starting material 
remained after 48 hours.  Next, a transfer hydrogenation reaction developed by Ram and 
Ehrenkaufer using 10% palladium on carbon and ammonium formate was then applied to 
the substrate (Entry 2), but again no reaction had occurred after 24 hours and only the 
substrate remained.228 Finally, hydrogenation of the nitro group using 10% palladium on 
carbon and hydrogen at atmospheric pressure was attempted on a small quantity of crude 
starting material (Entry 3).  Examination of the reaction mixture using 1H NMR 
spectroscopy indicated that reduction had possibly occurred, but the presence of original 
impurities prevented effective separation of the compound mixture and the ability to 
determine the overall success of the reaction.  Reduction of the nitro group using milder 
reaction conditions had, thus far, either failed completely or afforded inconclusive results.  
At this point in time, only lithium aluminium hydride had been successfully employed for 
the reduction of compound 247, albeit in a poor yield.  It was, therefore, decided that 
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progression with the intended synthetic route would ensue.  However, application of the 
palladium-catalysed hydrogenation under atmospheric conditions would be reconsidered 
for future reductions in this route when necessary.    
 
Entry Reagents Conditions Outcome 
1 NaBH4, NiCl2 MeOH, r.t. No Reaction 
2 NH4CO2H, 10% Pd/C MeOH, ' No Reaction  
3 10% Pd/C, H2 MeOH, r.t. Possible Reduction* 
* Confirmation and yield not determined due to problems separating reaction mixture 
 
Table 15. Reaction conditions trialed for aliphatic nitro group reduction  
 
The next step of the synthesis required coupling of the amine product of the previous 
reaction with "-aminobutyric acid, furnishing the target amide.  A wide range of peptide 
coupling agents and conditions are available, and in an attempt to aid purification and 
isolation of the product, EDCI and a catalytic quantity of DMAP were chosen as the 
preferred reagents.  Firstly, treatment of butyric acid 251 with benzyl chloroformate under 
Schotten-Baumann conditions afforded the Cbz-protected carboxylic acid 250 in a 70% 
yield,229 which was subsequently coupled with amine 246 to afford amide 245 in a good 
yield of 79% (Scheme 66). 





















0!5 °C then r.t.
 
 
Scheme 66. Amide coupling reaction  
 
With the isoquinoline precursor in hand, the next step involved cyclisation of amide 245 
via the Pictet-Gams modification of the Bischler-Napieralski reaction.  The Pictet-Gams 
! "#*!
variation utilises a cyclisation reagent, e.g. phosphorus pentaoxide and phosphorus 
oxychloride, for the cyclodehydration of a #-methoxy- or #-hydroxy-arylethanamine, 
enabling the direct formation of a fully aromatic isoquinoline.230 An initial attempt to 
cyclise amide 245 using modified conditions from Czarnocki et al. was unsuccessful 
(Scheme 67).223 Analysis of the 1H NMR spectrum of the crude reaction mixture bore no 
evidence of the desired isoquinoline, and under the acidic conditions employed, the Cbz 
protecting group had been removed.  It should be noted that phosphorus(V) oxybromide 
was utilised in this reaction due to availability, and that all further chemical manipulations 


















Scheme 67. Attempted cyclisation of amide 245 using Pictet-Gams conditions 
 
The failed attempt to form isoquinoline 252, coupled with the low to moderate yields 
obtained for the preparation of #-nitro alkoxide 247 and its ensuing reduction to amine 
246, led to the termination of this approach.  It was anticipated that a more efficient and 
direct preparation of Crispine C could be achieved using a slightly modified version of the 
original synthetic route.  
 
4.4.2 Synthesis of Amine 254: Cyanohydrin Synthesis  
 
In 1995, Zhao and Wan reported the high yielding preparation of cyanohydrin 253 by 
reaction of 3,4-dimethoxybenzaldehyde with potassium cyanide in the presence of 
ammonium chloride at ambient temperature (Scheme 68).231 Moreover, the authors 
indicated that the nitrile group could be reduced with ease to amine 254 in very good yield 
using lithium aluminium hydride.  However, despite repeated attempts to replicate the 
synthesis of cyanohydrin 253, no product was isolated.  
 
Formation of a cyanohydrin by the nucleophilic addition of cyanide to a carbonyl group is 
a reversible process.232 This is a probable explanation as to why attempts to prepare 
compound 253 were unsuccessful, and efforts to circumvent this problem were attempted.  
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It was envisaged that the inclusion of methyl iodide and a base to the resulting cyanohydrin 
would form alkoxide 255, thereby trapping the oxygen, and preventing reversion of the 
cyanide addition.  However, when aldehyde 249 was treated with potassium cyanide and, 
following a very quick extraction, reacted with methyl iodide and triethylamine, no desired 
product was formed and only starting material remained (Scheme 68).233 A subsequent 
attempt to synthesise 255 using a procedure adapted from Yadav et al.,234 utilising lithium 
tetrafluoroborate as the catalyst for coupling the aldehyde, cyanide and methyl iodide in 































Scheme 68. Attempted synthesis of cyanohydrins 253 and 255 
 
4.4.3 Synthesis of Amine 254: The Henry Reaction Revisited 
 
The failure to prepare amines 254 and 246 from cyanohydrin intermediates 253 and 255 
respectively, led to the decision to revisit the Henry reaction (Scheme 69).  However, 
where dehydration to form the nitroalkene had previously been encouraged, the current 
strategy aimed to prevent this.  The reaction conditions investigated for this transformation 
are listed below in Table 16.  When Hünigs base in tetrahydrofuran was employed for the 
transformation,235 no reaction occurred (Entry 1), and a similar result was obtained for 
triethylamine in toluene (Entry 2).  However, when the reaction was performed in neat 
triethylamine a product yield of 30% was obtained (Entry 3).  This yield was unexpected 
as inspection of the 1H NMR spectrum of crude material indicated a 3:1 mixture of product 
to aldehyde starting material; highlighting the reversibility of this reaction.  Next, the 
preparation of #-nitro alcohol 256 was attempted using the procedure of Muraoka and co-
workers.236 In the presence of 4 Å molecular sieves, the starting material was treated with 
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nitromethane in dimethylsulfoxide at ambient temperature, affording compound 256 in a 











Scheme 69. Synthesis of #-nitro alcohol 256 via a Henry reaction 
 
Entry Reagents Conditions Yield 256 (%) 
1 MeNO2, DIPEA THF, r.t. - 
2 MeNO2, Et3N Toluene, r.t. - 
3 MeNO2, Et3N r.t. 30 
4 MeNO2, DMSO 4 Å MS, r.t. 85 
 
Table 16. Reaction conditions trialed for the Henry reaction 
 
Previous, attempts at reduction of the aliphatic nitro group of compound 247 (Scheme 65, 
Table 15) had proved problematic, with only lithium aluminium hydride providing limited 
success.  Keen to improve this reaction and avoid the loss of product during work-up, the 
palladium-catalysed reduction of the nitro group with hydrogen at atmospheric pressure 
was considered (Scheme 70).  Application of these conditions to #-nitro alcohol 256 
afforded #-amino alcohol 255 in quantitative yield, which was subsequently coupled to the 
Cbz-protected butyric acid giving amide 257 in a good yield of 79%.  Initially, treatment of 
amide 257 with neat phosphorus(V) oxychloride under reflux resulted in the formation of 
the desired isoquinoline 252 in 24% yield.  Despite this being a low yielding reaction, the 
formation of compound 252 was a positive step.  However, it soon became apparent that 
this was a capricious reaction, as synthesis of the isoquinoline core could not be repeated.  
In an effort to replicate the synthesis of 252, the phosphorus(V) oxychloride was distilled 
prior to use to remove any phosphoric acid degradation product.  Additionally, both 
reaction temperature and amount of phosphorus(V) oxychloride used was reduced to 50 °C 
and 2.4 equivalents, respectively and dichloromethane was also trialed as the reaction 
solvent.  However, despite these modifications to the reaction conditions, decomposition of 
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Scheme 70. Synthesis of isoquinoline 252 
 
4.4.4 Replacement of the Cbz-Protecting Group 
 
In an attempt to overcome the problems encountered during cyclisation of the amide 
precursor to form the isoquinoline core, the acid-sensitive Cbz protecting group was 
replaced with the phthalimide group (Scheme 71).  Treatment of "-aminobutyric acid (251) 















Scheme 71.  Phthalimide protection of "-aminobutyric acid (259) 
 
Amine 255 and the protected butyric acid were then subject to the same peptide coupling 
conditions employed previously, resulting in the formation of amide 260 in a good yield of 
75% (Scheme 72).  With the new isoquinoline precursor in hand, the vital 
cyclodehydration reaction could now be investigated.  Using toluene as the reaction 
solvent, amide 260 was treated with freshly distilled phosphorus(V) oxychloride under 
reflux conditions to give the target Pictet-Gams product 261.  Variation of the number of 
reagent equivalents used, enabled an acceptable product yield of 66% for isoquinoline 261 
! "$$!
to be obtained when 3.0 equivalents of phosphorus(V) oxychloride was employed 
























Scheme 72. Synthesis of isoquinoline 261 
 
Entry POCl3 (eq.) Yield 261 (%) 
1 2.4 23 
2 2.5 43 
3 3.0 66 
4 Excess Trace 
 
Table 17. Optimisation of Pictet-Gams conditions 
 
Having optimised the synthesis of the isoquinoline core, the remaining steps of the 
synthetic route could now be undertaken (Scheme 73).  Incorporation of the guanidyl 
moiety was achieved using a two-step process.  First, removal of the phthalimide 
protecting group using hydrazine monohydrate afforded amine 244.  This was then 
immediately reacted with commercially available 
N,N’-bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine in the presence of Hünig’s 
base to give compound 262 in 82% yield over 2 steps.238,239 Finally, treatment of 
penultimate compound 262 with trifluoroacetic acid enabled removal of the Boc-protecting 












































In summary, the first total synthesis of Crispine C was achieved in seven steps and with an 
overall product yield of 25%, from commercially available 3,4-dimethoxybenzaldehde and 
"-aminobutyric acid.  The key transformation of the synthetic route required formation of 
the target isoquinoline core, which was achieved using the Pictet-Gams modification of the 
Bischler-Napieralski reaction.  The spectroscopic data obtained for the final isolated 
compound was in complete agreement with that reported in the literature for Crispine C by 





5.1 General Experimental 
 
All reagents and starting materials were obtained from commercial sources and used as 
received.  All dry solvents were purified using a PureSolv 500 MD solvent purification 
system.  All reactions were performed under an atmosphere of argon unless otherwise 
stated.  Brine is defined as a saturated solution of aqueous sodium chloride.  Flash column 
chromatography was carried out using Fisher Matrix flash 60.  Macherey-Nagel 
aluminium-backed plates pre-coated with silica gel 60 (UV254) were used for thin layer 
chromatography and were visualised using UV light or staining with potassium 
permanganate.  1H NMR and 13C NMR spectra were recorded on a Bruker DPX 400 or 
Bruker 500 spectrometer, with chemical shift values reported in ppm relative to 
tetramethylsilane (*H 0.00 and *C 0.0), residual chloroform (*H 7.26 and *C 77.16), 
dimethylsulfoxide (*H 2.50 and *C 39.52), or methanol (*H 3.31 and *C 49.00) as the 
standard.  Proton and carbon assignments are based on two-dimensional COSY and DEPT 
experiments, respectively.  Infrared spectra were recorded using Golden Gate apparatus on 
a JASCO FTIR 410 spectrometer, and mass spectra were obtained using a JEOL JMS-700 
or Bruker Microtof-q spectrometer.  Melting points were determined on a Gallenkamp 
melting point apparatus. 
 
5.2 TSPO Experimental 
 





A suspension of aniline (98) (2.20 mL, 23.8 mmol), diethyl oxalacetate (99) (5.00 g, 23.8 
mmol) and p-toluenesulfonic acid (4.53 g, 23.8 mmol) in cyclohexane (100 mL) was 
stirred vigorously under reflux with Dean-Stark conditions for 48 h.  After cooling to 
ambient temperature, the suspension was filtered, washed with cyclohexane and the filtrate 
concentrated in vacuo to yield the desired imine as a yellow oil.  Neat polyphosphoric acid 
(~10 g) was added to the imine and stirred vigorously at 120 °C for 1 h.  After cooling to 
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ambient temperature, excess acid was quenched by the slow addition of a saturated 
solution of aqueous sodium hydrogen carbonate (100 mL).  The aqueous mixture was 
diluted by the addition of chloroform (100 mL) and separated.  The aqueous fraction was 
washed with chloroform (3 + 100 mL), and the combined organic layers dried (MgSO4), 
filtered and concentrated in vacuo to yield a dark yellow solid.  Purification using flash 
column chromatography (methanol/dichloromethane, 1:9) afforded ethyl 4-
hydroxyquinoline-2-carboxylate (96) (1.92 g, 37%) as a light tan solid. Mp 215–216 °C 
(lit.,240 mp 213 °C); ,max/cm
–1 (neat) 2882 (CH), 1736 (CO), 1607 (C=C), 1560, 1518, 
1312, 1267, 1233, 1009; *H (400 MHz, CDCl3) 1.44 (3H, t, J 7.2 Hz, OCH2CH3), 4.49 
(2H, q, J 7.2 Hz, OCH2CH3), 6.99 (1H, d, J 1.6 Hz, ArH), 7.39 (1H, t, J 8.0 Hz, ArH), 7.43 
(1H, d, J 8.4 Hz, ArH), 7.67 (1H, ddd, J 8.4, 8.0, 1.6 Hz, ArH), 8.35 (1H, dd, J 8.0, 0.4 Hz, 
ArH), 9.01 (1H, br s, OH); *C (101 MHz, CDCl3) 14.1 (CH3), 63.4 (CH2), 111.7 (CH), 
118.0 (CH), 124.5 (CH), 126.4 (CH), 126.4 (C), 133.1 (CH), 136.4 (C), 139.0 (C), 163.0 
(C), 179.7 (C); m/z (EI) 217.0735 (M+. C12H11NO3 requires 217.0739), 189 (6%), 171 (22), 
143 (98), 115 (30), 89 (27), 83 (27), 49 (29). 
 





A solution of aniline (98) (4.50 mL, 49.4 mmol), diethyl oxalpropionate (100) (9.14 mL, 
49.4 mmol) and p-toluenesulfonic acid (0.070 g, 0.37 mmol) in cyclohexane (125 mL) was 
stirred vigorously under reflux with Dean-Stark conditions for 48 h.  After cooling to 
ambient temperature, the suspension was filtrered, washed with cyclohexane and the 
filtrate concentrated in vacuo to yield the desired imine as a yellow oil.  Neat 
polyphosphoric acid (~30 g) was added to the imine, and the resultant mixture stirred 
vigorously at 120 °C for 1 h.  On cooling to ambient temperature, excess acid was 
quenched by the slow addition of a saturated solution of aqueous sodium hydrogen 
carbonate (100 mL).  The resultant precipitate was removed by filtration and reconstituted 
in chloroform.  Insoluble impurities were then removed by hot filtration.  The organic layer 
was dried (MgSO4), filtered and concentrated in vacuo to yield an orange solid.  
Trituration using diethyl ether followed by petroleum ether, gave ethyl 
4-hydroxy-3-methylquinoline-2-carboxylate (97) (7.35 g, 65%) as a yellow solid.  
Spectroscopic data in accordance with the literature.89 Mp 176–177 °C (lit.,89 mp 176–178 
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°C); ,max/cm
–1 (neat) 3372 (OH), 3071 (CH), 1734 (CO), 1603 (C=C), 1547, 1516, 1221, 
1117, 1059; *H (400 MHz, CDCl3) 1.40 (3H, t, J 7.2 Hz, OCH2CH3), 2.43 (3H, s, CH3), 
4.44 (2H, q, J 7.2 Hz, OCH2CH3), 7.22–7.29 (1H, m, ArH), 7.41 (1H, d, J 8.4 Hz, ArH), 
7.51–7.58 (1H, m, ArH), 8.30 (1H, dd, J 8.4, 1.2 Hz, ArH), 9.50 (1H, br s, OH); *C (101 
MHz, CDCl3) 11.6 (CH3), 14.2 (CH3), 63.2 (CH2), 117.7 (CH), 122.5 (C), 123.7 (CH), 
123.8 (C), 126.4 (CH), 132.6 (CH), 133.2 (C), 138.5 (C), 164.2 (C), 179.6 (C); m/z (EI) 
231.0898 (M+. C13H13NO3 requires 231.0895), 202 (100%), 157 (90), 129 (60), 102 (32), 
77 (28). 
 





To a solution of ethyl 4-hydroxyquinoline-2-carboxylate (96) (3.36 g, 15.5 mmol) in 
acetonitrile (150 mL) was added phosphorus oxybromide (13.3 g, 46.4 mmol) followed by 
potassium carbonate (6.41 g, 46.4 mmol).  The resultant suspension was heated under 
reflux and stirred for 2 h.  After cooling to ambient temperature, the solution was 
concentrated in vacuo and water (100 mL) slowly added.  The crude product was extracted 
into ethyl acetate (3 + 100 mL), and the combined organic layers were concentrated in 
vacuo to yield a dark brown oil from which ethyl 4-bromoquinoline-2-carboxylate (94) 
(3.97 g, 92%) crystallized forming a solid. Mp 87–89 °C (lit.,241 mp 91–92 °C); ,max/cm
–1 
(neat) 2996 (CH), 1709 (CO), 1553 (C=C), 1458, 1366, 1312, 1196, 1146, 1105; *H (400 
MHz, CDCl3) 1.49 (3H, t, J 7.2 Hz, OCH2CH3), 4.56 (2H, q, J 7.2 Hz, OCH2CH3), 7.75 
(1H, ddd, J 8.4, 6.8, 1.2 Hz, ArH), 7.84 (1H, ddd, J 8.4, 6.8, 1.2 Hz, ArH), 8.24 (1H, dd, J 
8.4, 1.2 Hz, ArH), 8.34 (1H, d, J 8.4 Hz, ArH), 8.47 (1H, s, ArH); *C (101 MHz, CDCl3) 
14.4 (CH3), 62.7 (CH2), 125.1 (CH), 126.7 (CH), 128.9 (C), 130.0 (CH), 131.1 (CH), 131.2 
(CH), 135.4 (C), 147.8 (C), 147.9 (C), 164.2 (C); m/z (CI) 279.9974 (MH+. C12H11
79BrNO2 
requires 279.9973), 218 (52%), 202 (47), 157 (3), 85 (9). 
 





Ethyl 4-bromo-3-methylquinoline-2-carboxylate (95) was synthesised as described above 
for ethyl 4-bromoquinoline-2-carboxylate (94) using ethyl 
4-hydroxy-3-methylquinoline-2-carboxylate (97) (2.21 g, 9.56 mmol), phosphorus 
oxybromide (8.22 g, 28.7 mmol) and potassium carbonate (3.96 g, 28.7 mmol) in 
acetonitrile (100 mL).  Extraction afforded ethyl 4-bromo-3-methylquinoline-2-
carboxylate (95) (2.75 g, 98%) as a dark brown oil, which crystallised on standing to form 
a solid.  Spectroscopic data in accordance with the literature.89 Mp 50–51 °C (lit.,89 mp 48–
50 °C); ,max/cm
–1 (neat) 3117, 2990 (CH), 1713 (CO), 1622 (C=C), 1478, 1377, 1310, 
1206, 1146; *H (400 MHz, CDCl3) 1.47 (3H, t, J 7.2 Hz, OCH2CH3), 2.70 (3H, s, CH3), 
4.53 (2H, q, J 7.2 Hz, OCH2CH3), 7.67 (1H, ddd, J 8.4, 7.2, 1.6 Hz, ArH), 7.73 (1H, ddd, J 
8.4, 7.2, 1.6 Hz, ArH), 8.12–8.16 (1H, m, ArH), 8.22 (1H, dd, J 8.4, 0.8 Hz, ArH); *C (101 
MHz, CDCl3) 14.2 (CH3), 19.8 (CH3), 62.3 (CH2), 126.8 (CH), 128.5 (C), 129.1 (CH), 
129.4 (C), 129.9 (CH), 130.2 (CH), 137.2 (C), 146.0 (C), 151.2 (C), 166.4 (C); m/z (EI) 
293.0045 (M+. C13H12
79BrNO2 requires 293.0051), 264 (34%), 221 (59), 140 (100), 113 
(23), 69 (52), 44 (13). 
 





To a solution of ethyl 4-bromoquinoline-2-carboxylate (94) (0.200 g, 0.714 mmol) in 
N,N’-dimethylformamide (10 mL) was added benzeneboronic acid (0.174 g, 1.43 mmol), 
potassium phosphate (0.227 g, 1.07 mmol) and tetrakis(triphenylphosphine)palladium(0) 
(0.083 g, 0.072 mmol).  The resultant suspension was stirred vigorously at 120 °C for 24 h 
and then cooled to ambient temperature.  An additional aliquot of benzeneboronic acid 
(0.174 g, 1.43 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.083 g, 0.072 mmol) 
was added to the reaction mixture and stirred at 120 °C for a further 24 h.  On cooling to 
ambient temperature, the mixture was diluted with dichloromethane (50 mL).  The organic 
layer was then washed with water (3 + 30 mL), dried (MgSO4), filtered and concentrated in 
vacuo.  Purification using flash column chromatography (ethyl acetate/petroleum ether, 
15:85) afforded ethyl 4-phenylquinoline-2-carboxylate (103) (0.160 g, 81%) as a pale 
yellow solid. Spectroscopic data in accordance with the literature.89 Mp 114–116 °C (lit.,89 
mp 115–118 °C); ,max/cm
–1 (neat) 2972 (CH), 1711 (CO), 1587 (C=C), 1375, 1333, 1252, 
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1134, 1115, 1022; *H (400 MHz, CDCl3) 1.49 (3H, t, J 7.2 Hz, OCH2CH3), 4.57 (2H, q, J 
7.2 Hz, OCH2CH3), 7.48–7.56 (5H, m, 5 + ArH), 7.59 (1H, ddd, J 8.4, 6.8, 1.2 Hz, ArH), 
7.78 (1H, ddd, J 8.4, 6.8, 1.2 Hz, ArH), 7.97 (1H, dd, J 8.4, 0.8 Hz, ArH), 8.14 (1H, s, 
ArH), 8.38 (1H, d, J 8.4 Hz, ArH); *C (101 MHz, CDCl3) 14.4 (CH3), 62.3 (CH2), 121.3 
(CH), 125.7 (CH), 127.8 (C), 128.6 (CH), 128.7 (2 + CH), 128.7 (CH), 129.6 (2 + CH), 
130.0 (CH), 131.2 (CH), 137.6 (C), 147.8 (C), 148.2 (C), 149.8 (C), 165.5 (C); m/z (EI) 
277.1103 (M+. C18H15NO2 requires 277.1103), 233 (9%), 205 (100), 204 (30), 176 (10), 84 
(55). 
 





Ethyl 3-methyl-4-phenylquinoline-2-carboxylate (104) was synthesised as described above 
for ethyl 4-phenylquinoline-2-carboxylate (103) using ethyl 4-bromoquinoline-2-
carboxylate (95) (0.200 g, 0.680 mmol), benzeneboronic acid (0.108 g, 0.884 mmol), 
potassium phosphate (0.188 g, 0.884 mmol) and tetrakis(triphenylphosphine)palladium(0) 
(0.079 g, 0.068 mmol) in N,N’-dimethylformamide (10 mL). An additional aliquot of 
benzeneboronic acid (0.108 g, 0.884 mmol), potassium phosphate (0.188 g, 0.884 mmol) 
and tetrakis(triphenylphosphine)palladium(0) (0.079 g, 0.068 mmol) was added and the 
suspension stirred at 120 °C for a further 72 h.  Purification using flash column 
chromatography (ethyl acetate/petroleum ether, 2:3) afforded ethyl 3-methyl-4-
phenylquinoline-2-carboxylate (104) (0.100 g, 51%) as a pale yellow solid.  Spectroscopic 
data in accordance with the literature.89 Mp 105–107 °C (lit.,89 mp 110–112 °C); ,max/cm
–1 
(neat) 3076, 2981 (CH), 1725 (CO), 1593 (C=C), 1473, 1269, 1199, 1068, 861; *H (400 
MHz, CDCl3) 1.43 (3H, t, J 7.2 Hz, OCH2CH3), 2.34 (3H, s, CH3), 4.51 (2H, q, J 7.2 Hz, 
OCH2CH3), 6.84–6.92 (1H, m, ArH), 7.10–7.27 (2H, m, 2 + ArH), 7.37–7.47 (2H, m, 2 + 
ArH), 7.48–7.57 (2H, m, 2 + ArH), 7.66 (1H, ddd, J 8.4, 6.8, 1.6 Hz, ArH), 8.22 (1H, d, J 
8.4 Hz, ArH); *C (101 MHz, CDCl3) 14.2 (CH3), 16.8 (CH3), 62.2 (CH2), 126.1 (CH), 
126.5 (C), 127.9 (CH), 128.2 (CH), 128.3 (C), 128.8 (2 + CH), 129.2 (2 + CH), 129.3 
(CH), 129.5 (CH), 136.6 (C), 145.4 (C), 149.1 (C), 151.3 (C), 167.3 (C); m/z (CI) 
292.1333 (MH+. C19H18NO2 requires 292.1338), 220 (4%), 81 (7).  
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To a solution of ethyl 4-phenylquinoline-2-carboxylate (103) (0.160 g, 0.577 mmol) in a 
50% aqueous ethanol mixture (20 ml) was added ground sodium hydroxide (0.923 g, 2.31 
mmol), and the reaction mixture stirred vigorously under reflux for 18 h.  On cooling to 
ambient temperature, the ethanol was removed in vacuo, and the aqueous layer acidified 
(pH ~4) using a 1 M hydrochloric acid solution (~10 mL).  The crude product was 
extracted using dichloromethane (3 + 50 mL), dried (MgSO4), filtered and concentrated in 
vacuo to give 4-phenylquinoline-2-carboxylic acid (87) (0.128 g, 89%) as a brown solid, 
which was used without further purification.  Spectroscopic data in accordance with the 
literature.89 Mp 161–162 °C (lit.,89 mp 164–167 °C); ,max/cm
–1 (neat) 2972, 2930 (CH), 
1713 (CO), 1589 (C=C), 1462, 1379, 1229, 905, 845; *H (400 MHz, CDCl3) 7.51–7.60 
(5H, m, 5 + ArH), 7.67 (1H, ddd, J 8.4, 6.8, 1.2 Hz, ArH), 7.86 (1H, ddd, J 8.4, 6.8, 1.2 
Hz, ArH), 8.05 (1H, d, J 8.4 Hz, ArH), 8.22–8.26 (2H, m, 2 + ArH); *C (101 MHz, CDCl3) 
119.4 (CH), 126.2 (CH), 128.5 (C), 128.8 (2 + CH), 129.1 (CH), 129.2 (CH), 129.6 (2 + 
CH), 129.8 (CH), 130.8 (CH), 137.0 (C), 145.4 (C), 146.4 (C), 151.7 (C), 164.4 (C); m/z 
(CI) 250.0869 (MH+. C16H12NO2 requires 250.0868), 249 (6%), 206 (7), 174 (2), 85 (4), 69 
(5). 
 





3-Methyl-4-phenylquinoline-2-carboxylic acid (88) was synthesised as describe above for 
4-phenylquinoline-2-carboxylic acid (87) using ethyl 
3-methyl-4-phenylquinoline-2-carboxylate (104) (0.042 g, 0.14 mmol) and ground sodium 
hydroxide (0.023 g, 0.58 mmol) in a 50% aqueous ethanol mixture (10 mL).  Extraction 
afforded 3-methyl-4-phenylquinoline-2-carboxylic acid (88) (0.031 g, 82%) as an off white 
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solid, which was used without further purification.  Spectroscopic data in accordance with 
the literature.89 Mp 135–137 °C (lit.,89 mp 130–132 °C); ,max/cm
–1 (neat) 3044 (CH), 2932, 
1720 (CO), 1590 (C=C), 1473, 1368, 1322, 1232, 1068; *H (400 MHz, CDCl3) 2.64 (3H, s, 
CH3), 6.82&6.94 (1H, m, ArH), 7.20&7.27 (2H, m, 2 + ArH), 7.43 (1H, dd, J 8.4, 0.8 Hz, 
ArH), 7.50&7.60 (3H, m, 3 + ArH), 7.75 (1H, ddd, J 8.4, 6.8, 1.2 Hz, ArH), 8.17 (1H, d, J 
8.4 Hz, AH); *C (101 MHz, CDCl3) 17.4 (CH3), 126.5 (CH), 128.4 (CH), 128.8 (2 + CH), 
129.0 (CH), 129.2 (2 + CH), 129.6 (CH), 129.7 (C), 130.0 (CH), 130.2 (C), 136.3 (C), 
143.3 (C), 144.6 (C), 151.7 (C), 164.5 (C); m/z (CI) 264.1024 (MH+. C17H14NO2 requires 










A solution of 4-phenylquinoline-2-carboxylic acid (87) (0.128 g, 0.514 mmol) in 
dichloromethane (10 mL) was cooled to 0 °C, and to this was added a few drops of 
N,N’-dimethylformamide followed by oxalyl chloride (62.5 µL, 0.770 mmol). The 
resultant solution was allowed to warm to ambient temperature and then stirred under 
reflux for 14 h. After cooling to ambient temperature, the reaction mixture was 
concentrated in vacuo and excess oxalyl chloride removed by azeotroping with toluene (3 
+ 20 mL). The crude residue was then reconstituted in dichloromethane (10 mL) and 
cooled to 0 °C.  1-Methylpiperazine (0.285 mL, 2.57 mmol) was added to the solution 
dropwise and the reaction mixture stirred under reflux for a further 18 h. On cooling to 
ambient temperature, the mixture was diluted with water (10 mL) and the aqueous layer 
extracted using ethyl acetate (3 + 20 mL). The organic layer was dried (MgSO4), filtered 
and concentrated in vacuo. Purification using flash column chromatography (ethyl 
acetate/petroleum ether, 1:1) gave 
4-phenylquinoline-2-N-(4’-methylpiperazine)carboxamide (80) (0.100 g, 59%) as a brown 
solid.  Mp 112–114 °C; ,max/cm
–1 (neat) 2899, 2801 (CH), 1626 (CO), 1551 (C=C), 1439, 
1290, 1258, 1132, 1001; *H (400 MHz, CDCl3) 2.35 (3H, s, CH3), 2.47 (2H, br s, NCH2), 
2.58 (2H, br s, NCH2), 3.71–3.81 (2H, m, NCH2), 3.86–3.95 (2H, m, NCH2), 7.46–7.57 
(6H, m, 6 + ArH), 7.65 (1H, s, ArH), 7.75 (1H, ddd, J 8.0, 6.8, 1.2 Hz, ArH), 7.93–7.97 
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(1H, m, ArH), 8.16 (1H, d, J 8.0 Hz, ArH); *C (101 MHz, CDCl3) 42.3 (CH2), 46.0 (CH3), 
47.2 (CH2), 54.7 (CH2), 55.4 (CH2), 120.9 (CH), 125.8 (CH), 126.6 (C), 127.6 (CH), 128.7 
(2 + CH), 128.7 (CH), 129.6 (2 + CH), 129.9 (CH), 130.1 (CH), 137.6 (C), 147.2 (C), 
149.8 (C), 153.4 (C), 167.6 (C); m/z (EI) 331.1689 (M+. C21H21N3O requires 331.1685), 










3-Methyl-4-phenylquinoline-2-N-(4’-methylpiperazine)carboxamide (81) was synthesised 
as described above for 4-phenylquinoline-2-N-(4’-methylpiperazine)carboxamide (80) 
using 3-methyl-4-phenylquinoline-2-carboxylic acid (88) (0.014 g, 0.053 mmol), a few 
drops of N,N’-dimethylformamide, oxalyl chloride (6.7 µL, 0.079 mmol) and 
1-methylpiperazine (29.5 µL, 0.266 mmol) in dichloromethane (5 mL). Purification using 
flash column chromatography (methanol/dichloromethane, 1:9) afforded 3-methyl-4-
phenylquinoline-2-N-(4’-methylpiperazine)carboxamide (81) (0.008 g, 43%) as a yellow 
solid.  Mp 162–163 °C; ,max/cm
–1 (neat) 2936 (CH), 2787, 1626 (CO), 1582 (C=C), 1483, 
1445, 1290, 1132, 1017; *H (400 MHz, CDCl3) 2.23 (3H, s, CH3), 2.34 (3H, s, CH3), 2.40 
(2H, t, J 5.2 Hz, NCH2), 2.57 (2H, t, J 4.8 Hz, NCH2), 3.38 (2H, t, J 5.2 Hz, NCH2), 3.93 
(2H, t, J 4.8 Hz, NCH2), 7.26 (1H, d, J 1.6 Hz, ArH), 7.28 (1H, d, J 1.6 Hz, ArH), 7.37–
7.45 (2H, m, 2 + ArH), 7.46–7.58 (3H, m, 3 + ArH), 7.66 (1H, ddd, J 8.4, 6.0, 2.4 Hz, 
ArH), 8.10 (1H, d, J 8.4 Hz, ArH); *C (101 MHz, CDCl3) 16.2 (CH3), 41.4 (CH2), 46.1 
(CH3), 46.6 (CH2), 54.7 (CH2), 55.2 (CH2), 125.2 (C), 126.0 (CH), 127.0 (CH), 127.5 (C), 
128.1 (CH), 128.7 (2 + CH), 128.9 (CH), 129.2 (2 + CH), 129.4 (CH), 136.6 (C), 145.9 
(C), 148.2 (C), 155.4 (C), 167.7 (C); m/z (EI) 345.1841 (M+. C22H23N3O requires 













To a solution of ethyl 4-bromoquinoline-2-carboxylate (94) (0.100 g, 0.357 mmol) in 
N,N’-dimethylformamide (7 mL) was added 2-bromophenylboronic acid (0.093 g, 0.46 
mmol), potassium phosphate (0.099 g, 0.47 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (0.013 g, 0.011 mmol).  The resultant suspension 
was stirred vigorously at 90 °C for 24 h and then cooled to ambient temperature.  An 
additional aliquot of 2-bromophenylboronic acid (0.046 g, 0.23 mmol), potassium 
phosphate (0.049 g, 0.23 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.013 g, 
0.011 mmol) was added to the reaction mixture and stirred at 90 °C for a further 24 h.  On 
cooling to ambient temperature, the mixture was diluted with dichloromethane (20 mL).  
The organic layer was then washed with water (3 + 10 mL) and the aqueous layer back 
extracted with dichloromethane (10 mL).  The combined organic layer was dried (MgSO4), 
filtered and concentrated in vacuo.  Purification using flash column chromatography (ethyl 
acetate/petroleum ether, 1:4) afforded ethyl 4-(2’-bromophenyl)quinoline-2-carboxylate 
(110) (0.088 g, 69%) as a pale yellow solid.  Mp 76–78 °C; ,max/cm
–1 (neat) 3059, 2982 
(CH), 1713 (CO), 1555 (C=C), 1462, 1370, 1246, 1103, 1022; *H (400 MHz, CDCl3) 1.50 
(3H, t, J 7.2 Hz, OCH2CH3), 4.53–4.62 (2H, m, OCH2CH3), 7.32–7.42 (2H, m, 2 + ArH), 
7.44–7.50 (1H, m, ArH), 7.51–7.62 (2H, m, 2 + ArH), 7.75–7.82 (2H, m, 2 + ArH), 8.09 
(1H, s, ArH), 8.39 (1H, d, J 8.4 Hz, ArH); *C (101 MHz, CDCl3) 14.4 (CH3), 62.3 (CH2), 
121.7 (CH), 123.0 (C), 125.7 (CH), 127.5 (CH), 127.8 (C), 128.7 (CH), 130.2 (CH), 130.2 
(CH), 131.2 (CH), 131.2 (CH), 133.1 (CH), 138.4 (C), 147.9 (C), 147.9 (C), 148.7 (C), 
165.4 (C); m/z (CI) 356.0292 (MH+. C18H15
79BrNO2 requires 356.0286), 278 (10%), 276 
(20), 202 (9).   
 






Ethyl 4-(2’-bromophenyl)-3-methylquinoline-2-carboxylate (111) was synthesised as 
described above for ethyl 4-(2’-bromophenyl)quinoline-2-carboxylate (110) using ethyl 4-
bromo-3-methylquinoline-2-carboxylate (95) (0.300 g, 1.02 mmol), 2-bromophenylboronic 
acid (0.266 g, 1.33 mmol), potassium phosphate (0.282 g, 1.33 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (0.118 g, 0.102 mmol) in 
N,N’-dimethylformamide (15 mL).  After 24 h, an additional aliquot of 2-
bromophenylboronic acid (0.133 g, 0.663 mmol) and potassium phosphate (0.141 g, 0.663 
mmol) was added and the suspension stirred at 100 °C for a further 18 h.  Purification 
using flash column chromatography (ethyl acetate/petroleum ether, 1:4) gave ethyl 4-(2’-
bromophenyl)-3-methylquinoline-2-carboxylate (111) (0.121 g, 32%) as a pale yellow oil, 
which crystallised to form a solid on standing .  Mp 86–87 °C; ,max/cm
–1 (neat) 2982 (CH), 
1721 (CO), 1562 (C=C), 1470, 1373, 1242, 1200, 1134, 1069; *H (500 MHz, CDCl3) 1.47 
(3H, t, J 7.0 Hz, OCH2CH3), 2.28 (3H, s, CH3), 4.54 (2H, q, J 7.0 Hz, OCH2CH3), 7.15–
7.23 (2H, m, 2 + ArH), 7.36 (1H, td, J 8.0, 1.5 Hz, ArH), 7.43–7.49 (2H, m, 2 + ArH), 7.67 
(1H, ddd, J 8.4, 6.9, 1.2 Hz, ArH), 7.76 (1H, dd, J 8.0, 1.0 Hz, ArH), 8.21 (1H, d, J 8.4 Hz, 
ArH); *C (126 MHz, CDCl3) 14.3 (CH3), 16.4 (CH3), 62.1 (CH2), 123.3 (C), 125.4 (CH), 
126.9 (C), 127.5 (C), 127.8 (CH), 128.1 (CH), 129.2 (CH), 130.0 (CH), 130.0 (CH), 130.8 
(CH), 133.1 (CH), 137.7 (C), 145.7 (C), 147.4 (C), 151.3 (C), 167.2 (C); m/z (EI) 369.0365 
(M+. C19H16
79BrNO2 requires 369.0364), 340 (10%), 297 (60), 290 (39), 216 (100), 189 
(32), 108 (12).  
 






To a solution of ethyl 4-(2’-bromophenyl)quinoline-2-carboxylate (110) (0.632 g, 1.77 
mmol) in a 50% aqueous ethanol mixture (60 mL) was added ground sodium hydroxide 
(0.284 g, 7.10 mmol) and the reaction mixture stirred vigorously under reflux for 4 h.  On 
cooling to ambient temperature, the ethanol was removed in vacuo, and the aqueous layer 
acidified (pH ~4) using a 1 M hydrochloric acid solution (~10 mL).  The crude product 
was extracted using dichloromethane (3 + 50 mL) and washed with water (3 + 50 mL).  
The organic layer was dried (MgSO4), filtered and concentrated in vacuo to give 
4-(2’-bromophenyl)quinoline-2-carboxylic acid (89) (0.582 g, 100%) as a light yellow 
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solid, which was used without further purification.  Mp 65–66 °C; ,max/cm
–1 (neat) 3063, 
2924 (CH), 1713 (CO), 1589 (C=C), 1466, 1381, 1227, 903, 763; *H (400 MHz, CDCl3) 
7.33 (1H, dd, J 7.2, 1.6 Hz, ArH), 7.40 (1H, td, J 8.0, 2.0 Hz, ArH), 7.45–7.67 (3H, m, 3 + 
ArH), 7.77 (1H, dd, J 8.0, 1.2 Hz, ArH), 7.85 (1H, ddd, 8.4, 6.4, 1.6 Hz, ArH), 8.20 (1H, s, 
ArH), 8.27 (1H, d, J 8.4 Hz, ArH); *C (101 MHz, CDCl3) 120.1 (CH), 122.8 (C), 126.2 
(CH), 127.6 (CH), 128.5 (C), 129.4 (CH), 129.7 (CH), 130.6 (CH), 131.1 (CH), 131.1 
(CH), 133.2 (CH), 137.8 (C), 145.6 (C), 146.0 (C), 150.6 (C), 164.4 (C); m/z (CI) 
327.9983 (MH+. C16H11
79BrNO2 requires 327.9973), 284 (50%), 250 (100), 206 (57), 204 
(19), 174 (10). 
 






3-Methyl-4-(2’-bromophenyl)quinoline-2-carboxylic acid (90) was synthesised as 
described above for 4-(2’-bromophenyl)quinoline-2-carboxylic acid (89) using ethyl 
4-(2-bromophenyl)-3-methylquinoline-2-carboxylate (111) (0.051 g, 0.14 mmol) and 
ground sodium hydroxide (0.022 g, 0.55 mmol) in a 50% aqueous ethanol mixture (10 
mL).  Extraction afforded 3-methyl-4-(2’-bromophenyl)quinoline-2-carboxylic acid (90) 
(0.042 g, 89%) as a pale brown solid, which was used without further purification.  Mp 
130–132 °C; ,max/cm
–1 (neat) 3329 (OH), 2976 (CH), 1717 (CO), 1593 (C=C), 1368, 1321, 
1234, 1020, 762; *H (400 MHz, CDCl3) 2.61 (3H, s, CH3), 7.18&7.30 (1H, m, ArH), 
7.39&7.45 (1H, m, ArH), 7.49&7.60 (3H, m, 3 + ArH), 7.73&7.82 (2H, m, 2 + ArH), 8.17 
(1H, d, J 8.0 Hz, ArH); *C (101 MHz, CDCl3) 16.9 (CH3), 125.8 (CH), 127.9 (CH), 128.4 
(C), 128.8 (C), 129.1 (CH), 129.2 (C), 129.4 (CH), 130.1 (CH), 130.2 (CH), 130.7 (CH), 
133.2 (CH), 137.3 (C), 143.7 (C), 144.4 (C), 150.1 (C), 164.3 (C); m/z (EI) 341.0056 (M+. 
C17H12
79BrNO2 requires 341.0051), 297 (32%), 262 (100), 217 (100), 216 (100), 189 (55), 















A solution of 4-(2’-bromophenyl)quinoline-2-carboxylic acid (89) (0.075 g, 0.23 mmol) in 
dichloromethane (10 mL) was cooled to 0 °C, and to this was added a few drops of 
N,N’-dimethylformamide followed by oxalyl chloride (23.0 µL, 0.274 mmol).  The 
resultant solution was allowed to warm to ambient temperature and then stirred under 
reflux for 4 h.  After cooling to ambient temperature, the reaction mixture was 
concentrated in vacuo and excess oxalyl chloride removed by azeotroping with toluene (3 
+ 10 mL).  The crude residue was then reconstituted in dichloromethane (10 mL) and 
cooled to 0 °C.  Dimethylamine (2.0 M in tetrahydrofuran) (0.570 mL, 1.14 mmol) was 
added to the solution dropwise and the reaction mixture stirred under reflux for a further 24 
h.  On cooling to ambient temperature, the mixture was diluted with water (10 mL) and the 
aqueous layer extracted using ethyl acetate (3 + 10 mL).  The organic layer was dried 
(MgSO4), filtered and concentrated in vacuo.  Purification using flash column 
chromatography (methanol/dichloromethane, 1:99) afforded  
4-(2’-bromophenyl)quinoline-2-N-dimethylcarboxamide (82) (0.021 g, 26%) as a pale 
yellow oil.  ,max/cm
–1 (neat) 3059 (CH), 1640 (CO), 1553 (C=C), 1462, 1397, 1343, 1142, 
1026, 909; *H (400 MHz, CDCl3) 3.21 (6H, s, 2 + NCH3), 7.34–7.40 (2H, m, 2 + ArH), 
7.44–7.49 (1H, m, ArH), 7.51–7.54 (2H, m, 2 + ArH), 7.60 (1H, s, ArH), 7.74–7.79 (2H, 
m, 2 + ArH), 8.19 (1H, d, J 8.4 Hz, ArH); *C (101 MHz, CDCl3) 34.8 (CH3), 38.1 (CH3), 
120.1 (CH), 121.9 (C), 124.8 (CH), 125.5 (C), 126.4 (CH), 126.6 (CH), 129.0 (CH), 129.0 
(CH), 129.1 (CH), 130.2 (CH), 132.0 (C), 137.3 (C), 145.9 (C), 147.5 (C), 152.7 (C), 167.9 
(C); m/z (ESI) 377.0251 (MNa+. C18H15










3-Methyl-4-(2’-bromophenyl)quinoline-2-N-dimethylcarboxamide (83) was synthesised as 
described above for 4-(2’-bromophenyl)quinoline-2-N-dimethylcarboxamide (82) using 
3-methyl-4-(2-bromophenyl)quinoline-2-carboxylic acid (90) (0.042 g, 0.12 mmol), a few 
drops of N,N’-dimethylformamide, oxalyl chloride (15.6 µL, 0.184 mmol) and 
dimethylamine (2.0 M in tetrahydrofuran) (0.307 mL, 0.614 mmol) in dichloromethane (10 
mL).  Purification using flash column chromatography (ethyl acetate/petroleum ether, 7:3) 
afforded 3-methyl-4-(2’-bromophenyl)quinoline-2-N-dimethylcarboxamide (83) (0.017 g, 
38%) as a pale yellow oil.  ,max/cm
–1 (neat) 3063 (CH), 2934 (CH), 1641 (CO) 1499, 1393, 
1263, 1128, 1061, 909; *H (400 MHz, CDCl3) 2.16 (3H, s, CH3), 2.92 (3H, s, CH3), 3.22 
(3H, s, CH3), 7.20–7.28 (2H, m, 2 + ArH), 7.34–7.55 (3H, m, 3 + ArH), 7.67 (1H, ddd, J 
8.4, 6.8, 1.6 Hz, ArH), 7.77 (1H, dd, J 8.0, 1.2 Hz, ArH), 8.13 (1H, d, J 8.0 Hz, ArH); *C 
(101 MHz, CDCl3) 15.6 (CH3), 34.6 (CH3), 38.0 (CH3), 123.3 (C), 125.3 (CH), 125.6 (C), 
126.8 (C), 127.3 (CH), 127.8 (CH), 129.1 (CH), 129.5 (CH), 130.0 (CH), 130.7 (CH), 
133.1 (CH), 137.6 (C), 146.0 (C), 146.8 (C), 155.9 (C), 169.1 (C); m/z (CI) 369.0606 
(MH+. C19H18
79BrN2O requires 369.0602), 306 (5%), 291 (100), 250 (40), 206 (20), 113 
(19). 
 










To a solution of ethyl 4-bromoquinoline-2-carboxylate (94) (0.100 g, 0.357 mmol) in 
N,N’-dimethylformamide (5 mL) was added pyridin-4-ylboronic acid (0.053 g, 0.43 
mmol), potassium phosphate (0.091 g, 0.43 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (0.042 g, 0.036 mmol).  The resultant suspension 
was stirred vigorously at 120 °C for 24 h, and then cooled to ambient temperature.  An 
additional aliquot of pyridin-4-ylboronic acid (0.053 g, 0.43 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (0.042 g, 0.036 mmol) was added to the reaction 
mixture and stirred at 120 °C for a further 18 h.  On cooling to ambient temperature, the 
mixture was concentrated in vacuo and then reconstituted in dichloromethane (10 mL).  
The organic layer was then washed with water (3 + 10 mL), dried (MgSO4), filtered and 
concentrated in vacuo.  Purification using flash column chromatrography (ethyl acetate) 
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afforded ethyl 4-(pyridin-4’-yl)quinoline-2-carboxylate (114) (0.093 g, 94%) as a yellow 
oil.  ,max/cm
–1 (neat) 3055, 2986 (CH), 1721 (CO), 1582 (C=C), 1435, 1373, 1250, 1180, 
1111; *H (400 MHz, CDCl3) 1.50 (3H, t, J 7.2 Hz, CH2CH3), 4.59 (2H, q, J 7.2 Hz, 
CH2CH3), 7.48 (2H, app dd, J 4.4, 1.6 Hz, 3’-H and 5’-H), 7.65 (1H, ddd, J 8.4, 7.2, 1.2 
Hz, ArH), 7.81–7.90 (2H, m, 2 + ArH), 8.13 (1H, s, ArH), 8.42 (1H, d, J 8.4 Hz, ArH), 
8.82 (2H, app dd, J 4.4, 1.6 Hz, 2’-H and 6’-H); *C (101 MHz, CDCl3) 14.4 (CH3), 62.5 
(CH2), 120.9 (CH), 124.3 (2 + CH), 124.9 (CH), 126.8 (C), 129.3 (CH), 130.5 (CH), 131.5 
(CH), 145.4 (C), 146.8 (C), 147.9 (C), 148.2 (C), 150.3 (2 + CH), 165.2 (C); m/z (CI) 
279.1135 (MH+. C17H15N2O2 requires 279.1134), 207 (24%), 165 (6), 149 (9), 113 (13), 71 
(31).  
 









Ethyl 4-(furan-2’-yl)quinoline-2-carboxylate (115) was synthesised as described above for 
ethyl 4-(pyridin-4’-yl)quinoline-2-carboxylate (114) using ethyl 
4-bromoquinoline-2-carboxylate (94) (0.100 g, 0.357 mmol), furan-2-boronic acid (0.048 
g, 0.43 mmol), potassium phosphate (0.090 g, 0.42 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (0.042 g, 0.036 mmol) in 
N,N’-dimethylformamide (5 mL).  Purification using flash column chromatography (ethyl 
acetate/petroleum ether, 2:3) gave ethyl 4-(furan-2’-yl)quinoline-2-carboxylate (115) 
(0.081 g, 85%) as a yellow oil.  ,max/cm
–1 (neat) 3101, 2987 (CH), 1715 (CO), 1591 
(C=C), 1370, 1328, 1255, 1214, 1021; *H (400 MHz, CDCl3) 1.51 (3H, t, J 7.2 Hz, 
CH2CH3), 4.58 (2H, q, J 7.2 Hz, CH2CH3), 6.66 (1H, dd, J 3.2, 1.6 Hz, 4’-H), 7.08 (1H, d, 
J 3.2 Hz, 3’-H), 7.69 (1H, ddd, J 8.4, 6.8, 1.2 Hz, ArH), 7.73 (1H, d, J 1.6 Hz, 5’-H), 7.80 
(1H, ddd, J 8.4, 6.8, 1.2 Hz, ArH), 8.35 (1H, dd, J 8.4, 0.4 Hz, ArH), 8.42 (1H, s, ArH), 
8.57 (1H, dd, J 8.4, 0.4 Hz, ArH); *C (101 MHz, CDCl3) 14.4 (CH3), 62.4 (CH2), 112.2 
(CH), 112.9 (CH), 118.5 (CH), 125.3 (C), 125.4 (CH), 129.0 (CH), 130.0 (CH), 131.5 
(CH), 136.9 (C), 144.4 (CH), 148.0 (C), 148.7 (C), 150.8 (C), 165.4 (C); m/z (EI) 267.0898 
(M+. C16H13NO3 requires 267.0895), 195 (100%), 166 (38), 140 (30), 85 (100), 47 (53).   
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Ethyl 4-(thiophen-3’-yl)quinoline-2-carboxylate (116) was synthesised as described above 
for ethyl 4-(pyridin-4’-yl)quinoline-2-carboxylate (114) using ethyl 
4-bromoquinoline-2-carboxylate (94) (0.100 g, 0.357 mmol), 3-thienylboronic acid (0.055 
g, 0.43 mmol), potassium phosphate (0.091 g, 0.43 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (0.042 g, 0.036 mmol) in 
N,N’-dimethylformamide (5 mL).  Purification using flash column chromatography (ethyl 
acetate/petroleum ether, 3:7) afforded ethyl 4-(thiophen-3’-yl)quinoline-2-carboxylate 
(116) (0.077 g, 76%) as a pale yellow oil.  ,max/cm
–1 (neat) 3069 (CH), 1709 (CO), 1584 
(C=C), 1327, 1250, 1150, 1113, 1030, 810; *H (400 MHz, CDCl3) 1.50 (3H, t, J 7.2 Hz, 
CH2CH3), 4.58 (2H, q, J 7.2 Hz, CH2CH3), 7.39 (1H, dd, J 4.8, 1.2 Hz, 4’-H), 7.55 (1H, 
dd, J 4.8, 2.8 Hz, 5’-H), 7.60 (1H, dd, J 2.8, 1.2 Hz, 2’-H), 7.64 (1H, ddd, J 8.4, 6.8, 1.6 
Hz, ArH), 7.80 (1H, ddd, J 8.4, 6.8, 1.6 Hz, ArH), 8.14 (1H, dd, J 8.4, 1.2 Hz, ArH), 8.18 
(1H, s, ArH), 8.34 (1H, d, J 8.4 Hz, ArH); *C (101 MHz, CDCl3) 14.4 (CH3), 62.4 (CH2), 
121.0 (CH), 121.1 (CH), 125.6 (CH), 126.6 (CH), 127.8 (C), 128.7 (CH), 128.8 (CH), 
130.1 (CH), 131.2 (CH), 138.0 (C), 144.6 (C), 147.8 (C), 148.2 (C), 165.5 (C); m/z (EI) 
283.0665 (M+. C16H13NO2S requires 283.0667), 239 (18%), 211 (100), 184 (27), 139 (18), 
83 (10). 
 










To a solution of ethyl 4-(pyridin-4’-yl)quinoline-2-carboxylate (114) (0.093 g, 0.33 mmol) 
in a 50% aqueous ethanol mixture (10 ml) was added ground sodium hydroxide (0.053 g, 
1.3 mmol), and the reaction mixture stirred vigorously under reflux for 18 h. On cooling to 
ambient temperature, the ethanol was removed in vacuo, and the aqueous layer acidified 
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(pH ~4) using a 1 M hydrochloric acid solution (~10 mL). The crude product was extracted 
using dichloromethane (3 + 10 mL), dried (MgSO4), filtered and concentrated in vacuo to 
give 4-(pyridin-4’-yl)quinoline-2-carboxylic acid (91) (0.078 g, 93%) as an off white solid, 
which was used without further purification.  Mp >201 °C (decomp.); ,max/cm
–1 (neat) 
3067 (CH), 2376 (OH), 1717 (CO), 1612 (C=C), 1498, 1409, 1217, 1032, 895; *H (400 
MHz, DMSO-d6) 7.65 (2H, app dd, J 4.4, 1.6 Hz, 3’-H and 5’-H), 7.76 (1H, ddd, J 8.0, 
6.8, 1.2 Hz, ArH), 7.86–7.91 (1H, m, ArH), 7.94 (1H, ddd, J 8.0, 6.8, 1.2 Hz, ArH), 8.02 
(1H, s, ArH), 8.27 (1H, d, J 8.0 Hz, ArH), 8.80 (2H, app dd, J 4.4, 1.6 Hz, 2’-H and 6’-H); 
*C (101 MHz, DMSO-d6) 120.6 (CH), 124.2 (2 + CH), 124.9 (CH), 125.9 (C), 129.3 (CH), 
130.5 (CH), 130.6 (CH), 144.6 (C), 146.1 (2 + CH), 147.3 (C), 150.1 (2 + CH), 166.2 (C); 
m/z (ESI) 249.0661 (M&H–. C15H9N2O2 requires 249.0670). 
 









4-(Furan-2’-yl)quinoline-2-carboxylic acid (92) was synthesised as described above for 
4-(pyridin-4’-yl)quinoline-2-carboxylic acid (91) using ethyl 4-(furan-2’-yl)quinoline-2-
carboxylate (115) (0.081 g, 0.30 mmol) and ground sodium hydroxide (0.049 g, 1.2 mmol) 
in a 50% aqueous ethanol mixture (10 mL).  Extraction afforded 
4-(furan-2’-yl)quinoline-2-carboxylic acid (92) (0.058 g, 79%) as a yellow oil, which was 
used without further purification.  ,max/cm
–1 (neat) 3358 (OH), 2928 (CH), 1674 (CO), 
1593 (C=C), 1464, 1398, 1149, 1014, 801; *H (400 MHz, CDCl3) 6.69 (1H, dd, J 3.6, 1.6 
Hz, 4’-H), 7.17 (1H, d, J 3.6 Hz, 3’-H), 7.74–7.79 (2H, m, 5’-H and ArH), 7.86 (1H, ddd, J 
8.4, 6.8, 1.2 Hz, ArH), 8.19–8.23 (1H, m, ArH), 8.52 (1H, s, ArH), 8.67–8.72 (1H, m, 
ArH); *C (101 MHz, CDCl3) 112.5 (CH), 113.8 (CH), 116.5 (CH), 125.9 (C), 126.0 (CH), 
129.5 (CH), 129.9 (CH), 130.9 (CH), 138.6 (C), 145.1 (C), 145.5 (CH), 146.8 (C), 150.6 
(C), 164.2 (C); m/z (EI) 239.0586 (M+. C14H9NO3 requires 239.0582), 195 (100%), 166 














4-(Thiophen-3’-yl)quinoline-2-carboxylic acid (93) was synthesised as described above for 
4-(pyridin-4’-yl)quinoline-2-carboxylic acid (91) using ethyl 4-(thiophen-3’-yl)quinoline-
2-carboxylate (116) (0.077 g, 0.27 mmol) and ground sodium hydroxide (0.044 g, 1.1 
mmol) in a 50% aqueous ethanol mixture (10 mL).  Extraction afforded 
4-(thiophen-3’-yl)quinoline-2-carboxylic acid (93) (0.055 g, 80%) as a pale yellow oil, 
which was used without further purification.  ,max/cm
–1 (neat) 3097 (CH), 1681 (CO), 1592 
(C=C), 1513, 1360, 1156, 1024, 802, 766; *H (400 MHz, CDCl3) 7.39 (1H, dd, J 4.8, 1.2 
Hz, 4’-H), 7.57 (1H, dd, J 4.8, 2.8 Hz, 5’-H), 7.63 (1H, dd, J 2.8, 1.2 Hz, 2’-H), 7.70 (1H, 
ddd, J 8.4, 6.8, 1.2 Hz, ArH), 7.86 (1H, ddd, J 8.4, 6.8, 1.6 Hz, ArH), 8.20–8.24 (2H, m, 2 
+ ArH), 8.28 (1H, s, ArH); *C (101 MHz, CDCl3) 119.1 (CH), 126.0 (CH), 126.1 (CH), 
126.9 (CH), 128.4 (C), 128.6 (CH), 129.3 (CH), 129.9 (CH), 130.9 (CH), 137.6 (C), 145.5 
















A solution of 4-(pyridin-4’-yl)quinoline-2-carboxylic acid (117) (0.020 g, 0.080 mmol) in 
dichloromethane (5 mL) was cooled to 0 °C, and to this was added a few drops of 
N,N’-dimethylformamide followed by oxalyl chloride (10.1 µL, 0.120 mmol).  The 
resultant solution was allowed to warm to ambient temperature and then stirred under 
reflux for 18 h.  After cooling to ambient temperature, the reaction mixture was 
concentrated in vacuo and excess oxalyl chloride removed by azeotroping with toluene (3 
+ 5 mL).  The crude residue was then reconstituted in dichloromethane (5 mL) and cooled 
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to 0 °C.  1-Methylpiperazine (44.3 µL, 0.400 mmol) was added to the solution dropwise 
and the reaction mixture stirred under reflux for a further 3 h. On cooling to ambient 
temperature, the mixture was diluted with water (10 mL) and the aqueous layer extracted 
using ethyl acetate (3 + 10 mL). The organic layer was dried (MgSO4), filtered and 
concentrated in vacuo.  Purification using flash column chromatography 
(methanol/dichloromethane, 1:9) afforded 
4-(pyridin-4’-yl)quinoline-2-N-(4’’-methylpiperazine)carboxamide (84) (0.014 g, 53%) as 
a yellow oil.  ,max/cm
–1 (neat) 3433, 2926 (CH), 2795, 1667 (CO), 1587 (C=C), 1437, 
1290, 1257, 999; *H (400 MHz, CDCl3) 2.36 (3H, s, CH3), 2.48 (2H, t, J 4.8 Hz, NCH2), 
2.58 (2H, t, J 5.2 Hz, NCH2), 3.80 (2H, t, J 4.8 Hz, NCH2), 3.92 (2H, t, J 5.2 Hz, NCH2), 
7.47 (2H, d, J 5.2 Hz, 3’-H and 5’-H), 7.60 (1H, ddd, J 8.4, 7.2, 1.2 Hz, ArH), 7.68 (1H, s, 
ArH), 7.81 (1H, ddd, J 8.4, 7.2, 1.2 Hz, ArH), 7.82–7.86 (1H, m, ArH), 8.20 (1H, d, J 8.4 
Hz, ArH), 8.81 (2H, br s, 2’-H and 6’-H); *C (101 MHz, CDCl3) 42.4 (CH2), 46.1 (CH3), 
47.3 (CH2), 54.7 (CH2), 55.4 (CH2), 120.8 (CH), 124.2 (2 + CH), 125.0 (CH), 125.7 (C), 
128.3 (CH), 130.3 (CH), 130.5 (CH), 145.4 (C), 146.7 (C), 147.0 (C), 150.2 (2 + CH), 













4-(Furan-2’-yl)quinoline-2-N-(4’’-methylpiperazine)carboxamide (85) was synthesised as 
described above for 4-(pyridin-4’-yl)quinoline-2-N-(4’’-methylpiperazine)carboxamide 
(84) using 4-(furan-2’-yl)quinoline-2-carboxylic acid (118) (0.058 g, 0.24 mmol), a few 
drops of N,N’-dimethylformamide, oxalyl chloride (30.8 µL, 0.364 mmol) and 1-
methylpiperazine (0.134 mL, 1.21 mmol) in dichloromethane (10 mL).  Purification using 
flash column chromatography (methanol/dichloromethane, 1:9) gave 
4-(furan-2’-yl)quinoline-2-N-(4’’-methylpiperazine)carboxamide (85) (0.044 g, 56%) as a 
brown oil.  ,max/cm
–1 (neat) 3482, 2938 (CH), 2795, 1626 (CO), 1551 (C=C), 1472, 1290, 
1260, 1132; *H (400 MHz, CDCl3) 2.35 (3H, s, CH3), 2.45 (2H, br s, NCH2), 2.58 (2H, br 
s, NCH2), 3.74 (2H, t, J 4.8 Hz, NCH2), 3.92 (2H, t, J 4.8 Hz, NCH2), 6.64 (1H, dd, J 3.4, 
1.8 Hz, 4’-H), 7.04 (1H, d, J 3.4 Hz, 3’-H), 7.65 (1H, ddd, J 8.4, 6.8, 1.2 Hz, ArH), 7.70 
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(1H, d, J 1.8 Hz, 5’-H), 7.77 (1H, ddd, J 8.4, 6.8, 1.2 Hz, ArH), 7.94 (1H, s, ArH), 8.15 
(1H, dd, J 8.4, 0.8 Hz, ArH), 8.56 (1H, dd, J 8.4, 0.8 Hz, ArH); *C (101 MHz, CDCl3) 42.3 
(CH2), 46.1 (CH3), 47.2 (CH2), 54.7 (CH2), 55.4 (CH2), 112.2 (CH), 112.6 (CH), 118.2 
(CH), 124.2 (C), 125.5 (CH), 128.0 (CH), 129.9 (CH), 130.4 (CH), 136.9 (C), 144.3 (CH), 
147.7 (C), 150.9 (C), 153.4 (C), 167.5 (C); m/z (EI) 321.1484 (M+. C19H19N3O2 requires 














4-(Thiophen-3’-yl)quinoline-2-N-(4’’-methylpiperazine)carboxamide (86) was synthesised 
as described above for 4-(pyridin-4’-yl)quinoline-2-N-(4’’-methylpiperazine)carboxamide 
(84) using 4-(thiophen-3’-yl)quinoline-2-carboxylic acid (119) (0.055 g, 0.22 mmol), a few 
drops of N,N’-dimethylformamide, oxalyl chloride (27.3 µL, 0.323 mmol) and 1-
methylpiperazine (0.119 mL, 1.08 mmol) in dichloromethane (10 mL).  Purification using 
flash column chromatography (methanol/dichloromethane, 1:9) afforded 
4-(thiophen-3’-yl)quinoline-2-N-(4’’-methylpiperazine)carboxamide (86) (0.023 g, 32%) 
as a yellow oil.  ,max/cm
–1 (neat) 3065, 2801 (CH), 1626 (CO), 1589 (C=C), 1551, 1439, 
1258, 997, 891; *H (400 MHz, CDCl3) 2.35 (3H, s, CH3), 2.47 (2H, br s, NCH2), 2.58 (2H, 
br s, NCH2), 3.76 (2H, t, J 4.8 Hz, NCH2), 3.91 (2H, t, J 4.8 Hz, NCH2), 7.36 (1H, dd, J 
4.8, 1.2 Hz, 4’-H), 7.52 (1H, dd, J 4.8, 2.8 Hz, 5’-H), 7.55–7.61 (2H, m, 2’-H and ArH), 
7.70 (1H, s, ArH), 7.76 (1H, ddd, J 8.4, 6.8, 1.2 Hz, ArH), 8.12 (1H, dd, J 8.4, 0.8 Hz, 
ArH), 8.10–8.14 (1H, m, ArH); *C (101 MHz, CDCl3) 42.2 (CH2), 46.0 (CH3), 47.1 (CH2), 
54.6 (CH2), 55.3 (CH2), 120.6 (CH), 125.4 (CH), 125.7 (CH), 126.5 (CH), 126.6 (CH), 
127.7 (CH), 128.8 (C), 130.0 (CH), 130.2 (CH), 138.0 (C), 144.5 (C), 147.3 (C), 153.3 (C), 
167.6 (C); m/z (EI) 337.1247 (M+. C19H19N3O5 requires 337.1249), 267 (95%), 210 (100), 














4-(2’-Bromophenyl)quinoline-2-N-diethylcarboxamide (122) was synthesised as described 
above for 4-(pyridin-4’-yl)quinoline-2-N-(4’’-methylpiperazine)carboxamide (84) using 
4-(2’-bromophenyl)quinoline-2-carboxylic acid (89) (0.150 g, 0.457 mmol), a few drops of 
N,N’-dimethylformamide, oxalyl chloride (46.0 µL, 0.549 mmol) and diethylamine (0.236 
mL, 2.29 mmol) in dichloromethane (20 mL).  Purification using flash column 
chromatography (ethyl acetate/petroleum ether, 3:2) afforded 4-(2’-
bromophenyl)quinoline-2-N-diethylcarboxamide (122) (0.080 g, 46%) as a pale yellow oil.  
,max/cm
–1 (neat) 2981 (CH), 1627 (CO), 1551 (C=C), 1497, 1435, 1273, 1095, 1018, 910; 
*H (400 MHz, CDCl3) 1.25 (3H, t, J 7.2 Hz, NCH2CH3), 1.32 (3H, t, J 7.2 Hz, NCH2CH3), 
3.40–3.58 (2H, m, NCH2CH3), 3.63 (2H, qd, J 7.2, 1.6 Hz, NCH2CH3), 7.33–7.39 (2H, m, 
2 + ArH), 7.43–7.48 (1H, m, ArH), 7.49–7.53 (2H, m, 2 + ArH), 7.55 (1H, s, ArH), 7.72–
7.78 (2H, m, 2 + ArH), 8.18 (1H, d, J 8.4 Hz, ArH); *C (101 MHz, CDCl3) 13.0 (CH3), 
14.5 (CH3), 40.4 (CH2), 43.5 (CH2), 120.8 (CH), 123.0 (C), 125.7 (CH), 126.5 (C), 127.4 
(CH), 127.5 (CH), 129.9 (CH), 130.1 (CH), 130.1 (CH), 131.3 (CH), 133.0 (CH), 138.4 
(C), 147.0 (C), 148.3 (C), 154.3 (C), 168.6 (C); m/z (CI) 385.0736 (MH+. C20H20
81BrN2O 
requires 385.0741), 383 (100%), 351 (24), 303 (73).  
 







A schlenk tube was charged with copper(I) iodide (0.010 g, 0.052 mmol) and sodium 
iodide (0.300 g, 2.00 mmol), evacuated and then backfilled with argon.  N,N-
Dimethylethylenediamine (10.8 µL, 0.100 mmol) and 5-bromoindole (128) (0.197 g, 1.00 
mmol) were dissolved in 1,4-dioxane (1 mL) and added to the Schlenk tube under a stream 
of argon.  The tube was then sealed and the resultant mixture stirred vigorously at 110 °C 
for 72 h.  On cooling to ambient temperature, water (20 mL) was added and the crude 
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product extracted using dichloromethane (3 + 20 mL).  The organic layer was dried 
(MgSO4), filtered and concentrated in vacuo.  Purification using flash column 
chromatography (ethyl acetate/petroleum ether, 15:85) gave 5-iodoindole (129) (0.154 g, 
63%) as an off white solid.  Spectroscopic data in accordance with the literature.101 Mp 96–
97 °C (lit.,101 mp 99–100 °C); ,max/cm
–1 (neat) 3414 (NH), 3103 (CH), 1562 (C=C), 1442, 
1409, 1314, 1090, 999, 886; *H (400 MHz, CDCl3) 6.49 (1H, dd, J 3.1, 2.0 Hz, 2-H), 7.16–
7.21 (2H, m, 3-H and ArH), 7.44 (1H, dd, J 8.5, 1.5 Hz, ArH), 7.98–7.99 (1H, m, ArH), 
8.17 (1H, br s, NH); *C (101 MHz, CDCl3) 83.3 (C), 102.1 (CH), 112.9 (CH), 124.9 (CH), 
129.6 (CH), 130.3 (CH), 130.5 (C), 134.8 (C); m/z (ESI) 241.9462 (MH–. C8H5IN requires 
241.9472).  
 






To a solution of ethyl 4-bromoquinoline-2-carboxylate (94) (0.196 g, 0.699 mmol) in 
N,N’-dimethylformamide (10 mL) were added 2-nitrophenylboronic acid (0.140 g, 0.839 
mmol), potassium phosphate (0.178 g, 0.839 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (0.081 g, 0.070 mmol).  The resultant suspension 
was stirred at 120 °C for 24 h.  An additional aliquot of 2-nitrophenylboronic acid (0.140 
g, 0.839 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.081 g, 0.070 mmol) was 
added and the suspension stirred for a further 24 h.  After cooling to ambient temperature, 
the reaction mixture was concentrated in vacuo and reconstituted in dichloromethane (20 
mL).  The organic layer was washed with water (3 + 20 mL), dried (MgSO4), filtered and 
concentrated in vacuo. Purification using flash column chromatography (ethyl 
acetate/petroleum ether, 2:3) afforded ethyl 4-(2’-nitrophenyl)quinoline-2-carboxylate 
(131) (0.205 g, 91%) as a yellow solid.  Mp 156–157 °C; ,max/cm
–1 (neat) 2990 (CH), 1713 
(CO), 1512, 1350, 1251, 1136, 1107, 1020; *H (500 MHz, CDCl3) 1.49 (3H, t, J 7.1 Hz, 
CH2CH3), 4.52–4.62 (2H, m, CH2CH3), 7.43–7.48 (2H, m, 2 + ArH), 7.55 (1H, ddd, J 8.3, 
6.9, 1.2 Hz, ArH), 7.70 (1H, ddd, J 8.0, 7.5, 1.5 Hz, ArH), 7.75–7.80 (2H, m, 2 + ArH), 
8.05 (1H, s, ArH), 8.24 (1H, dd, J 8.0, 1.5 Hz, ArH), 8.39 (1H, d, J 8.3 Hz, ArH); *C (126 
MHz, CDCl3) 14.3 (CH3), 62.2 (CH2), 120.4 (CH), 124.4 (CH), 124.8 (CH), 127.5 (C), 
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129.1 (CH), 129.9 (CH), 130.2 (CH), 131.4 (CH), 132.3 (CH), 132.7 (C), 133.3 (CH), 
146.2 (C), 147.7 (C), 148.0 (C), 148.7 (C), 165.2 (C); m/z (EI) 322.0951 (M+. C18H14N2O4 
requires 322.0954), 278 (7%), 250 (100), 205 (10), 165 (9), 131 (11), 103 (9), 77 (7), 43 
(15).  
 






Tin(II) chloride dihydrate (0.700 g, 3.10 mmol) was added in one portion to a stirred 
solution of ethyl 4-(2’-nitrophenyl)quinoline-2-carboxylate (131) (0.200 g, 0.621 mmol) in 
ethanol (10 mL) and the reaction mixture stirred under reflux for 15 h.  After cooling to 
ambient temperature, a saturated solution of sodium hydrogen carbonate (20 mL) was 
added, and the crude product extracted with ethyl acetate (3 + 30 mL).  The organic layer 
was washed with water (30 mL), dried (MgSO4), filtered and concentrated in vacuo to 
afford ethyl 4-(2’-aminophenyl)quinoline-2-carboxylate (132) (0.180 g, 99%) as a yellow 
solid, which was used without further purification.  Mp 138–139 °C; ,max/cm
–1 (neat) 3356 
(NH), 2926 (CH), 1716 (CO), 1494, 1452, 1375, 1247, 1230, 1108; *H (400 MHz, CDCl3) 
1.48 (3H, t, J 7.1 Hz, CH2CH3), 4.56 (2H, q, J 7.1 Hz, CH2CH3), 6.86 (1H, d, J 8.0 Hz, 
ArH), 6.92 (1H, td, J 7.5, 1.2 Hz, ArH), 7.15 (1H, dd, J 7.5, 1.2 Hz, ArH), 7.32 (1H, td, J 
8.0, 1.5 Hz, ArH), 7.59 (1H, ddd, J 8.0, 6.8, 1.2 Hz, ArH), 7.74–7.82 (2H, m, 2 + ArH), 
8.17 (1H, s, ArH), 8.38 (1H, d, J 8.0, 0.7 Hz, ArH); *C (101 MHz, CDCl3) 14.4 (CH3), 62.3 
(CH2), 115.8 (CH), 118.6 (CH), 122.2 (CH), 122.6 (C), 125.9 (CH), 128.0 (C), 128.8 (CH), 
130.0 (CH), 130.3 (CH), 130.6 (CH), 131.3 (CH), 143.7 (C), 147.5 (C), 148.2 (C), 148.4 
(C), 165.4 (C); m/z (EI) 292.1208 (M+. C18H16N2O4 requires 292.1212), 219 (18), 190 (3), 
165 (2), 83 (3), 47 (18). 
 






To a solution of ethyl 4-(2’-aminophenyl)quinoline-2-carboxylate (132) (0.030 g, 
0.10 mmol) in acetonitrile (1 mL) was added p-toluenesulfonic acid monohydrate (0.059 g, 
0.31 mmol) at ambient temperature.  The resulting solution was then cooled to 0 °C and a 
solution of potassium iodide (0.043 g, 0.26 mmol) and sodium nitrite (0.014 g, 0.20 mmol) 
in water (0.10 mL) was added dropwise over a period of 0.25 h.  The reaction mixture was 
stirred at 0 °C for 1 h, and then allowed to gradually warm to ambient temperature and 
stirred overnight.  The reaction mixture was made alkaline (pH ~9) by the addition of a 
saturated solution of sodium hydrogen carbonate, and excess iodine quenched by the 
addition of a 0.5 M sodium thiosulfate solution (~2 mL).  The crude mixture was extracted 
with dichloromethane (2 + 10 mL), dried (MgSO4), filtered and concentrated in vacuo.  
Purification using flash column chromatography (ethyl acetate/petroleum ether, 3:2) gave 
ethyl 4-(2’-iodophenyl)quinoline-2-carboxylate (126) (0.034 g, 83%) as a pale yellow 
solid. Mp 107–109 °C; ,max/cm
–1 (neat) 2928 (CH), 1717 (CO), 1555 (C=C), 1458, 1370, 
1250, 1231, 1105, 1015; *H (500 MHz, CDCl3) 1.50 (3H, t, J 7.1 Hz, CH2CH3), 4.54–4.61 
(2H, m, CH2CH3), 7.20 (1H, td, J 8.0, 1.5 Hz, ArH), 7.32 (1H, dd, J 7.5, 1.5 Hz, ArH), 
7.49–7.50 (2H, m, 2 + ArH), 7.57 (1H, ddd, J 8.5, 6.5, 1.5 Hz, ArH), 7.79 (1H, ddd, J 8.5, 
6.5, 1.5 Hz, ArH), 8.04 (1H, s, ArH), 8.05 (1H, d, J 1.5 Hz, ArH), 8.40 (1H, d, J 8.5 Hz, 
ArH); *C (126 MHz, CDCl3) 14.3 (CH3), 62.2 (CH2), 98.2 (C), 121.5 (CH), 125.7 (CH), 
127.6 (C), 128.2 (CH), 128.6 (CH), 130.0 (CH), 130.1 (CH), 130.2 (CH), 131.2 (CH), 
139.5 (CH), 142.5 (C), 148.0 (C), 148.1 (C), 151.5 (C), 165.3 (C); m/z (EI) 403.0065 (M+. 
C18H14INO2 requires 403.0069), 388 (12%), 358 (6), 330 (70), 205 (18), 136 (24), 84 
(100).  
 






To a solution of ethyl 4-(2’-iodophenyl)quinoline-2-carboxylate (126) (0.133 g, 0.330 
mmol) in a 50% aqueous ethanol mixture (5 ml) was added ground sodium hydroxide 
(0.053 g, 1.3 mmol), and the reaction mixture stirred vigorously under reflux for 24 h.  On 
cooling to ambient temperature, the ethanol was removed in vacuo, and the aqueous layer 
acidified (pH ~4) using a 1 M hydrochloric acid solution (~10 mL).  The crude product 
was extracted using dichloromethane (3 + 10 mL), dried (MgSO4), filtered and 
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concentrated in vacuo to yield 4-(2’-iodophenyl)quinoline-2-carboxylic acid (133) (0.124 
g, 100%) as a yellow solid, which was used without further purification. Mp 166–168 °C; 
,max/cm
–1 (neat) 2922 (CH), 2340 (OH), 1707 (CO), 1593 (C=C), 1462, 1377, 1227, 1015; 
*H (500 MHz, CDCl3) 7.22 (1H, td, J 8.0, 1.0 Hz, ArH), 7.31 (1H, dd, J 7.6, 1.5 Hz, ArH), 
7.52 (1H, td, J 7.6, 1.0 Hz, ArH), 7.57 (1H, d, J 8.3 Hz, ArH), 7.64 (1H, t, J 7.6 Hz, ArH), 
7.85 (1H, t, J 7.6 Hz, ArH), 8.05 (1H, d, J 8.0 Hz, ArH), 8.16 (1H, s, ArH), 8.25 (1H, d, J 
8.3 Hz, ArH); *C (126 MHz, CDCl3) 97.8 (C), 119.8 (CH), 126.3 (CH), 128.3 (CH), 128.4 
(C), 129.2 (CH), 129.8 (CH), 130.1 (CH), 130.3 (CH), 130.9 (CH), 139.6 (CH), 142.0 (C), 
145.7 (C), 146.3 (C), 153.3 (C), 164.0 (C); m/z (EI) 374.9755 (M+. C16H10INO2 requires 










A solution of 4-(2’-iodophenyl)quinoline-2-carboxylic acid (133) (0.045 g, 0.12 mmol) in 
dichloromethane (5 mL) was cooled to 0 °C, and to this was added a few drops of 
N,N’-dimethylformamide followed by oxalyl chloride (15.1 µL, 0.178 mmol).  The 
resultant solution was allowed to warm to ambient temperature and then stirred under 
reflux for 18 h.  After cooling to ambient temperature, the reaction mixture was 
concentrated in vacuo and excess oxalyl chloride removed by azeotroping with toluene (3 
+ 10 mL).  The crude residue was then reconstituted in dichloromethane (5 mL) and cooled 
to 0 °C.  Diethylamine (61.4 µL, 0.593 mmol) was added to the solution dropwise and the 
reaction mixture stirred under reflux for a further 24 h.  On cooling to ambient 
temperature, the mixture was diluted with water (5 mL) and the aqueous layer extracted 
using ethyl acetate (3 + 5 mL).  The organic layer was dried (MgSO4), filtered and 
concentrated in vacuo.  Purification using flash column chromatography (ethyl 
acetate/petroleum ether, 9:1) afforded 4-(2’-iodophenyl)quinoline-2-N-diethylcarboxamide 
(120) (0.021 g, 51%) as a pale yellow oil, which crystallised to form a solid on standing. 
Mp 64–66 °C; ,max/cm
–1 (neat) 2969 (CH), 1626 (CO), 1464, 1404, 1275, 1096, 1015; *H 
(400 MHz, CDCl3) 1.25 (3H, t, J 7.1 Hz, CH2CH3), 1.33 (3H, t, J 7.1 Hz, CH2CH3), 3.39–
3.60 (2H, m, CH2CH3), 3.64 (2H, q, J 7.1 Hz, CH2CH3), 7.19 (1H, td, J 7.8, 1.4, Hz, ArH), 
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7.33 (1H, dd, J 7.8, 1.7 Hz, ArH), 7.45–7.54 (4H, m, 4 + ArH), 7.76 (1H, ddd, J 8.3, 6.6, 
1.6 Hz, ArH), 8.02 (1H, dd, J 7.8, 1.4 Hz, ArH), 8.19 (1H, d, J 8.3 Hz, ArH); *C (101 
MHz, CDCl3) 13.0 (CH3), 14.6 (CH3), 40.4 (CH2), 43.5 (CH2), 98.4 (C), 120.6 (CH), 125.8 
(CH), 126.3 (C), 127.5 (CH), 128.2 (CH), 130.0 (2 + CH), 130.1 (CH), 130.2 (CH), 139.3 
(CH), 142.4 (C), 147.1 (C), 151.2 (C), 154.4 (C), 168.6 (C); m/z (EI) 430.0544 (M+. 











4-(2’-Iodophenyl)quinoline-2-N-morpholinecarboxamide (121) was synthesised as 
described above for 4-(2’-iodophenyl)quinoline-2-N-diethylcarboxamide (120) using 4-
(2’-iodophenyl)quinoline-2-carboxylic acid (133) (0.045 g, 0.12 mmol), a few drops of 
N,N’-dimethylformamide, oxalyl chloride (15.1 µL, 0.178 mmol) and morpholine (51.9 
µL, 0.593 mmol) in dichloromethane (5 mL).  Purification using flash column 
chromatography (ethyl acetate) afforded 4-(2’-iodophenyl)quinoline-2-N-
morpholinecarboxamide (121) (0.032 g, 60%) as a yellow solid. Mp 118–120 °C; ,max/cm
–
1 (neat) 2853 (CH), 1628 (CO), 1551, 1466, 1404, 1273, 1244, 1111; *H (400 MHz, 
CDCl3) 3.68–3.96 (8H, m, 4 + CH2), 7.20 (1H, td, J 7.8, 1.6 Hz, ArH), 7.33 (1H, dd, J 7.8, 
1.6 Hz, ArH), 7.47–7.57 (3H, m, 3 + ArH), 7.58 (1H, s, ArH), 7.77 (1H, ddd, J 8.4, 6.6, 1.7 
Hz, ArH), 8.03 (1H, dd, J 7.8, 1.2 Hz, ArH), 8.18 (1H, d, J 8.4 Hz, ArH); *C (101 MHz, 
CDCl3) 42.9 (CH2), 47.9 (CH2), 66.9 (CH2), 67.1 (CH2), 98.3 (C), 121.3 (CH), 125.9 (CH), 
126.5 (C), 127.9 (CH), 128.2 (CH), 130.1 (CH), 130.1 (CH), 130.2 (CH), 130.3 (CH), 
139.5 (CH), 142.3 (C), 147.0 (C), 151.5 (C), 152.9 (C), 167.5 (C); m/z (EI) 444.0332 (M+. 













To a solution of ethyl 4-bromoquinoline-2-carboxylate (94) (0.200 g, 0.714 mmol) in 
N,N’-dimethylformamide (15 mL) was added 3-bromophenylboronic acid (0.172 g, 0.857 
mmol), potassium phosphate (0.182 g, 0.857 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (0.082 g, 0.071 mmol).  The resultant suspension 
was stirred vigorously at 120 °C for 24 h and then cooled to ambient temperature.  An 
additional aliquot of 3-bromophenylboronic acid (0.172 g, 0.857 mmol), potassium 
phosphate (0.182 g, 0.857 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.082 g, 
0.071 mmol) was added to the reaction mixture and stirred at 120 °C for a further 24 h.  On 
cooling to ambient temperature, the mixture was concentrated in vacuo and then 
reconstituted in dichloromethane (20 mL).  The organic layer was then washed with water 
(3 + 20 mL), dried (MgSO4), filtered and concentrated in vacuo.  Purification using flash 
column chromatrography (ethyl acetate/petroleum ether, 1:1) afforded ethyl 
4-(3’-bromophenyl)quinoline-2-carboxylate (136) (0.197 g, 78%) as a pale yellow solid.  
Mp 102–104 °C; ,max/cm
–1 (neat) 2980 (CH), 1715 (CO), 1584 (C=C), 1373, 1333, 1246, 
1132, 1107, 1018; *H (400 MHz, CDCl3) 1.50 (3H, t, J 7.2 Hz, CH2CH3), 4.58 (2H, q, J 
7.2 Hz, CH2CH3), 7.40–7.50 (2H, m, 2 + ArH), 7.60–7.71 (3H, m, 3 + ArH), 7.81 (1H, 
ddd, J 8.4, 6.8, 1.2 Hz, ArH), 7.91 (1H, dd, J 8.4, 0.8 Hz, ArH), 8.11 (1H, s, ArH), 8.39 
(1H, dd, J 8.4. 0.4 Hz, ArH); *C (101 MHz, CDCl3) 14.4 (CH3), 62.4 (CH2), 121.2 (CH), 
122.8 (C), 125.3 (CH), 127.4 (C), 128.2 (CH), 129.0 (CH), 130.2 (2 + CH), 131.3 (CH), 
131.8 (CH), 132.4 (CH), 139.5 (C), 147.8 (C), 148.1 (C), 148.2 (C), 165.3 (C); m/z (EI) 
355.0202 (M+. C18H14
79BrNO2 requires 355.0208), 203 (63%), 176 (12), 101 (4). 
 






To a solution of ethyl 4-(3’-bromophenyl)quinoline-2-carboxylate (136) (0.157 g, 0.441 
mmol) in a 50% aqueous ethanol mixture (20 mL) was added ground sodium hydroxide 
(0.071 g, 1.8 mmol), and the reaction mixture stirred vigorously under reflux for 18 h.  On 
cooling to ambient temperature, the ethanol was removed in vacuo, and the aqueous layer 
acidified (pH ~4) using a 1 M hydrochloric acid solution (~10 mL).  The crude product 
was extracted using dichloromethane (3 + 20 mL) and washed with water (3 + 20 mL).  
The organic fraction was dried (MgSO4), filtered and concentrated in vacuo to give 
4-(3’-bromophenyl)quinoline-2-carboxylic acid (137) (0.136 g, 94%) as an orange solid, 
which was used without further purification.  Mp 91–92 °C; ,max/cm
–1 (neat) 3067 (CH), 
1710 (CO), 1586 (C=C), 1462, 1375, 1229, 1072, 901, 765; *H (400 MHz, CDCl3) 7.51–
7.60 (3H, m, 3 + ArH), 7.63–7.72 (2H, m, 2 + ArH), 7.85 (1H, ddd, J 8.4, 6.8, 1.2 Hz, 
ArH), 8.05 (1H, d, J 8.0 Hz, ArH), 8.22–8.26 (2H, s, 2 + ArH); *C (101 MHz, CDCl3) 
119.4 (CH), 126.2 (CH), 128.5 (C), 128.6 (CH), 128.8 (CH), 129.1 (CH), 129.2 (CH), 
129.6 (CH), 129.8 (CH), 130.8 (CH), 132.1 (C), 137.0 (C), 145.4 (C), 146.5 (C), 151.7 (C), 
164.4 (C); m/z (ESI) 325.9812 (MH-. C16H9









A solution of 4-(3’-bromophenyl)quinoline-2-carboxylic acid (137) (0.136 g, 0.414 mmol) 
in dichloromethane (10 mL) was cooled to 0 °C, and to this was added a few drops of 
N,N’-dimethylformamide followed by oxalyl chloride (52.6 µL, 0.622 mmol).  The 
resultant solution was allowed to warm to ambient temperature and then stirred under 
reflux for 18 h.  After cooling to ambient temperature, the reaction mixture was 
concentrated in vacuo and excess oxalyl chloride removed by azeotroping with toluene (3 
+ 10 mL). The crude residue was then reconstituted in dichloromethane (10 mL) and 
cooled to 0 °C.  Diethylamine (0.214 mL, 2.07 mmol) was added to the solution dropwise 
and the reaction mixture stirred under reflux for a further 18 h. On cooling to ambient 
temperature, the mixture was diluted with water (10 mL) and the aqueous layer extracted 
using dichloromethane (3 + 10 mL). The organic layer was dried (MgSO4), filtered and 
concentrated in vacuo.  Purification using flash column chromatography (ethyl 
! "'#!
acetate/petroleum ether, 1:1) afforded 4-(3’-bromophenyl)quinoline-2-N-
diethylcarboxamide (139) (0.090 g, 57%) as a colourless oil.  ,max/cm
–1 (neat) 2977 (CH), 
2933, 1627 (CO), 1553 (C=C), 1480, 1406, 1271, 1097, 908; *H (400 MHz, CDCl3) 1.27 
(3H, t, J 7.2 Hz, CH2CH3), 1.32 (3H, t, J 7.2 Hz, CH2CH3), 3.49 (2H, q, J 7.2 Hz, 
CH2CH3), 3.63 (2H, q, J 7.2 Hz, CH2CH3), 7.46–7.56 (5H, m, 5 + ArH), 7.61 (1H, s, ArH), 
7.71–7.78 (1H, m, ArH), 7.95 (1H, d, J 8.0 Hz, ArH), 8.17 (1H, d, J 8.4 Hz, ArH); *C (101 
MHz, CDCl3) 13.0 (CH3), 14.5 (CH3), 40.3 (CH2), 43.5 (CH2), 120.4 (CH), 125.8 (CH), 
126.5 (C), 127.3 (CH), 128.6 (2 + CH), 128.9 (C), 129.6 (2 + CH), 129.7 (CH), 130.2 
(CH), 137.7 (C), 147.3 (C), 149.5 (C), 154.4 (C), 168.8 (C); m/z (CI) 385.0738 (MH+. 
C20H20
81BrN2O requires 385.0741), 381 (18%), 345 (14), 305 (100), 233 (9), 206 (7). 
 






To a solution of 4-iodoaniline (155) (0.657 g, 3.00 mmol) in nitromethane (5 mL) was 
added phenylacetylene (151) (0.494 mL, 4.50 mmol), ethyl glyoxalate solution (50% in 
toluene) (154) (0.595 mL, 3.00 mmol) and iodine (0.152 g, 0.600 mmol).  The resultant 
solution was stirred vigorously at ambient temperature for 72 h and then diluted with ethyl 
acetate (20 mL).  The organic layer was washed with 0.1 M sodium thiosulfate solution (20 
mL) and water (20 mL), dried (MgSO4), filtered and concentrated in vacuo.  Purification 
by trituration with diethyl ether gave ethyl 6-iodo-4-phenylquinoline-2-carboxylate (149) 
(0.608 g, 50%) as a pale yellow solid.  Mp 200–201 °C; ,max/cm
–1 (neat) 3048 (CH), 1721 
(CO), 1481, 1366, 1250, 1111, 1018, 826, 702; *H (400 MHz, CDCl3) 1.49 (3H, t, J 7.2 
Hz, CH2CH3), 4.56 (2H, q, J 7.2 Hz, CH2CH3), 7.49–7.61 (5H, m, 5 + ArH), 8.03 (1H, dd, 
J 8.8, 1.6 Hz, ArH), 8.09 (1H, d, J 8.8 Hz, ArH), 8.13 (1H, s, ArH), 8.33 (1H, d, J 1.6 Hz, 
ArH); *C (101 MHz, CDCl3) 14.4 (CH3), 62.4 (CH2), 95.4 (C), 122.0 (CH), 128.9 (2 + 
CH), 129.0 (CH), 129.3 (C), 129.5 (2 + CH), 132.7 (CH), 134.6 (CH), 136.9 (C), 138.9 
(CH), 147.1 (C), 148.2 (C), 148.8 (C), 165.2 (C); m/z (EI) 403.0067 (M+. C18H14INO2 










Ethyl 6-fluoro-4-phenylquinoline-2-carboxylate (150) was synthesised as described above 
for 6-iodo-4-phenylquinoline-2-carboxylate (149) using 4-fluoroaniline (156) (94.6 µL, 
1.00 mmol), phenylacetylene (151) (0.165 mL, 1.50 mmol), ethyl glyoxalate solution (50% 
in toluene) (154) (0.198 mL, 1.00 mmol) and iodine (0.051 g, 0.20 mmol) in nitromethane 
(2 mL).  Purification by trituration with diethyl ether afforded ethyl 
6-fluoro-4-phenylquinoline-2-carboxylate (150) (0.169 g, 57%) as a pale yellow solid. Mp 
154–155 °C; ,max/cm
–1 (neat) 2986 (CH), 1713 (CO), 1512, 1466, 1373, 1227, 1196, 1026, 
833, 702; *H (400 MHz, CDCl3) 1.49 (3H, t, J 7.1 Hz, CH2CH3), 4.57 (2H, q, J 7.1 Hz, 
CH2CH3), 7.49–7.60 (7H, m, 7 + ArH), 8.15 (1H, s, ArH), 8.35–8.41 (1H, m, ArH); *C 
(100 MHz, CDCl3) 14.4 (CH3), 62.3 (CH2), 109.2 (CH, d, JC-C-F 23.4 Hz), 120.5 (CH, d, 
JC-C-F 26.2 Hz), 121.8 (CH), 128.9 (C, d, JC-C-C-F 10.0 Hz), 128.9 (2 + CH), 129.0 (CH), 
129.4 (2 + CH), 133.8 (CH, d, JC-C-C-F 9.4 Hz), 137.1 (C), 145.4 (C), 147.3 (C, d, J 2.9 Hz), 
149.3 (C, d, JC-C-C-C-F 5.9 Hz), 161.9 (C, d, JC-F 251.0 Hz), 165.3 (C); m/z (CI) 296.1088 
(MH+. C18H15FNO2 requires 296.1087), 224 (6%), 198 (5), 113 (22), 85 (45), 73 (100). 
 






To a solution of ethyl 6-iodo-4-phenylquinoline-2-carboxylate (149) (0.078 g, 0.19 mmol) 
in a 50% aqueous ethanol mixture (10 ml) was added ground sodium hydroxide (0.031 g, 
0.77 mmol), and the reaction mixture stirred under reflux for 18 h.  On cooling to ambient 
temperature, the ethanol was removed in vacuo, and the aqueous layer acidified (pH ~4) 
using a 1 M hydrochloric acid solution (~10 mL).  The crude product was extracted using 
dichloromethane (3 + 20 mL), washed with water (2 + 20 mL), dried (MgSO4), filtered and 
concentrated in vacuo.  Purification by trituration with diethyl ether afforded 
! "'%!
6-iodo-4-phenylquinoline-2-carboxylic acid (147) (0.051 g, 70%) as a yellow solid.  Mp 
198–200 °C; ,max/cm
–1 (neat) 2901 (CH), 1705 (CO), 1582 (C=C), 1458, 1366, 1250, 
1134, 972, 787; *H (400 MHz, CDCl3) 7.48–7.63 (5H, m, 5 + ArH), 7.94 (1H, d, J 9.0 Hz, 
ArH), 8.09 (1H, dd, J 9.0, 1.8 Hz, ArH), 8.24 (1H, s, ArH), 8.40 (1H, d, J 1.8 Hz, ArH); *C 
(101 MHz, CDCl3) 96.0 (C), 120.2 (CH), 129.1 (2 + CH), 129.4 (CH), 129.5 (2 + CH), 
129.9 (C), 131.2 (CH), 135.1 (CH), 136.4 (C), 139.8 (CH), 145.5 (C), 145.8 (C), 150.6 (C), 
164.0 (C); m/z (CI) 375.9832 (MH+. C16H11INO2 requires 375.9835), 332 (8%), 250 (41), 
206 (4), 113 (3), 69 (7). 
 






6-Fluoro-4-phenylquinoline-2-carboxylic acid (148) was synthesised as described above 
for 6-iodo-4-phenylquinoline-2-carboxylic acid (147) using ethyl 
6-fluoro-4-phenylquinoline-2-carboxylate (150) (0.160 g, 0.542 mmol) and ground sodium 
hydroxide (0.087 g, 2.2 mmol) in a 50% aqueous ethanol solution (10 mL).  Purification by 
trituration with diethyl ether yielded 6-fluoro-4-phenylquinoline-2-carboxylic acid (148) 
(0.119 g, 82%) as a colourless solid.  Mp 129–131 °C; ,max/cm
–1 (neat) 3228 (OH), 3053 
(CH), 1704 (CO), 1588 (C=C), 1485, 1451, 1373, 1315, 1061, 810; *H (500 MHz, CDCl3) 
7.49–7.68 (7H, m, 7 + ArH), 8.23–8.27 (2H, m, 2 + ArH); *C (126 MHz, CDCl3) 109.8 
(CH, d, JC-C-F 23.6 Hz), 120.0 (CH), 121.4 (CH, d, JC-C-F 26.3 Hz), 129.0 (2 + CH), 129.3 
(2 + CH), 129.4 (CH), 129.7 (C, d, JC-C-C-F 9.7 Hz), 132.6 (CH, d, JC-C-C-F 9.4 Hz), 136.6 
(C), 143.7 (C), 145.0 (C), 151.1 (C, d, JC-C-C-C-F 5.7 Hz), 162.2 (C, d, J C-F 252.5 Hz), 164.2 
(C); m/z (EI) 267.0694 (M+. C16H10FNO2 requires 267.0696), 223 (16%), 135 (5), 82 


















A solution of 6-iodo-4-phenylquinoline-2-carboxylic acid (147) (0.051 g, 0.14 mmol) in 
dichloromethane (10 mL) was cooled to 0 °C, and to this was added a few drops of 
N,N’-dimethylformamide followed by oxalyl chloride (17.3 µL, 0.204 mmol).  The 
resultant solution was allowed to warm to ambient temperature and then stirred under 
reflux for 18 h.  After cooling to ambient temperature, the reaction mixture was 
concentrated in vacuo and excess oxalyl chloride removed by azeotroping with toluene (3 
+ 20 mL).  The crude residue was then reconstituted in dichloromethane (10 mL) and 
cooled to 0 °C.  Morpholine (59.5 µL, 0.680 mmol) was added to the solution dropwise 
and the reaction mixture stirred under reflux for a further 5 h.  On cooling to ambient 
temperature, the mixture was diluted with water (10 mL) and the aqueous layer extracted 
using dichloromethane (3 + 10 mL).  The organic layer was dried (MgSO4), filtered and 
concentrated in vacuo. Purification using flash column chromatography 
(methanol/dichloromethane, 1:9) afforded 
6-iodo-4-phenylquinoline-2-N-morpholinecarboxamide (141) (0.055 g, 92%) as a pale 
yellow solid.  Mp 116–118 °C; ,max/cm
–1 (neat) 2853 (CH), 1628 (CO), 1468, 1439, 1271, 
1244, 1111, 1028; *H (400 MHz, CDCl3) 3.72–3.91 (8H, m, 4 + CH2), 7.48–7.59 (5H, m, 5 
+ ArH), 7.69 (1H, s, ArH), 7.86 (1H, d, J 8.8 Hz, ArH), 8.00 (1H, dd, J 8.8, 2.0 Hz, ArH), 
8.30 (1H, d, J 2.0 Hz, ArH); *C (101 MHz, CDCl3) 42.9 (CH2), 47.9 (CH2), 66.9 (CH2), 
67.1 (CH2), 94.1 (C), 121.8 (CH), 128.3 (C), 128.9 (2 + CH), 129.0 (CH), 129.4 (2 + CH), 
131.7 (CH), 134.7 (CH), 136.8 (C), 138.8 (CH), 146.1 (C), 148.8 (C), 153.3 (C), 167.2 
(C); m/z (CI) 445.0415 (MH+. C20H18IN2O2 requires 445.0413), 319 (100%), 206 (4), 116 

















6-Iodo-4-phenylquinoline-2-N-(4’-methylpiperazine)carboxamide (142) was synthesised 
as described above for 6-iodo-4-phenylquinoline-2-N-morpholinecarboxamide (141) using 
6-iodo-4-phenylquinoline-2-carboxylic acid (147) (0.065 g, 0.17 mmol), a few drops of 
N,N’-dimethylformamide, oxalyl chloride (22.0 µL, 0.260 mmol) and 1-methylpiperazine 
(96.1 µL, 0.866 mmol) in dichloromethane (5 mL).  Purification using flash column 
chromatography (methanol/dichloromethane, 1:9) gave 6-iodo-4-phenylquinoline-2-N-(4’-
methylpiperazine)carboxamide (142) (0.036 g, 46%) as a pale brown solid.  Mp 132–133 
°C; ,max/cm
–1 (neat) 2916 (CH), 2790, 1631 (CO), 1547 (C=C), 1446, 1289, 1131, 1024; 
*H (500 MHz, CDCl3) 2.37 (3H, s, CH3), 2.51 (2H, br s, NCH2), 2.60 (2H, br s, NCH2), 
3.73–3.81 (2H, m, NCH2), 3.92 (2H, br s, NCH2), 7.48–7.58 (5H, m, 5 + ArH), 7.65 (1H, 
s, ArH), 7.87 (1H, d, J 8.9 Hz, ArH), 8.00 (1H, dd, J 8.9, 1.9 Hz, ArH), 8.30 (1H, d, J 1.9 
Hz, ArH); *C (126 MHz, CDCl3) 42.2 (CH2), 45.9 (CH3), 47.0 (CH2), 54.6 (CH2), 55.3 
(CH2), 93.9 (C), 121.6 (CH), 128.3 (C), 128.9 (2 + CH), 129.0 (CH), 129.4 (2 + CH), 
131.7 (CH), 134.6 (CH), 136.8 (C), 138.8 (CH), 146.1 (C), 148.7 (C), 153.7 (C), 167.2 
(C); m/z (CI) 458.0730 (MH+. C21H21IN3O requires 458.0729), 391 (35%), 327 (18), 248 










6-Iodo-4-phenylquinoline-2-N-diethylcarboxamide (143) was synthesised as described 
above for 6-iodo-4-phenylquinoline-2-N-morpholinecarboxamide (141) using 
6-iodo-4-phenylquinoline-2-carboxylic acid (147) (0.175 g, 0.466 mmol), a few drops of 
N,N’-dimethylformamide, oxalyl chloride (59.2 µL, 0.700 mmol) and diethylamine (0.241 
! "'(!
mL, 2.33 mmol) in dichloromethane (10 mL).  Purification using flash column 
chromatography (ethyl acetate/petroleum ether, 4:1) afforded 6-iodo-4-phenylquinoline-2-
N-diethylcarboxamide (143) (0.062 g, 31%) as yellow oil.  ,max/cm
–1 (neat) 2972 (CH), 
1624 (CO), 1589 (C=C), 1547, 1476, 1460, 1377, 1269, 1098; *H (400 MHz, CDCl3) 1.27 
(3H, t, J 6.8 Hz, CH3), 1.31 (3H, t, J 7.2 Hz, CH3), 3.47 (2H, q, J 6.8 Hz, CH2), 3.62 (2H, 
q, J 7.2 Hz, CH2), 7.49–7.58 (5H, m, 5 + ArH), 7.61 (1H, s, ArH), 7.88 (1H, d, J 8.8 Hz, 
ArH), 7.99 (1H, dd, J 8.8, 1.6 Hz, ArH), 8.29 (1H, d, J 1.6 Hz, ArH); *C (101 MHz, 
CDCl3) 12.9 (CH3), 14.5 (CH3), 40.4 (CH2), 43.5 (CH2), 93.5 (C), 121.2 (CH), 128.2 (C), 
128.9 (2 + CH), 128.9 (CH), 129.5 (2 + CH), 131.8 (CH), 134.6 (CH), 137.0 (C), 138.6 
(CH), 146.2 (C), 148.5 (C), 154.8 (C), 168.4 (C); m/z (CI) 431.0626 (MH+. C20H20IN2O 











6-Fluoro-4-phenylquinoline-2-N-morpholinecarboxamide (144) was synthesised as 
described above for 6-iodo-4-phenylquinoline-2-N-morpholinecarboxamide (141) using 
6-fluoro-4-phenylquinoline-2-carboxylic acid (148) (0.048 g, 0.18 mmol), a few drops of 
N,N’-dimethylformamide, oxalyl chloride (22.8 µL, 0.269 mmol) and morpholine (78.6 
µL, 0.898 mmol) in dichloromethane (10 mL).  Purification using flash column 
chromatography (diethyl ether/petroleum ether, 9:1) afforded 
6-fluoro-4-phenylquinoline-2-N-morpholinecarboxamide (144) (0.037 g, 61%) as a pale 
yellow oil.  ,max/cm
–1 (neat) 2855 (CH), 1622 (CO), 1474, 1435, 1229, 1196, 1111, 1028; 
*H (400 MHz, CDCl3) 3.71–3.93 (8H, m, 4 + CH2), 7.48–7.59 (7H, m, 7 + ArH), 7.73 (1H, 
s, ArH), 8.16 (1H, dd, J 9.2, 5.6 Hz, ArH); *C (101 MHz, CDCl3) 42.9 (CH2), 47.9 (CH2), 
66.9 (CH2), 67.1 (CH2), 109.3 (CH, d, JC-C-F 23.4 Hz), 120.3 (CH, d, JC-C-F 25.9 Hz), 121.7 
(CH), 127.7 (C, d, JC-C-C-F 9.5 Hz), 128.9 (2 + CH), 129.0 (CH), 129.3 (2 + CH), 132.7 
(CH, d, JC-C-C-F 9.3 Hz), 137.1 (C), 144.2 (C), 149.4 (C, d, JC-C-C-C-F 5.3 Hz), 152.3 (C), 
161.4 (C, d, JC-F 250.6 Hz), 167.3 (C); m/z (CI) 337.1348 (MH
+. C20H18FN2O2 requires 












6-Fluoro-4-phenylquinoline-2-N-(4’-methylpiperazine)carboxamide (145) was synthesised 
as described above for 6-iodo-4-phenylquinoline-2-N-morpholinecarboxamide (141) using 
6-fluoro-4-phenylquinoline-2-carboxylic acid (148) (0.065 g, 0.24 mmol), a few drops of 
N,N’-dimethylformamide, oxalyl chloride (30.9 µL, 0.365 mmol) and 1-methylpiperazine 
(0.135 mL, 1.22 mmol) in dichloromethane (10 mL).  Purification using flash column 
chromatography (methanol/dichloromethane, 1:9) afforded 
6-fluoro-4-phenylquinoline-2-N-(4’-methylpiperazine)carboxamide (145) (0.048 g, 56%) 
as a yellow oil.  ,max/cm
–1 (neat) 2938 (CH), 2793, 1622 (CO), 1437, 1290, 1229, 1198, 
1138, 1001; *H (400 MHz, CDCl3) 2.35 (3H, s, CH3), 2.47 (2H, br s, NCH2), 2.57 (2H, br 
s, NCH2), 3.76 (2H, t, J 4.8 Hz, NCH2), 3.91 (2H, t, J 4.8 Hz, NCH2), 7.39–7.59 (7H, m, 7 
+ ArH), 7.68 (1H, s, ArH), 8.16 (1H, dd, J 8.8, 5.2 Hz, ArH); *C (101 MHz, CDCl3) 42.3 
(CH2), 46.0 (CH3), 47.2 (CH2), 54.7 (CH2), 55.4 (CH2), 109.3 (CH, d, JC-C-F 23.5 Hz), 
120.2 (CH, d, JC-C-F 26.0 Hz), 121.5 (CH, d, JC-C-C-F 3.5 Hz), 127.6 (C, d, JC-C-C-F 9.8 Hz), 
128.8 (2 + CH), 128.9 (CH), 129.3 (2 + CH), 132.7 (CH, d, JC-C-C-F 9.2 Hz), 137.1 (C), 
144.3 (C), 149.3 (C, d, JC-C-C-C-F 5.6 Hz), 152.7 (C, d, JC-C-C-C-F 2.9 Hz), 161.3 (C, d, JC-F 
249.0 Hz), 167.4 (C); m/z (CI) 350.1665 (MH+. C21H21FN3O requires 350.1669), 184 










6-Fluoro-4-phenylquinoline-2-N-diethylcarboxamide (146) was synthesised as described 
above for 6-iodo-4-phenylquinoline-2-N-morpholinecarboxamide (141) using 
6-fluoro-4-phenylquinoline-2-carboxylic acid (148) (0.119 g, 0.445 mmol), a few drops of 
! "'*!
N,N’-dimethylformamide, oxalyl chloride (56.5 µL, 0.668 mmol) and diethylamine (0.230 
mL, 2.23 mmol) in dichloromethane (15 mL).  Purification using flash column 
chromatography (diethyl ether/petroleum ether, 4:1) afforded 
6-fluoro-4-phenylquinoline-2-N-diethylcarboxamide (146) (0.040 g, 28%) as a brown oil.  
,max/cm
–1 (neat) 2974 (CH), 2934, 1622 (CO), 1593 (C=C), 1481, 1269, 1229, 1200, 1096; 
*H (400 MHz, CDCl3) 1.28 (3H, t, J 7.2 Hz, CH3), 1.32 (3H, t, J 7.2 Hz, CH3), 3.49 (2H, q, 
J 7.2 Hz, CH2), 3.63 (2H, q, J 7.2 Hz, CH2), 7.48–7.58 (7H, m, 7 + ArH), 7.64 (1H, s, 
ArH), 8.16 (1H, dd, J 9.2, 5.6 Hz, ArH); *C (101 MHz, CDCl3) 12.9 (CH3), 14.5 (CH3), 
40.4 (CH2), 43.5 (CH2), 109.2 (CH, d, JC-C-F 23.2 Hz), 120.0 (CH, d, JC-C-F 25.7 Hz), 121.1 
(CH), 127.4 (C, d, JC-C-C-F 9.5 Hz), 128.8 (2 + CH), 128.8 (CH), 129.3 (2 + CH), 132.7 
(CH, d, JC-C-C-F 9.2 Hz), 137.2 (C), 144.3 (C), 149.0 (C, d, JC-C-C-C-F 6.0 Hz), 153.8 (C, d, 
JC-C-C-C-F 2.7 Hz), 161.2 (C, d, JC-F 248.7 Hz), 168.5 (C); m/z (CI) 323.1562 (MH
+. 








To a suspension of magnesium sulfate (1.0 g) in dichloromethane (20 mL) was added 2-
iodoaniline (163) (0.300 g, 1.37 mmol) followed by ethyl glyoxalate solution (50% in 
toluene) (154) (0.27 mL, 1.37 mmol).  The resultant suspension was stirred at ambient 
temperature for 24 h and then filtered.  Phenylacetylene (151) (0.150 mL, 1.37 mmol) and 
copper(II) triflate (0.099 g, 0.27 mmol) was added to the filtrate and the reaction mixture 
stirred at ambient temperature for a further 48 h.  The mixture was washed with water (2 + 
20 mL).  The organic layer was dried (MgSO4), filtered and concentrated in vacuo.  
Purification using flash column chromatography (diethyl ether/petroleum ether, 1:9) 
followed by crystallisation in hexane afforded ethyl 
8-iodo-4-phenylquinoline-2-carboxylate (164) (0.121 g, 22%) as a colourless solid.  Mp 
102–104 °C; ,max/cm
–1 (neat) 2987 (CH), 1722 (CO), 1601 (C=C), 1488, 1373, 1244, 
1120, 1026; *H (500 MHz, CDCl3) 1.52 (3H, t, J 7.0 Hz, CH3CH2), 4.55 (2H, q, J 7.0 Hz, 
CH3CH2), 7.28 (1H, dd, J 8.5, 7.5 Hz, ArH), 7.49–7.58 (5H, m, 5 + ArH), 7.95 (1H, dd, J 
8.5, 1.0 Hz, ArH), 8.15 (1H, s, ArH), 8.42 (1H, dd, J 7.5, 1.0 Hz, ArH); *C (126 MHz, 
! "(+!
CDCl3) 14.3 (CH3), 62.2 (CH2), 105.5 (C), 122.1 (CH), 126.7 (CH), 128.5 (C), 128.7 (2 + 
CH), 128.9 (CH), 129.4 (CH), 129.6 (2 + CH), 137.1 (C), 140.8 (CH), 147.0 (C), 148.6 
(C), 150.8 (C), 165.0 (C); m/z (ESI) 425.9947 (MNa+. C18H14INNaO2 requires 425.9961). 
 






To a solution of ethyl 8-iodo-4-phenylquinoline-2-carboxylate (164) (0.050 g, 0.12 mmol) 
in a 50% aqueous ethanol mixture (5 ml) was added ground sodium hydroxide (0.020 g, 
0.50 mmol) and the reaction mixture stirred under reflux for 18 h.  On cooling to ambient 
temperature, the ethanol was removed in vacuo, and the aqueous layer acidified (pH ~4) 
using a 1 M hydrochloric acid solution (~3 mL).  The crude product was extracted using 
dichloromethane (3 + 5 mL), washed with water (2 + 5 mL), dried (MgSO4), filtered and 
concentrated in vacuo.  Purification by trituration with hexane afforded 
8-iodo-4-phenylquinoline-2-carboxylic acid (166) (0.039 g, 84%) as a colourless solid.  
Mp 128–130 °C; ,max/cm
–1 (neat) 3310 (OH), 3061 (CH), 1763 (CO), 1599 (C=C), 1489, 
1443, 1408, 1383, 1319; *H (500 MHz, CDCl3) 7.37 (1H, dd, J 8.0, 7.5 Hz, ArH), 7.47–
7.60 (5H, m, 5 + ArH), 8.03 (1H, dd, J 8.0, 0.5 Hz, ArH), 8.28 (1H, s, ArH), 8.45 (1H, dd, 
J 7.5, 0.5 Hz, ArH); *C (126 MHz, CDCl3) 103.6 (C), 120.3 (CH), 127.1 (CH), 128.9 (2 + 
CH), 129.3 (C), 129.4 (CH), 129.6 (2 + CH), 130.1 (CH), 136.5 (C), 141.4 (CH), 145.3 
(C), 145.8 (C), 152.9 (C), 163.7 (C); m/z (EI) 374.9752 (M+. C16H10INO2 requires 












A solution of 8-iodo-4-phenylquinoline-2-carboxylic acid (166) (0.039 g, 0.10 mmol) in 
dichloromethane (3 mL) was cooled to 0 °C, and to this was added a few drops of 
N,N’-dimethylformamide followed by oxalyl chloride (13.2 µL, 0.156 mmol). The 
resultant solution was allowed to warm to ambient temperature and then stirred under 
reflux for 18 h. After cooling to ambient temperature, the reaction mixture was 
concentrated in vacuo and excess oxalyl chloride removed by azeotroping with toluene (3 
+ 5 mL).  The crude residue was then reconstituted in dichloromethane (3 mL) and cooled 
to 0 °C.  Morpholine (45.5 µL, 0.520 mmol) was added to the solution dropwise and the 
reaction mixture stirred under reflux for a further 5 h.  On cooling to ambient temperature, 
the mixture was diluted with water (5 mL) and the aqueous layer extracted using 
dichloromethane (3 + 5 mL).  The organic layer was dried (MgSO4), filtered and 
concentrated in vacuo.  Purification using flash column chromatography 
(methanol/dichloromethane, 1:99) gave 
8-iodo-4-phenylquinoline-2-N-morpholinecarboxamide (162) (0.026 g, 57%) as a 
colourless solid.  Mp 119–120 °C; ,max/cm
–1 (neat) 2855 (CH), 1626 (CO), 1460, 1437, 
1267, 1246, 1109, 1026; *H (400 MHz, CDCl3) 3.88–3.93 (4H, m, 2 + NCH2), 3.96 (2H, t, 
J 4.6 Hz, OCH2), 4.20 (2H, t, J 4.6 Hz, OCH2), 7.27 (1H, m, ArH), 7.47–7.56 (5H, m, 5 + 
ArH), 7.91 (1H, s, ArH), 7.93 (1H, dd, J 8.4, 1.2 Hz, ArH), 8.37 (1H, dd, J 7.3, 1.2 Hz, 
ArH); *C (101 MHz, CDCl3) 43.5 (CH2), 48.4 (CH2), 67.1 (CH2), 67.9 (CH2), 104.5 (C), 
123.0 (CH), 126.8 (CH), 127.6 (C), 128.7 (2 + CH), 128.9 (2 + CH), 129.6 (2 + CH), 137.1 
(C), 140.6 (CH), 145.5 (C), 150.7 (C), 153.0 (C), 166.1 (C); m/z (EI) 444.0334 (M+. 
C20H17IN2O2 requires 444.0335), 358 (25%), 331 (100), 203 (91), 176 (30), 86 (31), 83 
(42). 
 







Ethyl 4-chloroacetoacetate (179) (1.04 mL, 7.61 mmol) was added to a solution of 
2-aminobenzophenone (178) (1.50 g, 7.61 mmol) in N,N’-dimethylformamide (10 mL) in a 
Schlenk tube.  Chlorotrimethylsilane (3.86 mL, 30.4 mmol) was then added dropwise and 
the tube was sealed.  The resultant reaction mixture was stirred at 100 °C for 24 h.  After 
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cooling to ambient temperature the solution was diluted with dichloromethane (50 mL) and 
washed with water (3 + 50 mL).  The organic layer was dried (MgSO4), filtered and 
concentrated in vacuo.  Purification using flash column chromatography (ethyl 
acetate/petroleum ether, 1:4) gave ethyl 2-(chloromethyl)-4-phenylquinoline-3-carboxylate 
(177) (2.43 g, 98%) as a yellow solid. Mp 108–109 °C (lit.,140 mp 111–112 °C); ,max/cm
–1 
(neat) 2982 (CH), 2959 (CH), 1709 (CO), 1562 (C=C), 1404, 1300, 1234, 1065, 883; *H 
(500 MHz, CDCl3) 0.95 (3H, t, J 7.5 Hz, OCH2CH3), 4.06 (2H, q, J 7.5 Hz, OCH2CH3), 
5.03 (2H, s, CH2Cl), 7.35–7.39 (2H, m, 2 + ArH), 7.46–7.52 (4H, m, 4 + ArH), 7.62 (1H, 
dd, J 8.5, 0.5 Hz, ArH), 7.77 (1H, ddd, J 8.5, 7.0, 1.5 Hz, ArH), 8.16 (1H, d, J 8.5 Hz, 
ArH); *C (126 MHz, CDCl3) 13.4 (CH3), 45.9 (CH2), 61.5 (CH2), 126.3 (C), 126.3 (C), 
126.6 (CH), 127.7 (CH), 128.2 (2 + CH), 128.5 (CH), 129.3 (2 + CH), 129.7 (CH), 130.6 
(CH), 135.8 (C), 147.5 (C), 148.1 (C), 153.1 (C), 167.5 (C); m/z (EI) 325.0876 (M+. 
C19H16
35ClNO2 requires 325.0870), 280 (52%), 262 (53), 232 (18), 217 (49), 204 (24), 176 
(25). 
 







Method A: A solution of ethyl 2-(chloromethyl)-4-phenylquinoline-3-carboxylate (177) 
(0.100 g, 0.307 mmol) in a 1:1 mixture of ethanol and 6 M hydrochloric acid solution (20 
mL total) was stirred under reflux for 4 days.  On cooling to ambient temperature, the 
ethanol was removed in vacuo and the aqueous layer made alkaline (pH ~10) by the slow 
addition of solid sodium carbonate.  The crude product was extracted using chloroform (3 
+ 20 mL), and the organic layer dried (MgSO4), filtered and concentrated in vacuo.  
Purificaiton by flash column chromatography (ethyl acetate/petroleum ether, 2:3) gave 9-
phenylfuro[3,4-b]quinolin-1(3H)-one (176) (0.058 g, 73%) as a yellow solid. Mp 201–
203 °C (lit.,145 mp 203–204 °C); ,max/cm
–1 (neat) 2957 (CH), 2843, 1771 (CO), 1603 
(C=C), 1449, 1219, 1119, 1049, 1028, 889; *H (500 MHz, CDCl3) 5.45 (2H, s, OCH2), 
7.43–7.49 (2H, m, 2 + ArH), 7.57–7.61 (4H, m, 4 + ArH), 7.89–7.93 (2H, m, 2 + ArH), 
8.19–8.22 (1H, m, ArH); *C (126 MHz, CDCl3) 69.6 (CH2), 113.5 (C), 127.1 (C), 127.4 
(CH), 128.1 (CH), 128.3 (2 + CH), 129.4 (CH), 129.5 (CH), 129.8 (2 + CH), 131.7 (C), 
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132.6 (CH), 151.3 (C), 151.5 (C), 163.6 (C), 167.9 (C); m/z (EI) 261.0794 (M+. C17H11NO2 
requires 261.0790), 232 (56%), 204 (42), 203 (32), 176 (21), 151 (9), 131 (8), 91 (10). 
  
Method B: A solution of ethyl 2-(chloromethyl)-4-phenylquinoline-3-carboxylate (177) 
(0.200 g, 0.614 mmol) in dimethylsulfoxide (3 mL) was stirred at 120 °C for 18 h and then 
cooled to ambient temperature.  Water (10 mL) was added to the mixture and the resultant 
precipitate collected by filtration.  The crude product was then reconstituted in ethyl 
acetate (20 mL) and washed with water (3 + 20 mL), dried (MgSO4), filtered and 
concentrated in vacuo.  Purification using flash column chromatography (ethyl 
acetate/petroleum ether, 2:3) afforded 9-phenylfuro[3,4-b]quinolin-1(3H)-one (176) (0.101 
g, 63%) as a yellow solid.  Spectroscopic data as reported above. 
 
Method C: A solution of silver nitrate (1.06 g, 6.22 mmol) in a 2:1 aqueous dioxane 
mixture (30 mL) was heated to 90 °C.  To this was added a solution of ethyl 
2-(chloromethyl)-4-phenylquinoline-3-carboxylate (177) (0.810 g, 2.49 mmol) in 1,4-
dioxane (10 mL) dropwise, and the resultant mixture stirred at 90 °C for 48 h.  On cooling 
to ambient temperature, an additional aliquot of silver nitrate (1.06 g, 6.22 mmol) in a 50% 
aqueous 1,4-dioxane mixture (20 mL) was added to the reaction mixture, which was heated 
to and stirred at 90 °C for a further 24 h.  The mixture was then cooled to ambient 
temperature and the 1,4-dioxane removed in vacuo.  The remaining aqueous layer was 
extracted using ethyl acetate (2 + 50 mL), and the organic layer dried (MgSO4), filtered 
and concentrated in vacuo.  Purification using flash column chromatography (ethyl 
acetate/petroleum ether, 2:3) afforded 9-phenylfuro[3,4-b]quinolin-1(3H)-one (176) (0.377 
g, 58%) as a pale yellow solid.  Spectroscopic data as reported above. 
 
Method D: To a solution of 9-phenyl-1H,3H-furo[3,4-b]quinolin-1-ol (182) (3.29 g, 12.5 
mmol) in chloroform (150 mL) was added activated manganese(IV) oxide (32.6 g, 374 
mmol) in one portion.  The resultant suspension was stirred vigorously at ambient 
temperature for 4 h and then filtered through Celite!.  After washing with chloroform (200 
mL), the solvent was removed in vacuo to afford 9-phenylfuro[3,4-b]quinolin-1(3H)-one 
(176) (2.72 g, 83%) as a white solid, which was used without further purification.  











Indium(III) chloride (0.679 g, 3.07 mmol) was added to 2-aminobenzophenone (178) 
(5.00 g, 15.3 mmol) and diethyl acetylenedicarboxylate (180) (2.95 mL, 18.4 mmol), and 
the neat mixture stirred at 80 °C for 3 h.  On cooling to ambient temperature, water 
(50 mL) was added and the mixture extracted using ethyl acetate (150 mL).  The organic 
layer was then washed with water (100 mL) and brine (100 mL), dried (MgSO4), filtered 
and concentrated in vacuo.  Purification using flash column chromatography (ethyl 
acetate/hexane, 15:85) afforded ethyl 4-phenylquinoline-2,3-dicarboxylate (181) (5.36 g, 
100%) as a yellow solid.  Spectroscopic data in accordance with the literature.144 Mp 89–
91 °C (lit.,144 mp 95–96 °C); ,max/cm
–1 (neat) 2984 (CH), 1741 (CO), 1722 (CO), 1560 
(C=C), 1441, 1376, 1247, 1202, 1048, 768; *H (400 MHz, CDCl3) 0.99 (3H, t, J 7.2 Hz, 
OCH2CH3), 1.46 (3H, t, J 7.2 Hz, OCH2CH3), 4.09 (2H, q, J 7.2 Hz, OCH2CH3), 4.54 (2H, 
q, J 7.2 Hz, OCH2CH3), 7.34–7.40 (2H, m, 2 + ArH), 7.47–7.53 (3H, m, 3 + ArH), 7.57 
(1H, ddd, J 8.4, 6.4, 1.6 Hz, ArH), 7.63 (1H, d, J 8.4, 1.6, 0.6 Hz, ArH), 7.81 (1H, ddd, J 
8.4, 6.4, 1.6 Hz, ArH), 8.38 (1H, ddd, J 8.4, 1.6, 0.6 Hz, ArH); *C (101 MHz, CDCl3) 13.6 
(CH3), 14.2 (CH3), 61.6 (CH2), 62.6 (CH2), 126.6 (CH), 127.1 (C), 127.5 (C), 128.2 (2 + 
CH), 128.7 (CH), 129.0 (CH), 129.4 (2 + CH), 130.7 (CH), 130.9 (CH), 134.8 (C), 145.9 
(C), 147.1 (C), 148.0 (C), 165.3 (C), 167.2 (C); m/z (EI) 349.1311 (M+. C21H19NO4 









A solution of ethyl 4-phenylquinoline-2,3-dicarboxylate (181) (4.72 g, 13.5 mmol) in 
tetrahydrofuran (50 mL) was heated under reflux with vigorous stirring.  To this was added 
dropwise, a solution of sodium borohydride (5.11 g, 135 mmol) in methanol (50 mL), and 
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the resultant reaction mixture stirred under reflux for 15 h.  After cooling to ambient 
temperature, excess sodium borohydride was quenched by the dropwise addition of a 
saturated solution of ammonium chloride (~50 mL).  The crude reaction mixture was 
extracted using dichloromethane (3 + 50 mL) and washed with water (2 + 50 mL), dried 
(MgSO4), filtered and concentrated in vacuo.  Trituration with diethyl ether afforded 9-
phenyl-1H,3H-furo[3,4-b]quinolin-1-ol (182) (3.29 g, 93%) as a pale yellow solid.  Mp 
208–210 °C; ,max/cm
–1 (neat) 3327 (OH), 2927 (CH), 1727, 1538, 1486, 1443, 1213, 1026, 
749; *H (400 MHz, DMSO-d6) 4.87 (1H, dd, J 15.7, 0.8 Hz, CHHO), 4.98 (1H, d, J 15.7 
Hz, CHHO), 5.02 (1H, br s, CHOH), 6.87–6.94 (2H, m, 2 + ArH), 7.04 (1H, d, J 6.8 Hz, 
ArH), 7.10–7.17 (2H, m, 2 + ArH), 7.18–7.28 (4H, m, 4 + ArH), 10.0 (1H, br s, CHOH); 
*C (101 MHz, DMSO-d6) 65.0 (CH2), 95.2 (C), 116.2 (CH), 123.1 (CH), 124.3 (C), 126.2 
(CH), 127.5 (CH), 127.6 (2 + CH), 128.3 (2 + CH), 130.8 (CH), 136.1 (C), 146.8 (C), 









A suspension of lithium aluminium hydride (0.581 g, 15.3 mmol) in tetrahydrofuran (25 
mL) was cooled to 0 °C, and to this was added dropwise, a solution of 9-phenylfuro[3,4-
b]quinolin-1(3H)-one (176) (1.00 g, 3.83 mmol) in tetrahydrofuran (25 mL).  The 
temperature of the reaction mixture was maintained at 0 °C and stirred vigorously for 3 h.  
After gradually warming to ambient temperature, the mixture was quenched by the 
dropwise addition of a 1 M hydrochloric acid solution, and then extracted using ethyl 
acetate (3 + 25 mL).  The organic layer was dried (MgSO4), filtered and concentrated in 
vacuo to afford a colourless residue which was dissolved in methanol (50 mL).  10% 
Palladium on carbon (1.00 g) was added to the reaction flask and the resultant suspension 
stirred at ambient temperature for 15 h.  The suspension was then filtered through a pad of 
Celite!, washed with methanol and concentrated in vacuo.  Trituration with diethyl ether 
afforded 2,3-bis(hydroxymethyl)-4-phenylquinoline (175) (0.777 g, 77%) as a white solid. 
Mp 171–173 °C (lit.,145 mp 175–177 °C); ,max/cm
–1 (neat) 3422 (OH), 3074, 2991 (CH), 
1571 (C=C), 1490, 1442, 1231, 1022, 1006; *H (400 MHz, CD3OD) 4.59 (2H, s, CH2OH), 
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5.11 (2H, s, CH2OH), 7.34–7.38 (2H, m, 2 + ArH), 7.41 (1H, dd, J 8.4, 1.2 Hz, ArH) ), 
7.44–7.50 (1H, m, ArH), 7.51–7.60 (3H, m, 3 + ArH), 7.73 (1H, ddd, J 8.4, 6.4, 1.2 Hz, 
ArH), 8.11 (1H, d, J, 8.4 Hz, ArH); *C (101 MHz, CD3OD) 59.1 (CH2), 64.7 (CH2), 127.8 
(CH), 127.9 (CH), 128.6 (C), 129.4 (CH), 129.5 (CH), 129.5 (2 + CH), 130.0 (C), 130.8 
(CH), 130.8 (2 + CH), 137.3 (C), 147.4 (C), 150.4 (C), 160.9 (C); m/z (CI) 266.1186 
(MH+. C17H16NO2 requires 266.1181), 264 (50%), 248 (42), 218 (21), 206 (4), 151 (3). 
 







To a solution of 2,3-bis(hydroxymethyl)-4-phenylquinoline (175) (0.777 g, 2.93 mmol) in 
chloroform (50 mL) was added activated manganese(IV) oxide (7.64 g, 87.9 mmol) in one 
portion.  The resultant suspension stirred vigorously at ambient temperature for 4 h and 
then filtered through Celite!.  After washing with chloroform (100 mL), the solvent was 
removed in vacuo to afford 9-phenylfuro[3,4-b]quinolin-3(1H)-one (174) (0.700 g, 92%) 
as a white solid, which was used without further purification.  Spectroscopic data in 
accordance with the literature.145 Mp 188–190 °C (lit.,145 mp 190–192 °C); ,max/cm
–1 
(neat) 3005 (CH), 1775 (CO), 1582 (C=C), 1414, 1371, 1152, 1121, 1055, 1007; *H (400 
MHz, CDCl3) 5.41 (2H, s, OCH2), 7.45 (2H, dd, J 8.0, 2.0 Hz, 2 + ArH), 7.57–7.70 (4H, 
m, 4 + ArH), 7.84–7.90 (1H, m, ArH), 7.92 (1H, d, J 8.4 Hz, ArH), 8.46 (1H, d, J 8.4 Hz, 
ArH); *C (101 MHz, CDCl3) 67.8 (CH2), 125.7 (CH), 127.9 (C), 128.9 (2 + CH), 129.3 (2 
+ CH), 129.4 (CH), 129.6 (CH), 130.7 (CH), 131.5 (CH), 132.3 (C), 133.6 (C), 143.9 (C), 
144.4 (C), 150.7 (C), 168.7 (C); m/z (ESI) 284.0677 (MNa+. C17H11NNaO2 requires 
284.0682). 
 








To a solution of diethylamine (0.238 mL, 2.30 mmol) in dichloromethane (20 mL) was 
added trimethylaluminium solution (2.0 M in toluene) (1.15 mL, 2.30 mmol) dropwise, 
and the mixture stirred at ambient temperature for 0.3 h.  A solution of 9-phenylfuro[3,4-
b]quinolin-3(1H)-one (174) (0.300 g, 1.15 mmol) in dichloromethane (20 mL) was then 
added dropwise and the resultant reaction mixture stirred under reflux for 15 h.  On 
cooling to ambient temperature, the reaction was quenched by the careful addition of a 1 M 
hydrochloric acid solution (25 mL), and the crude mixture extracted using 
dichloromethane (2 + 20 mL).  The organic layer was dried (MgSO4), filtered and 
concentrated in vacuo.  Purification using flash column chromatography (ethyl 
acetate/petroleum ether, 1:3) gave 3-(hydroxymethyl)-4-phenylquinoline-2-N-
diethylcarboxamide (172) (0.235 g, 61%) as a pale yellow solid.  Spectroscopic data in 
accordance with the literature.138 Mp 117–119 °C; ,max/cm
–1 (neat) 3408 (OH), 2972, 2932 
(CH), 1613 (CO), 1483, 1443, 1267, 1216, 1069; *H (400 MHz, CDCl3) 1.27 (3H, t, J 7.2 
Hz, NCH2CH3), 1.36 (3H, t, J 7.2 Hz, NCH2CH3), 3.42 (2H, q, J 7.2 Hz, NCH2CH3), 3.68 
(2H, q, J 7.2 Hz, NCH2CH3), 4.12 (1H, t, J 6.4 Hz, CH2OH), 4.39 (2H, d, J 6.4 Hz, 
CH2OH), 7.41–7.58 (7H, m, 7 + ArH), 7.72 (1H, ddd, J 8.4, 6.8, 1.6 Hz, ArH), 8.12 (1H, 
ddd, J 8.4, 1.2, 0.8 Hz, ArH); *C (101 MHz, CDCl3) 12.9 (CH3), 14.2 (CH3), 40.3 (CH2), 
43.7 (CH2), 59.7 (CH2), 127.0 (CH), 127.4 (CH), 127.6 (C), 128.4 (3 + CH), 129.4 (C), 
129.6 (CH), 129.8 (CH), 129.9 (2 + CH), 135.2 (C), 146.1 (C), 149.3 (C), 155.1 (C), 169.8 
(C); m/z (ESI) 357.1576 (MNa+. C21H22N2NaO2 requires 357.1573); Anal. Calcd for 
C21H22N2O2: C, 75.42; H, 6.63; N, 8.38. Found: C, 75.03; H, 6.57; N, 8.23. 
 








3-(Hydroxymethyl)-4-phenylquinoline-2-N-methyl-N-benzylcarboxamide (173) was 
synthesised as describe above for 3-(hydroxymethyl)-4-phenylquinoline-2-N-
diethylcarboxamide (172) using N-benzylmethylamine (0.295 mL, 2.30 mmol), 
trimethylaluminium solution (2.0 M in toluene) (1.15 mL, 2.30 mmol) and 9-
phenylfuro[3,4-b]quinolin-3(1H)-one (174) (0.300 g, 1.15 mmol) in dichloromethane (40 
mL).  Purification using flash column chromatography (ethyl acetate/petroleum ether, 1:4) 
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followed by trituration with diethyl ether afforded 3-(hydroxymethyl)-4-phenylquinoline-
2-N-methyl-N-benzylcarboxamide (173) (0.245 g, 56%) as a white solid.  Spectroscopic 
data in accordance with literature.44 NMR spectra showed a 1:1 mixture of rotamers, of 
which only the signals for one rotamer are recorded.  Mp 143–145 °C; ,max/cm
–1 (neat) 
3428 (OH), 2960 (CH), 1623 (CO), 1486, 1395, 1263, 1062, 980, 703; *H (500 MHz, 
CDCl3) 3.19 (3H, s, NCH3), 4.08 (1H, t, J 7.0 Hz, CH2OH), 4.45 (2H, d, J 7.0 Hz, 
CH2OH), 4.72 (2H, s, CH2Ph), 7.27–7.35 (3H, m, 3 + ArH), 7.37–7.57 (9H, m, 9 + ArH), 
7.69–7.76 (1H, m, ArH), 8.10 (1H, d, J 8.5 Hz, ArH); *C (126 MHz, CDCl3) 33.5 (CH3), 
55.1 (CH2), 59.7 (CH2), 126.9 (CH), 127.6 (CH), 127.6 (C), 127.8 (CH), 127.8 (CH), 127.9 
(CH), 128.3 (CH), 128.4 (2 + CH), 128.6 (CH), 128.9 (CH), 129.5 (CH), 129.8 (CH), 
129.8 (2 + CH), 135.2 (2 + C), 136.4 (C), 146.1 (C), 149.5 (C), 154.4 (C), 170.5 (C); m/z 
(ESI) 405.1559 (MNa+. C25H22N2NaO2 requires 405.1573). 
 








To a solution of 3-(hydroxymethyl)-4-phenylquinoline-2-N-diethylcarboxamide (172) 
(0.100 g, 0.299 mmol) in dichloromethane (10 mL) was added thionyl chloride (0.654 mL, 
8.97 mmol) and the reaction mixture stirred under reflux for 24 h.  On cooling to ambient 
temperature, the mixture was concentrated in vacuo and azeotroped with toluene (3 + 10 
mL) to remove excess thionyl chloride.  Purification using flash column chromatography 
(diethyl ether/petroleum ether, 1:1) gave 3-(chloromethyl)-4-phenylquinoline-2-N-
diethylcarboxamide (185) (0.105 g, 100%) as a colourless oil.  ,max/cm
–1 (neat) 2981 (CH), 
2936, 1630 (CO), 1560 (C=C), 1482, 1443, 1270, 1218, 1127, 1067, 728; *H (500 MHz, 
CDCl3) 1.30 (3H, t, J 7.0 Hz, NCH2CH3), 1.35 (3H, t, J 7.5 Hz, NCH2CH3), 3.28 (2H, q, J 
7.0 Hz, NCH2CH3), 3.68 (2H, q, J 7.5 Hz, NCH2CH3), 4.70 (2H, s, CH2Cl), 7.36–7.40 (2H, 
m, 2 + ArH), 7.41–7.49 (2H, m, 2 + ArH), 7.51–7.59 (3H, m, 3 + ArH), 7.73 (1H, ddd, J 
8.5, 6.5, 1.5 Hz, ArH), 8.13 (1H, d, J 8.5 Hz, ArH); *C (126 MHz, CDCl3) 12.3 (CH3), 13.5 
(CH3), 39.2 (CH2), 40.3 (CH2), 43.6 (CH2), 125.9 (C), 126.9 (CH), 127.3 (C), 127.4 (CH), 
128.6 (2 + CH), 128.7 (CH), 129.4 (2 + CH), 129.6 (CH), 130.2 (CH), 134.9 (C), 146.4 
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3-(Chloromethyl)-4-phenylquinoline-2-N-methyl-N-benzylcarboxamide (186) was 
synthesised as described above for 3-(chloromethyl)-4-phenylquinoline-2-N-
diethylcarboxamide (185) using 3-(hydroxymethyl)-4-phenylquinoline-2-N-methyl-N-
benzylcarboxamide (173) (0.031 g, 0.081 mmol) and thionyl chloride (0.177 mL, 2.43 
mmol) in dichloromethane (5 mL).  Purification using flash column chromatography 
(diethyl ether/hexane, 1:1) afforded 3-(chloromethyl)-4-phenylquinoline-2-N-methyl-N-
benzylcarboxamide (186) (0.032 g, 100%) as a pale yellow solid.  Spectroscopic data in 
accordance with the literature.44  NMR spectra showed a 1.5:1 mixture of rotamers, of 
which only the signals for the major rotamer are recorded.  Mp 124–125 °C (lit.,44 mp 
130–132 °C); ,max/cm
–1 (neat) 3064 (CH), 1637 (CO), 1485, 1443, 1396, 1262, 1115, 
1055; *H (500 MHz, CDCl3) 2.94 (3H, s, NCH3), 4.75 (2H, s, CH2Cl), 4.91 (2H, s, 
CH2Ph), 7.29–7.35 (1H, m, ArH), 7.36–7.63 (11H, m, ArH), 7.68–7.78 (1H, m, ArH), 8.14 
(1H, d, J 8.4 Hz, ArH) ; *C (126 MHz, CDCl3) 36.3 (CH3), 40.2 (CH2), 50.6 (CH2), 126.2 
(C), 126.9 (CH), 127.3 (C), 127.5 (CH), 127.6 (CH), 127.8 (CH), 128.4 (CH), 128.5 (CH), 
128.6 (2 + CH), 128.7 (CH), 129.3 (2 + CH), 129.5 (CH), 129.6 (CH), 130.3 (CH), 134.8 
(C), 136.4 (C), 146.5 (C), 149.6 (C), 155.2 (C), 168.9 (C); m/z (ESI) 423.1219 (MNa+. 
C25H21











To a solution of 18-crown-6 (0.038 g, 0.14 mmol) in acetonitrile (2.5 mL) was added 
potassium fluoride (0.041 g, 0.71 mmol) and the resultant suspension stirred at ambient 
temperature for 0.5 h.  A solution of 3-(chloromethyl)-4-phenylquinoline-2-N-
diethylcarboxamide (185) (0.050 g, 0.14 mmol) in acetonitrile (2.5 mL) was then added 
dropwise to the reaction mixture and stirred under reflux for 24 h.  On cooling to ambient 
temperature, water (10 mL) was added to the mixture and then extracted using 
dichloromethane (3 + 15 mL).  The organic layer was dried (MgSO4), filtered and 
concentrated in vacuo.  Purification using flash column chromatography (diethyl 
ether/petroleum ether, 1:1), followed by washing with acetonitrile gave 3-(fluoromethyl)-
4-phenylquinoline-2-N-diethylcarboxamide (170) (0.028 g, 60%) as a white solid.  
,max/cm
–1 (neat) 2976, 2936 (CH), 1634 (CO), 1560 (C=C), 1481, 1269, 1213, 1069, 970; 
*H (400 MHz, CDCl3) 1.22 (3H, t, J 7.2 Hz, NCH2CH3), 1.34 (3H, t, J 7.2 Hz, NCH2CH3), 
3.28 (2H, q, J 7.2 Hz, NCH2CH3), 3.67 (2H, q, J 7.2 Hz, NCH2CH3), 5.38 (2H, d, J 47.8 
Hz, CH2F), 7.32–7.38 (2H, m, 2 + ArH), 7.46–7.57 (5H, m, 5 + ArH), 7.73–7.78 (1H, m, 
ArH), 8.16 (1H, d, J 8.4 Hz, ArH); *C (101 MHz, CDCl3) 12.6 (CH3), 13.7 (CH3), 39.4 
(CH2), 43.2 (CH2), 79.2 (CH2F, d, JC-F 162.2), 123.4 (C, d, JC-C-F 15.1 Hz), 127.0 (CH), 
127.1 (C, d, JC-C-C-C-F 1.8 Hz), 127.4 (CH), 128.5 (2 + CH), 128.7 (CH), 129.6 (CH), 129.7 
(2 + CH), 130.5 (CH, d, JC-C-C-C-C-F 1.5 Hz), 134.8 (C), 147.1 (C, d, JC-C-C-F 2.9 Hz), 150.7 
(C, d, JC-C-C-F 4.9 Hz), 155.9 (C, d, JC-C-C-C-F 1.7 Hz), 168.2 (C); m/z (ESI) 359.1520 
(MNa+. C21H21FN2NaO requires 359.1530). 
 








3-(Fluoromethyl)-4-phenylquinoline-2-N-methyl-N-benzylcarboxamide (171) was 
synthesised as described above for 3-(fluoromethyl)-4-phenylquinoline-2-N-
diethylcarboxamide (170) using 18-crown-6 (0.020 g, 0.076 mmol), potassium fluoride 
(0.023 g, 0.40 mmol) and 3-(chloromethyl)-4-phenylquinoline-2-N-methyl-N-
benzylcarboxamide (186) (0.031 g, 0.077 mmol) in acetonitrile (5 mL). Purification using 
flash column chromatography (diethyl ether/petroleum ether, 2:3), followed by washing 
with acetonitrile afforded 3-(fluoromethyl)-4-phenylquinoline-2-N-methyl-N-
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benzylcarboxamide (171) (0.023 g, 79%) as a colourless oil.  NMR spectra showed a 1:1 
mixture of rotamers, of which only the signals for one rotamer is recorded.  ,max/cm
–1 
(neat) 2926 (CH), 1636 (CO), 1560 (C=C), 1485, 1397, 1119, 1055, 968; *H (500 MHz, 
CDCl3) 2.89 (3H, s, NCH3), 4.90 (2H, s, CH2Ph), 5.40 (2H, d, J 47.7 Hz, CH2F), 7.28–7.41 
(5H, m, 5 + ArH), 7.42–7.58 (7H, m, 7 + ArH), 7.72–7.80 (1H, m, ArH), 8.18 (1H, d, J 8.5 
Hz, ArH); m/z (ESI) 407.1511 (MNa+. C25H21FN2NaO requires 407.1530). 
 
5.3 HPLC Methods for Physicochemical Analysis133 
 
All physicochemical analyses were performed using a Dionex Ultimate 3000 series, and 
data acquisition and processing performed using Chromeleon 6.8 Chromatography 
software.  Standard and test compounds were dissolved in 1:1 organic/aqueous phases, and 
prepared to a concentration of 0.5 mg/mL.  The HPLC system was set to 25 °C, and UV 
detection achieved using a diode array detector (190 – 800 nm).  Analysis was performed 
using 5 µL sample injections. 
 
C18 chromatography for determination of lipophilicity (LogP)  
 
LogP values were determined using a Phenomenex Luna 5 micron C18 100 A (50 + 3 mm) 
column.  The retention time for each compound of interest was measured using filtered 
acetonitrile and 0.01 mM phosphate buffered saline as the mobile phase at pH 7.4, pH 2.5 
and pH 10.0, and pH was adjusted by the addition of concentrated hydrochloric acid and 
0.05 M sodium hydroxide solution respectively.  The mobile phase flow rate was set at 1.0 
mL/min.  The CHI value for all compounds of interest was determined by measuring the 
retention time of each compound under the following mobile phase conditions: 0–10.5 
min, 0–100% acetonitrile; 10.5–11.5 min, 100% acetonitrile; 11.5–12.0 min, 100–0% 
acetonitrile; 12.0–15.0 min, 0% acetonitrile.  System calibration was achieved using the 
following compounds and plotting their mean CHI values against the measured retention 
time under all three pH conditions: theophylline (CHI = 15.76), phenyltetrazole (CHI = 
20.18), benzimidazole (CHI = 30.71), colchicine (CHI = 41.37), acetophenone (CHI = 
64.90), indole (CHI = 69.15), propiophenone (CHI = 78.41), butyrophenone (CHI = 88.49) 
and valerophenone (CHI = 97.67).  Using the calibration curves obtained and the following 




CHI Log D = 0.054 CHI & 1.467   
   
where CHI Log D is the CHI value projected to the logarithmic scale 
 
Log P = 0.054 CHIN + 1.32 A & 1.88     
 
where CHIN = CHI values the compound in a neutral form, and A = Abraham H-bond 
acidity parameter, which was determined using ADME Suite 5.0 software. 
 
Immobilised Artificial Membrane (IAM) chromatography for determination of 
membrane permeability (Pm) and membrane partition coefficient (Km) 
 
Pm and Km values were determined using previously developed methodology on a 
Registech IAM.PC.DD2 (15 cm + 4.6 mm) column.  Acetonitrile and 0.01 mM phosphate 
buffered saline at pH 7.4 was used as the mobile phase, with a flow rate of 1.0 mL/min.  
The retention time of each compound was measured under an isocratic mobile phase with 
the percentage acetonitrile ranging from 30–40%.  The retention time of citric acid, as an 
unretained compound, under an isocratic mobile phase of 100% phosphate buffered saline 
was used for system corrections.  The following equations were used to calculate Pm and 




where kIAM = solute capacity factor on the column, tr = compound retention time and t0 = 
unretained compound retention time 
 
       
 
where Vs = volume of the IAM interphase created by the immobilized phospholipids, Vm = 
total volume of the solvent within the IAM column and Km = membrane partition 
coefficient 
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where the specific weight of PhC (*PhC) = 1.01779 g/mL and C10/C3 (*C10/C3) = 0.86 g/mL; 
WPhC = 133 mg, WC10 = 12.73 mg and WC3 = 2.28 mg 
 
       
 
where fr = flow rate 
 
       
 
where Pm = permeability and MW = molecular weight 
 
Human Serum Albumin (HSA) chromatography for determination of percentage of 
plasma protein binding (%PPB) 
 
%PPB values were determined using previously developed methodology on a ChromTech 
HSA 5 µm (3.0 + 50 mm) column.  Isopropanol and 0.01 mM phosphate buffered saline at 
pH 7.4 was used as the mobile phase, with a flow rate of 1.8 mL/min. The retention time of 
each compound was measured under the following mobile phase conditions: 0–3 min, 0–
30% IPA; 3–10 min, 30% IPA; 10.5–11.0 min, 30–0% IPA; 11.0–15.0 min, 0% IPA. 
System calibration was achieved using the following compounds and plotting %PPB 
values against their mean retention times: warfarin (%PPB = 98.0), nizatidine (%PPB = 
35.0), bromazepam (%PPB = 60.0), carbamazepine (%PPB = 75.0), budesonide (%PPB = 
88.0), nicardipine (%PPB = 95.0), ketoprofen (%PPB = 98.7), indomethacin (%PPB = 
99.0) and diclofenac (%PPB = 99.8).  For each standard compound, the literature %PPB 
value was converted to its corresponding Log k value, which when plotted against tr on the 
HSA column, afforded a line equation from which the Log k value of the unknown 
compounds could be extracted. The Log k values of the unknown compounds could then 
be converted to %PPB.  Log k and subsequent %PPB calculation for the compounds of 
interest were performed using Excel 2008 Software. 
 




   
5.4 Radioligand Binding Methodology242 
 
Preparation of Rat Brain Membranes 
 
Whole brains from male Sprague-Dawley rats (200–300 g) were obtained and immediately 
added to 25 mL of ice-cold Tris-Base buffer (50 nM, pH 7.4) and thoroughly homogenised 
using a Polytron. The resultant homogenates were centrifuged at 39100 g for 10 min (4 °C) 
using a Beckman J2-21M/E centrifuge. After discarding the supernatant, the pellet was 
resuspended in 25 mL of ice-cold buffer and the centrifugation process repeated. The 
resultant pellet was then resuspended in 10 mL of ice-cold buffer and the homogenate 
stored at &50 °C until further use.  Total protein content of the brain homogenate was 
measured using the Bicinchoninic acid (BCA) based protein assay.  A Bio-Rad solution 
(solution A/solution B, 50:1) was prepared and 1 mL added to centrifuge tubes.  To each 
tube was added 50 µL of pre-prepared bovine serum albumin (BSA) standards in 50 mM 
tris-base buffer (pH 7.4) in the following pre-defined concentrations: 2000, 1500, 1000, 
750, 500, 250, 125, 25, and 0 µg/mL.  5µL of the freshly prepared brain homogenate was 
added to three centrifuge tubes.  The tubes were thoroughly vortexed and incubated at 37 
°C for 0.5 h.  After incubation, the tubes were left at ambient temperature for 5 min and the 
absorbance measured at 562 nm using a spectrophotometer.  A calibration curve was 
generated by plotting absorbance against protein content, which was subsequently used to 
determine the protein content of the rat brain homogenate.     
 
Competition Binding Assays 
 
Brain homogenate stock was diluted to give a final assay concentration of approximately 
0.6 mg of protein. Total binding was determined using a final concentration of 1 nM 
[3H]PK11195, and non-specific binding was measured using a final concentration of 8 µM 
unlabelled PK11195 in the presence of [3H]PK11195. The Ki value of the compound was 
determined using a range of competitor concentrations (3 pM–300 µM). Assays were 
carried out in triplicate, and a typical assay consisted of 100 µL labelled competitor, 100 
µL test compound and 200 µL of brain homogenate to give a final assay volume of 400 µL 
(with <1% ethanol present). The assay components were thoroughly mixed and then 
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incubated at 5 °C for 1.5 h. The binding assay was terminated by the rapid filtration 
through Whatman GF/B glass fiber filters, which were pre-soaked in 0.3% w/v 
polyethylenimine, using a 24-well Brandel cell harvester. Filters received 3 rapid washes 
with ice-cold tris-base buffer and were added to prepared scintillation vials containing 10 
mL of Eco-scint. After a minimum of 48 h at ambient temperature, tritium counts were 
measured using a liquid scintillation counter. The resultant radioactive counts were used to 
determine the Ki value of the compound of interest by performing non-linear regression 
analysis using GraphPad Prism 4.0 (GraphPad Softare Inc).  Mean and standard deviation 
(n = 3) was calculated using Excel 2008 software. 
 
5.5 Stability Testing 
 
3-(Fluoromethyl)-4-phenylquinoline-2-N-diethylcarboxamide (170) (2 mg, 0.005 mmol) 
was dissolved in a 1:1 mixture of 0.01 mM phosphate buffered saline and acetonitrile (2 
mL) and incubated at 37 ° C.  5 µL of the solution was injected onto the HPLC system 
(conditions described below in section 5.6) at various time points (0, 1, 2, 4, 6 and 24 h).  
The purity of the compound at these time points was detemined by measuring the area 
under the peaks of the resultant UV chromatograms. 
    
5.6 Radiochemistry 
 
Manual Synthesis of [18F]AB5186 
 
A v-vial containing 0.3 µL of non-carrier added [18F]fluoride (455 MBq) was decapped; to 
this was added 250 µL of a solution containing 0.106 M Kryptofix! K222 and 0.0347 M 
potassium carbonate, and then immediately recapped.  The fluoride was dried by passing a 
constant stream of argon over the solution at 100 °C.  Additional aliquots of anhydrous 
acetonitrile (3 + 0.5 mL) was added to facilitate azeotropic drying (approximately 30 min).  
A solution of the chloride precursor 185 (2.4 mg) in acetonitrile (0.5 mL) was then added 
to the v-vial and the reaction allowed to proceeded for 12 mins at 100 °C.  After removal 
from the heating block, the reaction mixture was allowed to cool for a few minutes before 




Semi-Preparative HPLC Purification of [18F]AB5186 
 
The crude [18F]AB5186 reaction mixture was loaded onto a Phenomenex Synergi 4 µm 
Hydro-RP 80A (150 + 10.00 mm) column.  Acetonitrile and water was used as the mobile 
phase, with a flow rate of 3 mL/min.  Purification was achieved using the following 
isocratic mobile phase: 0 min, 70% acetonitrile; 15 min, 70% acetonitrile; 15.1 min, 95% 
acetonitrile; 25 min, 95% acetonitrile.  The radiolabelled product was detected using a 
radiodetector, and collected at approximately 8 min.  The fraction containing [18F]AB5186 
was concentrated in vacuo and then reconstituted in 2 mL of a 10% ethanol/0.9% saline 
solution.  Passing the sample through a pre-treated 13 mm 0.2 µm filter then completed 
formulation of the radiotracer.  The identity of the radiolabelled product was confirmed by 
co-injection with a cold sample of AB5186.  Quality control was performed by analytical 
HPLC, using a Phenomenex Synergi 4µm Hydro-RP 80A (150 + 4.60 mm) column and the 
mobile phase described above for the semi-prep HPLC purification step.  Radiochemical 
purity was determined by measuring the area under the peaks on the chromatogram. 
 
Measurement of Specific Activity of [18F]AB5186 
 
A concentration response curve was generated on the semi-preparative HPLC system used 
for purification of [18F]AB5186, by injection of 10 µL samples of unlabelled AB5186 in 
the following concentrations: 1 mg/mL, 0.5 mg/mL, 0.1 mg/mL, 0.05 mg/mL, 0.01 mg/mL 
and 0.005 mg/mL in a 7:3 acetonitrile/water mixture.  The UV response (mV/min) of each 
concentration was then plotted against the corresponding moles of unlabelled AB5186.  
For calculation of the specific activity, the entire crude radiolabelling reaction mixture was 
injected onto the semi-preparative HPLC system, and the resulting UV response (mV/min) 
of the relevant peak measured.  The UV response was then used to calculate the number of 
moles of [18F]AB5186 present.  Recording the amount of radioactivity present immediately 
before injection onto the column, in conjunction with integration of the relevant peak of 









In vitro Autoradiography with [3H]PK11195 and [18F]AB5186 
 
The brain from an orthotopic mouse model of human glioblastoma generated by injecting 
105 cultured G7 glioblastoma cells into the caudate nucleus of a CD1 nude mouse was 
used.  Coronal sections (20 µm thick) were cut in a cryostat at &20 °C from the frozen 
brain, mounted onto poly-L-lysine coated slides and stored at &50 °C until further use.  All 
incubations and washing steps of the autoradiographic protocol were performed in a 
freshly prepared 50 mM Tris-base buffer (pH 7.4).  Slide mounted brain sections were 
thawed and pre-washed three times in buffer for 5 min.  The slides were then incubated 
with either 1 nM [3H]PK11195 (85.7 Ci/mmol, Perkin-Elmer) or 3 nM [18F]AB5186 170 
(7.67 MBq/nmol) for 1 h at ambient temperature.  Non-specific binding was determined in 
adjacent sections by incubating then with either 1 nM [3H]PK11195 or [18F]AB5186 170 in 
the presence of 10 µM PK11195 (Tocris, UK).  At the end of the incubation, sections were 
washed twice in ice-cold buffer for 5 min, and then dipped into ice-cold distilled water for 
10 sec.  The slides were subsequently dried at ambient temperature either overnight 
([3H]PK11195) or for approximately 10 min ([18F]AB5186) by passing a gentle stream of 
cool air over them.  Slides were exposed to [3H]-hyperfilm (Amersham, UK) for 21 days 
([3H]PK11195) or 1 h ([18F]AB5186) and then developed.  Optical density measurements 
were made from the resulting autoradiograms using MCID basic 7.0 software (MCID, 
UK). 
 












A solution of sodium methoxide (0.685 g, 12.7 mmol) in methanol (20 mL) was cooled to 
0 °C, and to this was added dimethyl phosphite (208) (1.08 mL, 11.8 mmol) dropwise.  
2-Carboxybenzaldehyde (204) (1.50 g, 9.99 mmol) was then added in portions to the 
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reaction mixture, which was gradually warmed to ambient temperature and stirred for 2 h.  
Methanesulfonic acid (0.908 mL, 14.0 mmol) was added dropwise to the reaction mixture 
and a white suspension formed.  The mixture was concentrated in vacuo and resuspended 
in water (20 mL).  The crude product was extracted using dichloromethane (3 + 20 mL) 
and washed with water (2 + 20 mL).  The organic layer was dried (MgSO4), filtered and 
concentrated in vacuo.  Purification by trituration with diethyl ether afforded (±)-3-
dimethoxyphosphoryl-3H-2-benzofuran-1-one (203) (2.33 g, 96%) as a white solid.  
Spectroscopic data in accordance with the literature. Mp 90–93 °C; ,max/cm
–1 (neat) 2963 
(CH), 1763 (CO), 1466, 1285 (P=O), 1258, 1194, 1024, 895, 849; *H (400 MHz, CD3OD) 
3.72 (3H, d, J 10.8 Hz, OCH3), 3.91 (3H, d, J 11.2 Hz, OCH3), 6.10 (1H, d, J 10.8 Hz, 3-
H), 7.64–7.70 (1H, m, ArH), 7.73–7.77 (1H, m, ArH), 7.83 (1H, t, J 7.6 Hz, ArH), 7.94 
(1H, dd, J 7.6, 0.8 Hz, ArH); *C (126 MHz, CD3OD) 53.7 (CH3, d, JC-O-P 7.1 Hz), 54.1 
(CH3, d, JC-O-P 6.7 Hz), 75.3 (CH, d, JC-P 166.1 Hz), 123.5 (CH), 125.1 (C, d, JC-C-P 4.2 
Hz), 125.6 (CH), 130.0 (CH), 134.7 (CH), 144.0 (C, d, JC-C-C-P 4.3 Hz), 170.1 (C); m/z (CI) 
243.0423 (MH+. C10H12O5P requires 243.0422), 242 (33%), 213 (8), 133 (87), 105 (6). 
 















A solution of 3-dimethoxyphosphoryl-3H-2-benzofuran-1-one (203) (2.00 g, 8.26 mmol) 
and 2-fluoro-5-formylbenzonitrile (207) (1.17 g, 7.85 mmol) in tetrahydrofuran (40 mL) 
was cooled to 0 °C, and to this was added triethylamine (1.51 mL, 8.26 mmol) dropwise.  
The resultant solution was allowed to warm to ambient temperature and vigorously stirred 
for 24 h.  The resultant suspension was concentrated in vacuo and water (40 mL) added to 
the residue.  After stirring at ambient temperature for 0.5 h, the product was collected by 
vacuum filtration and stringently washed with water (2 + 50 mL), hexane (2 + 50 mL) and 
diethyl ether (2 + 50 mL) before drying under high vacuum to give 2-fluoro-5-[(Z/E)-(3’’-
oxo-2’’-benzofuran-1’’-ylidene)methyl]benzonitrile (202) (1.97 g, 95%) as a white solid. 
NMR spectra showed a 75:25 mixture of E and Z isomers, of which only the signals for the 
major isomer are recorded.  The product was carried forward without prior separation of 
the isomers. Mp 203–205 °C; ,max/cm
–1 (neat) 2990 (CH), 2332 (CN), 1713 (CO), 1514, 
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1352, 1252, 1233, 1136, 1022; *H (500 MHz, DMSO-d6) 6.96 (1H, s, 1’-H), 7.63 (1H, t, J 
9.1 Hz, ArH), 7.70–7.74 (1H, m, ArH), 7.90–7.94 (1H, m, ArH), 7.99 (1H, dt, J 8.0, 1.0 
Hz, ArH), 8.08 (1H, dt, J 8.0, 1.0 Hz, ArH), 8.15–8.21 (2H, m, 2 + ArH); *C (126 MHz, 
DMSO-d6) 100.9 (C, d, JC-C-F 16.2 Hz), 103.4 (CH), 113.7  (C), 117.3 (CH, d, JC-C-F 20.1 
Hz), 120.9 (CH), 122.6 (C), 125.3 (CH), 130.9 (CH), 131.0 (C, d, JC-C-C-C-F 3.8 Hz), 134.2 
(CH), 135.3 (CH), 136.7 (CH, d, JC-C-C-F 9.0 Hz), 139.6 (C), 145.4 (C), 161.5 (C, d, JC-F 
258.3 Hz), 165.9 (C); m/z (EI) 265.0543 (M+. C16H8FNO2 requires 265.0539), 237 (15%), 
208 (93), 182 (12), 133 (24), 104 (28), 84 (41). 
 

















To a suspension of 2-fluoro-5-[(Z/E)-(3’’-oxo-2’’-benzofuran-1’’-
ylidene)methyl]benzonitrile (202) (3.84 g, 14.5 mmol) in water (100 mL) was added a 
13 N sodium hydroxide solution (15 mL), and the resultant mixture stirred vigorously at 
90 °C for 24 h.  After cooling to 70 °C, hydrazine monohydrate (10.0 mL, 0.207 mol) was 
added to the reaction mixture dropwise and stirred for a further 72 h.  On cooling to 
ambient temperature, the mixture was acidified (pH ~4) by the addition of a 6 M 
hydrochloric acid solution.  The resultant precipitate was collected by vacuum filtration 
and washed with water (3 + 100 mL) and diethyl ether (3 + 100 mL) before drying under 
high vacuum to afford 2-fluoro-5-[(4’’-oxo-3’’H-phthalazin-1’’-yl)methyl]benzoic acid 
(201) (4.31 g, 100%) as a pale pink solid.  Mp 251–252 °C; ,max/cm
–1 (neat) 3142 (NH), 
2927 (CH), 1695 (CO), 1631 (C=C), 1500, 1316, 1268, 1236, 1084; *H (500 MHz, DMSO-
d6) 4.34 (2H, s, 1’-H2), 7.21 (1H, dd, J 8.5, 2.0 Hz, ArH), 7.53–7.58 (1H, m, ArH), 7.78–
7.84 (2H, m, 2 + ArH), 7.89 (1H, td, J 8.0, 1.5 Hz, ArH), 7.96 (1H, d, J 8.0 Hz, ArH), 8.26 
(1H, dd, J 8.0, 1.0 Hz, ArH), 12.5 (1H, s, NH); *C (126 MHz, DMSO-d6) 36.3 (CH2), 
116.9 (CH, d, JC-C-F 22.6 Hz), 119.3 (C, d, JC-C-F 10.9 Hz), 125.4 (CH), 126.0 (CH), 127.9 
(C), 129.1 (C), 131.5 (CH), 131.7 (CH), 133.5 (CH), 134.2 (C, d, JC-C-C-C-F 3.7 Hz), 134.7 
(CH, d, JC-C-C-F 8.7 Hz), 144.8 (C), 159.3 (C), 159.8 (C, d, JC-F 255.5 Hz), 164.8 (C, d, JC-C-
C-F 2.8 Hz); m/z (CI) 299.0828 (MH
+. C16H12FN2O3 requires 299.0832), 287 (10%), 255 
(21), 147 (7), 127 (31), 113 (18). 
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A solution of piperazine (206) (2.00 g, 23.2 mmol) in dichloromethane (50 mL) was 
cooled to 0 °C, and to this was added a solution of di-tert-butyl dicarbonate (209) (2.53 g, 
11.6 mmol) in dichloromethane (25 mL) dropwise over a period of 0.5 h.  The resultant 
suspension was stirred at 0 °C for 3 h, and then allowed to warm to ambient temperature.  
The organic layer was then washed with water (3 + 50 mL), dried (MgSO4), filtered and 
concentrated in vacuo to give tert-butyl piperazine-1-carboxylate (205) (1.89 g, 88%) as a 
colourless solid, which was used without further purification. Mp 46–48°C (lit.,208 mp 46–
47 °C); ,max/cm
–1 (neat) 3325 (NH), 2978 (CH), 1684 (CO), 1422, 1242, 1163, 1121, 
1005; *H (400 MHz, CD3OD) 1.48 (9H, s, O
tBu), 2.75–2.79 (4H, m, 2 + NCH2), 3.40 (4H, 
t, J 4.8 Hz, 2 + NCH2); *C (101 MHz, CD3OD) 28.6 (3 + CH3), 45.1 (2 + br CH2), 46.2 (2 
+ CH2), 81.3 (C), 156.5 (C); m/z (EI) 187 (MH
+, 100%) 175 (83), 131 (95), 102 (11). 
 
tert-Butyl 4-{2’-fluoro-5’-[(4’’’-oxo-3’’’H-
























To a solution of 2-fluoro-5-[(4’’-oxo-3’’H-phthalazin-1’’-yl)methyl]benzoic acid (201) 
(0.500 g, 1.68 mmol) in N,N’-dimethylformamide (50 mL) was added triethylamine (0.350 
mL, 2.51 mmol) followed by O-benzotriazole-N,N,N’,N’-
tetramethyluroniumhexafluorophosphate (0.699 g, 1.84 mmol).  The reaction mixture was 
stirred at ambient temperature for 1 h, after which it was heated to 50 °C and tert-butyl 
piperazine-1-carboxylate (205) (0.312 g, 1.68 mmol) added.  After stirring for a further 72 
h, water (50 mL) was added and the mixture stirred for a further 2 h before being cooled to 
0 °C.  The resultant precipitate was collected by vacuum filtration and stringently washed 
with water (2 + 25 mL), diethyl ether (2 + 25 mL) and isopropan-2-ol (2 + 25 mL) to 
! "*"!
afford tert-butyl 4-{2’-fluoro-5’-[(4’’’-oxo-3’’’H-
phthalazin-1’’’-yl)methyl]benzoyl}piperazine-1-carboxylate (200) (0.533 g, 68%) as a pale 
yellow solid.  Mp 215–216 °C; ,max/cm
–1 (neat) 3206 (NH), 2976 (CH), 1640 (CO), 1495, 
1410, 1364, 1248, 1163, 1013; *H (400 MHz, CDCl3) 1.47 (9H, s, O
tBu), 3.27 (2H, br s, 
NCH2), 3.38 (2H, t, J 4.8 Hz, NCH2), 3.51 (2H, br s, NCH2), 3.75 (2H, br s, NCH2), 4.27 
(2H, s, 1’’-H2), 7.04 (1H, t, J 9.2 Hz, ArH), 7.27–7.37 (2H, m, 2 + ArH), 7.68–7.79 (3H, 
m, 3 + ArH), 8.44–8.48 (1H, m, ArH), 9.69 (1H, s, NH); *C (101 MHz, CDCl3) 28.4 (3 + 
CH3), 37.7 (CH2), 42.0 (2 + CH2), 46.9 (2 + CH2), 80.4 (C), 116.2 (CH, d, JC-C-F 22.3 Hz), 
123.9 (C, d, JC-C-F 17.3 Hz), 125.1 (CH), 127.2 (CH), 128.3 (C), 129.2 (CH, d, JC-C-C-F 3.5 
Hz), 129.5 (C), 131.6 (CH, d, JC-C-C-F 8.3 Hz), 131.7 (CH), 133.7 (CH), 134.3 (C, d, JC-C-C-
C-F 3.8 Hz), 145.6 (C), 154.5 (C), 157.0 (C, d, JC-F 247.8 Hz), 160.4 (C), 165.1 (C); m/z 
(EI) 466.2018 (M+. C25H27FN4O4 requires 466.2016), 393 (12%), 366 (38), 281 (100), 254 
(33), 196 (13), 166 (40), 91 (90). 
 























To a suspension of tert-butyl 4-{2’-fluoro-5’-[(4’’’-oxo-3’’’H-
phthalazin-1’’’-yl)methyl]benzoyl}piperazine-1-carboxylate (200) (0.533 g, 1.14 mmol) in 
ethanol (15 mL) was added a 6 M hydrochloric acid solution (30 mL), and the resultant 
reaction mixture stirred vigorously at ambient temperature for 18 h.  The ethanol was 
removed in vacuo and the aqueous layer made alkaline (pH ~10) by the dropwise addition 
of a 4 M sodium hydroxide solution.  The product was extracted using dichloromethane (3 
+ 50 mL) and the combined organic layer dried (MgSO4), filtered and concentrated in 
vacuo.  Purification by trituration using a 1:1 diethyl ether/petroleum ether mixture gave 
4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-1-one (199) (0.294 g, 
70%) as a white solid.  Mp 193–195 °C; ,max/cm
–1 (neat) 3468 (NH), 2942 (CH), 1628 
(CO), 1466, 1437, 1354, 1227, 1022, 770; *H (400 MHz, CDCl3) 2.07 (1H, br s, NH), 2.81 
(2H, br s, NCH2), 2.95 (2H, t, J 4.4 Hz, NCH2), 3.28 (2H, br s, NCH2), 3.77 (2H, br s, 
NCH2), 4.29 (2H, s, 1’-H2), 7.02 (1H, t, J 8.8 Hz, ArH), 7.26–7.37 (2H, m, 2 + ArH), 7.70–
7.80 (3H, m, 3 + ArH), 8.45–8.50 (1H, m, ArH), 11.46 (1H, br s, NH); *C (101 MHz, 
! "*#!
CDCl3) 37.7 (CH2), 43.1 (CH2), 45.7 (CH2), 46.2 (CH2), 48.2 (CH2), 116.1 (CH, d, JC-C-F 
22.1 Hz), 124.3 (C, d, JC-C-F 18.2 Hz), 125.1 (CH), 127.1 (CH), 128.3 (C), 129.1 (CH, d, 
JC-C-C-F 3.7 Hz), 129.6 (C), 131.2 (CH, d, JC-C-C-F 8.1 Hz), 131.6 (CH), 133.6 (CH), 134.2 
(C, d, JC-C-C-C-F 3.1 Hz), 145.6 (C), 157.0 (C, d, JC-F 247.6 Hz), 160.8 (C), 165.0 (C); m/z 
(EI) 366.1486 (M+. C20H19FN4O2 requires 366.1492), 325 (13%), 298 (27), 281 (100), 254 






























To a stirred solution of 4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-
1-one (199) (0.023 g, 0.063 mmol) in dichloromethane (3 mL) was added 4-fluorobenzyl 
chloride (7.9 µL, 0.066 mmol) followed by N,N’-diisopropylethylamine (21.9 µL, 0.126 
mmol).  The resultant reaction mixture was stirred at ambient temperature for 12 h, and 
then water (5 mL) was added.  The mixture was washed with water (2 + 5 mL) and the 
organic layer dried (MgSO4), filtered and concentrated in vacuo.  Purification using flash 
column chromatography (methanol/dichloromethane, 1:9) afforded 4-{3’’-[4’’’-(4’’’’’-
fluorobenzyl)piperazine-1’’’-carbonyl]-4’’-fluorobenzyl}-2H-phthalazin-1-one (216) 
(0.011 g, 38%) as an off-white solid.  Mp 109–111 °C; ,max/cm
–1 (neat) 3185 (NH), 2916 
(CH), 1637 (CO), 1508, 1437, 1348, 1221, 1148, 999; *H (400 MHz, CDCl3) 2.34 (2H, br 
s, NCH2), 2.50 (2H, t, J 5.2 Hz, NCH2), 3.28 (2H, br s, NCH2), 3.48 (2H, s, 1’’’’-H2), 
3.75–3.82 (2H, m, NCH2), 4.28 (2H, s, 1’-H2), 6.96–7.04 (3H, m, 3 + ArH), 7.24–7.34 
(4H, m, 4 + ArH), 7.69–7.78 (3H, m, 3 + ArH), 8.44–8.50 (1H, m, ArH), 10.86 (1H, s, 
NH); *C (101 MHz, CDCl3) 37.8 (CH2), 42.0 (CH2), 47.1 (CH2), 52.5 (CH2), 53.0 (CH2), 
62.0 (CH2), 115.2 (2 + CH, d, JC-C-F 21.2 Hz), 116.1 (CH, d, JC-C-F 21.8 Hz), 124.3 (C, d, 
JC-C-F 18.3 Hz), 125.1 (CH), 127.2 (CH), 128.3 (C), 129.1 (CH, d, JC-C-C-F 3.8 Hz), 129.6 
(C), 130.5 (2 + CH, d, JC-C-C-F 7.9 Hz), 131.2 (CH, d, JC-C-C-F 7.9 Hz), 131.6 (CH), 133.3 
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(C, d, JC-C-C-C-F 3.0 Hz), 133.7 (CH), 134.1 (C, d, JC-C-C-C-F 3.4 Hz), 145.6 (C), 157.0 (C, d, 
JC-F 247.7 Hz), 160.5 (C), 162.1 (C, d, JC-F 245.0 Hz), 164.8 (C); m/z (ESI) 475.1929 






























To a solution of 4-fluorobenzoic acid (0.029 g, 0.21 mmol) in dichloromethane (5 mL) was 
added N,N’-diisopropylethylamine (60.8 µL, 0.349 mmol) followed by O-benzotriazole-
N,N,N’,N’-tetramethyluroniumhexafluorophosphate (0.080 g, 0.21 mmol).  The resultant 
reaction mixture was stirred vigorously under reflux for 1 h, after which a solution of 
4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-1-one (199) (0.064 g, 
0.17 mmol) in dichloromethane (5 mL) was added dropwise, and stirred for a further 24 h.  
On cooling to ambient temperature, water (5 mL) was added and the organic layer washed 
with water (3 + 10 mL) and a saturated sodium bicarbonate solution (10 mL), dried 
(MgSO4), filtered and concentrated in vacuo.  Purification using flash column 
chromatography (methanol/dichloromethane, 3:97) afforded 4-{3’’-[4’’’-(4’’’’-
fluorobenzoyl)piperazine-1’’’-carbonyl]-4’’-fluorobenzyl}-2H-phthalazin-1-one (217) 
(0.064 g, 75%) as a white solid.  Mp 166–168 °C; ,max/cm
–1 (neat) 3202 (NH), 2922 (CH), 
1629 (CO), 1425, 1285, 1223, 1152, 1005, 847; *H (400 MHz, CDCl3) 3.20–4.05 (8H, m, 4 
+ NCH2), 4.29 (2H, s, 1’-H2), 6.98–7.14 (3H, m, 3 + ArH), 7.30–7.45 (4H, m, 4 + ArH), 
7.68–7.79 (3H, m, 3 + ArH), 8.45–8.49 (1H, m, ArH), 11.37 (1H, s, NH); *C (101 MHz, 
CDCl3) 37.7 (CH2), 42.1 (2 + CH2), 47.0 (2 + CH2), 115.8 (2 + CH, d, JC-C-F 21.9 Hz), 
116.2 (CH, d, JC-C-F 22.0 Hz), 123.6 (C, d, JC-C-F 17.8 Hz), 125.0 (CH), 127.2 (CH), 128.3 
(C), 129.3 (CH, d, JC-C-C-F 3.5 Hz), 129.5 (2 + CH, d, JC-C-C-F 8.7 Hz), 131.1 (C, d, JC-C-C-C-F 
3.5 Hz), 131.6 (CH), 131.8 (CH, d, JC-C-C-F 8.0 Hz), 133.7 (CH), 134.5 (C, d, JC-C-C-C-F 3.5 
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Hz), 145.5 (C), 157.0 (C, d, JC-F 247.4 Hz), 160.8 (2 + C), 163.6 (C, d, JC-F 250.7 Hz), 

































phthalazin-1-one (218) was synthesised as described above for 4-{3’’-[4’’’-(4’’’’-
fluorobenzoyl)piperazine-1’’’-carbonyl]-4’’-fluorobenzyl}-2H-phthalazin-1-one (217) 
using 2-fluorobenzoic acid (0.047 g, 0.34 mmol), N,N’-diisopropylethylamine (97.0 µL, 
0.557 mmol), O-benzotriazole-N,N,N’,N’-tetramethyluroniumhexafluorophosphate (0.127 
g, 0.334 mmol) and 4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-1-
one (199) (0.102 g, 0.278 mmol) in dichloromethane (10 mL).  Purification using flash 
column chromatography (methanol/dichloromethane, 3:97) afforded 4-{3’’-[4’’’-(2’’’’-
fluorobenzoyl)piperazine-1’’’-carbonyl]-4’’-fluorobenzyl}-2H-phthalazin-1-one (218) 
(0.072 g, 53%) as a white solid.  NMR spectra showed a 56:44 mixture of rotamers, of 
which only the signals for one rotamer is recorded. Mp 246–248 °C; ,max/cm
–1 (neat) 3043 
(CH), 1684, 1641 (CO), 1464, 1433, 1289, 1251, 1007, 749; *H (CDCl3, 400 MHz) 3.20–
4.10 (8H, m, 4 + NCH2), 4.30 (2H, s, 1’-H2), 6.96–7.50 (7H, m, 7 + ArH), 7.67–7.81 (3H, 
m, 3 + ArH), 8.42–8.49 (1H, m, ArH), 10.17 (1H, s, NH); *C (CDCl3, 101 MHz) 37.7 
(CH2), 41.8 (CH2), 42.2 (CH2), 46.8 (CH2), 47.4 (CH2), 115.9 (CH, d, JC-C-F 21.4 Hz), 
116.1 (CH, d, JC-C-F 20.4 Hz), 123.4 (C, d, JC-C-F 17.8 Hz), 123.7 (C, d, JC-C-F 18.3 Hz), 
125.0 (br CH), 125.0 (CH), 127.3 (CH), 128.4 (C), 129.3 (br CH), 129.5 (C), 131.7 (br 
CH), 131.8 (br CH), 131.9 (br CH), 133.7 (2 + CH), 134.4 (C, d, JC-C-C-C-F 2.9 Hz), 145.5 
(C), 157.1 (C, d, JC-F 247.5 Hz), 158.1 (C, d, JC-F 247.8 Hz), 160.3 (C), 165.2 (C), 165.5 































To a solution of 4-fluoro-2-methylbenzoic acid (0.042 g, 0.27 mmol) in dichloromethane 
(5 mL) was added ethyl 3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.052 g, 
0.27 mmol) and the reaction mixture stirred at ambient temperature for 0.5 h.  
4-(Dimethylamino)pyridine (0.017 g, 0.14 mmol) was then added and the mixture stirred 
for a further 0.5 h.  A solution of 4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-
phthalazin-1-one (199) (0.100 g, 0.273 mmol) in dichloromethane (5 mL) was then added 
dropwise and the resultant reaction mixture stirred vigorously under reflux for 24 h.  On 
cooling to ambient temperature, water (5 mL) was added and the organic layer washed 
with water (3 + 5 mL) and a saturated sodium bicarbonate solution (5 mL), dried (MgSO4), 
filtered and concentrated in vacuo.  Purification using flash column chromatography 
(methanol/dichloromethane, 2:98) afforded 
4-{3’’-[4’’’-(4’’’’-fluoro-2’’’’-methylbenzoyl)piperazine-1’’’-carbonyl]-4’’-fluorobenzyl}
-2H-phthalazin-1-one (219) (0.043 g, 31%) as a white solid.  NMR spectra showed a 59:41 
mixture of rotamers, of which only the signals for one rotamer is recorded. Mp 175–177 
°C; ,max/cm
–1 (neat) 3188 (NH), 2926 (CH), 1632 (CO), 1462, 1429, 1256, 1159, 1063, 
1003; *H (400 MHz, CDCl3) 2.32 (3H, s, CH3), 3.15–3.45 (4H, m, 2 + NCH2), 3.55–4.10 
(4H, m, 2 + NCH2), 4.30 (2H, s, 1’-H2), 6.85–7.18 (4H, m, 4 + ArH), 7.26–7.39 (2H, m, 2 
+ ArH), 7.67–7.81 (3H, m, 3 + ArH), 8.43–8.50 (1H, m, ArH), 10.30 (1H, s, NH); *C (126 
MHz, CDCl3) 19.2 (CH3), 37.7 (CH2), 41.8 (CH2), 42.4 (CH2), 46.5 (CH2), 46.9 (CH2), 
113.2 (CH, d, JC-C-F 21.5 Hz), 116.3 (CH, d, JC-C-F 20.6 Hz), 117.5 (CH, d, JC-C-F 21.1 Hz), 
123.6 (C, d, JC-C-F 17.0 Hz), 125.0 (CH), 127.2 (CH), 127.8 (CH, d, JC-C-C-F 8.6 Hz), 128.3 
(C), 129.3 (CH, d, JC-C-C-F 3.2 Hz), 129.6 (C), 131.5 (C, d, JC-C-C-C-F 7.3 Hz), 131.6 (CH), 
131.8 (CH), 133.7 (CH), 134.5 (C, d, JC-C-C-C-F 3.4 Hz), 137.4 (C, d, JC-C-C-F 8.1 Hz), 145.5 
(C), 157.0 (C, d, JC-F 246.4 Hz), 160.7 (C), 162.9 (C, d, JC-F 248.8 Hz), 165.3 (C), 169.6 

































To a solution of 4-fluorophenylacetic acid (0.043 g, 0.28 mmol) in N,N’-
dimethylformamide (5 mL) was added N,N’-diisopropylethylamine (93.4 µL, 0.546 mmol) 
followed by O-benzotriazole-N,N,N’,N’-tetramethyluroniumhexafluorophosphate (0.105 g, 
0.277 mmol), and the reaction mixture stirred vigorously at ambient temperature for 1 h.  
A solution of 4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-1-one 
(199) (0.100 g, 0.273 mmol) in N,N’-dimethylformamide (5 mL) was then added dropwise, 
and the resultant reaction mixture heated to and stirred at 50 °C for a further 24 h.  On 
cooling to ambient temperature, dichloromethane was added (10 mL) and the organic layer 
washed with water (3 + 10 mL) and a saturated sodium bicarbonate solution (10 mL), dried 
(MgSO4), filtered and concentrated in vacuo.  Purification using flash column 
chromatography (methanol/dichloromethane, 4:96) afforded 4-(3’’-{4’’’-[(4’’’’’-
fluorophenyl)acetyl]piperazine-1’’’-carbonyl}-4’’-fluorobenzyl)-2H-phthalazin-1-one 
(220) (0.063 g, 46%) as white solid.  NMR spectra showed a 57:43 mixture of rotamers, of 
which only the signals for one rotamer is recorded. Mp 216–218 °C; ,max/cm
–1 (neat) 2899 
(CH), 2346, 1636 (CO), 1586 (C=C), 1508, 1431, 1219, 1157, 1011; *H (400 MHz, CDCl3) 
3.03–3.85 (10H, m, 4 + NCH2 and 2’’’’-H2), 4.28 (2H, br s, 1’-H2), 6.95–7.07 (3H, m, 3 + 
ArH), 7.13–7.24 (2H, m, 2 + ArH), 7.27–7.36 (2H, m, 2 + ArH), 7.66–7.79 (3H, m, 3 + 
ArH), 8.44–8.49 (1H, m, ArH), 11.01 (1H, s, NH); *C (101 MHz, CDCl3) 37.7 (CH2), 39.9 
(CH2), 42.0 (2 + CH2), 45.7 (CH2), 46.7 (CH2), 115.7 (2 + CH, d, JC-C-F 21.4 Hz), 116.2 
(CH, d, JC-C-F 22.0 Hz), 123.5 (C, d, JC-C-F 17.6 Hz), 125.0 (CH), 127.2 (CH), 128.3 (C), 
129.2 (CH, d, JC-C-C-F 2.3 Hz), 129.5 (C), 130.2 (C), 130.2 (2 + CH, d, JC-C-C-F 7.9 Hz), 
131.6 (CH), 131.8 (CH, d, JC-C-C-F 8.1 Hz), 133.7 (CH), 134.5 (C, d, JC-C-C-C-F 3.4 Hz), 
145.5 (C), 157.0 (C, d, JC-F 247.6 Hz), 160.8 (C), 161.9 (C, d, JC-F 247.6 Hz), 165.2 (C), 




































To a solution of 3-(4-fluorobenzoyl)propionic acid (0.053 g, 0.27 mmol) in 
dichloromethane (5 mL) was added ethyl 3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (0.052 g, 0.27 mmol) and the reaction mixture stirred at ambient 
temperature for 0.5 h.  4-(Dimethylamino)pyridine (0.017 g, 0.14 mmol) was then added 
and the mixture stirred for a further 0.5 h.  A solution of 4-[4’’-fluoro-3’’-(piperazine-1’’’-
carbonyl)benzyl]-2H-phthalazin-1-one (199) (0.100 g, 0.273 mmol) in dichloromethane (5 
mL) was then added dropwise and the resultant reaction mixture stirred vigorously under 
reflux for 24 h.  On cooling to ambient temperature, water (5 mL) was added and the 
organic layer washed with water (3 + 5 mL) and a saturated sodium bicarbonate solution (5 
mL), dried (MgSO4), filtered and concentrated in vacuo.  Purification using flash column 
chromatography (methanol/dichloromethane, 4:96) gave 4-(3’’-{4’’’-[(4’’’’’-
fluorophenyl)butane-1’’’’,4’’’’-dione]piperazine-1’’’-carbonyl}-4’’-fluorobenzyl)-2H-
phthalazin-1-one (221) (0.050 g, 34%) as a pale yellow solid.  NMR spectra showed a 
56:44 mixture of rotamers, of which only the signals for one rotamer is recorded. Mp 128–
130 °C; ,max/cm
–1 (neat) 3208 (NH), 2909 (CH), 1636 (CO), 1595 (C=C), 1433, 1356, 
1225, 1155, 1011; *H (400 MHz, CDCl3) 2.82 (2H, t, J 6.4 Hz, 2’’’’-H2), 3.24–3.46 (4H, 
m, NCH2 and 3’’’’-H2), 3.50–3.98 (6H, m, 3 + NCH2), 4.28 (2H, s, 1’-H2), 7.05 (1H, t, J 
8.8 Hz, ArH), 7.10–7.16 (2H, m, 2 + ArH), 7.30–7.39 (2H, m, 2 + ArH), 7.68–7.81 (3H, 
m, 3 + ArH), 8.00–8.06 (2H, m, 2 + ArH), 8.44–8.49 (1H, m, ArH), 10.33 (1H, s, NH); *C 
(101 MHz, CDCl3) 27.0 (CH2), 33.4 (CH2), 37.7 (CH2), 42.0 (CH2), 42.1 (CH2), 45.1 
(CH2), 46.8 (CH2), 115.7 (2 + CH, d, JC-C-F 21.8 Hz), 116.2 (CH, d, JC-C-F 21.9 Hz), 123.7 
(C, d, JC-C-F 17.6 Hz), 125.0 (CH), 127.2 (CH), 128.3 (C), 129.2 (CH, d, JC-C-C-F 3.0 Hz), 
129.6 (C), 130.8 (2 + CH, d, JC-C-C-F 9.4 Hz), 131.6 (CH), 131.7 (CH, d, JC-C-C-F 8.0 Hz), 
133.2 (C), 133.6 (CH), 134.5 (C, d, JC-C-C-C-F 3.3 Hz), 145.5 (C), 157.0 (C, d, JC-F 247.4 
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Hz), 160.7 (C), 165.3 (C), 165.8 (C, d, JC-F 254.8 Hz), 170.5 (C), 197.4 (C); m/z (ESI) 






























To a solution of 4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-1-one 
(199) (0.034 g, 0.093 mmol) in dichloromethane (3 mL) was added 4-methoxybenzyl 
chloride (13.3 µL, 0.0977 mmol) followed by N,N’-diisopropylethylamine (32.3 µL, 0.185 
mmol).  The resultant reaction mixture was stirred at ambient temperature for 24 h, and 
then diluted by the addition of water (5 mL).  The organic layer was separated, dried 
(MgSO4), filtered and concentrated in vacuo.  Purification using flash column 
chromatography (methanol/dichloromethane, 4:96) afforded 4-{4’’-fluoro-3’’-[4’’’-(4’’’’’-
methoxybenzyl)piperazine-1’’’-carbonyl]benzyl}-2H-phthalazin-1-one (222) (0.019 g, 
42%) as a white solid.  Mp 96–97 °C; ,max/cm
–1 (neat) 3171 (NH), 2913 (CH), 1636 (CO), 
1613 (C=C), 1512, 1246, 1229, 1026, 997; *H (400 MHz, CDCl3) 2.32 (2H, br s, NCH2), 
2.48 (2H, t, J 4.8 Hz, NCH2), 3.27 (2H, br s, NCH2), 3.46 (2H, s, 1’’’’-H2), 3.74–3.81 (5H, 
m, NCH2 and OCH3), 4.26 (2H, s, 1’-H2), 6.83–6.88 (2H, m, 2 + ArH), 7.01 (1H, t, J 9.2 
Hz, ArH), 7.19–7.25 (2H, m, 2 + ArH), 7.26–7.32 (2H, m, 2 + ArH), 7.68–7.78 (3H, m, 3 
+ ArH), 8.43–8.47 (1H, m, ArH), 9.85 (1H, s, NH); *C (101 MHz, CDCl3) 37.8 (CH2), 42.0 
(CH2), 47.1 (CH2), 52.5 (CH2), 53.0 (CH2), 55.3 (CH3), 62.2 (CH2), 113.7 (2 + CH), 116.1 
(CH, d, JC-C-F 22.0 Hz), 124.4 (C, d, JC-C-F 18.3 Hz), 125.1 (CH), 127.2 (CH), 128.4 (C), 
129.1 (CH, d, JC-C-C-F 3.8 Hz), 129.6 (2 + C), 130.3 (2 + CH), 131.2 (CH, d, JC-C-C-F 8.0 
Hz), 131.6 (CH), 133.6 (CH), 134.1 (C, d, JC-C-C-C-F 3.6 Hz), 145.6 (C), 157.1 (C, d, JC-F 
247.6 Hz), 158.9 (C), 160.3 (C), 164.8 (C); m/z (EI) 486.2057 (M+. C28H27FN4O3 requires 

































To a solution of 3-methoxybenzoic acid (0.032 g, 0.21 mmol) in N,N’-dimethylformamide 
(5 mL) was added N,N’-diisopropylethylamine (71.0 µL, 0.415 mmol) followed by O-
benzotriazole-N,N,N’,N’-tetramethyluroniumhexafluorophosphate (0.080 g, 0.21 mmol), 
and the reaction mixture stirred vigorously at ambient temperature for 1 h.  A solution of 
4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-1-one (199) (0.076 g, 
0.21 mmol) in N,N’-dimethylformamide (5 mL) was then added dropwise, and the 
resultant reaction mixture heated to 50 °C and stirred for a further 24 h.  On cooling to 
ambient temperature, dichloromethane (10 mL) was added and the organic layer washed 
with water (3 + 10 mL) and a saturated sodium bicarbonate solution (10 mL), dried 
(MgSO4), filtered and concentrated in vacuo.  Purification using flash column 
chromatography (methanol/dichloromethane, 4:96) afforded 4-{4’’-fluoro-3’’-[4’’’-(3’’’’-
methoxybenzoyl)piperazine-1’’’-carbonyl]benzyl}-2H-phthalazin-1-one (223) (0.041 g, 
40%) as a pale yellow solid. Mp 143–145 °C; ,max/cm
–1 (neat) 3202 (NH), 2900 (CH), 
1632 (CO), 1464, 1431, 1288, 1225, 1149, 1008; *H (400 MHz, CDCl3) 3.15–4.00 (11H, 
m, 4 + NCH2 and OCH3), 4.28 (2H, s, 1’-H2), 6.88–7.12 (4H, m, 4 + ArH), 7.27–7.38 (3H, 
m, 3 + ArH), 7.68–7.82 (3H, m, 3 + ArH), 8.42–8.50 (1H, m, ArH), 9.92 (1H, s, NH); *C 
(101 MHz, CDCl3) 37.7 (CH2), 42.2 (2 + br CH2), 47.0 (2 + br CH2), 55.4 (CH3), 112.6 
(CH), 115.9 (CH), 116.2 (CH, d, JC-C-F 22.3 Hz), 119.0 (CH), 123.7 (C, d, JC-C-F 17.9 Hz), 
125.0 (CH), 127.2 (CH), 128.4 (C), 129.3 (CH, d, JC-C-C-F 3.5 Hz), 129.6 (C), 129.8 (CH), 
131.6 (CH), 131.7 (CH, d, JC-C-C-F 8.1 Hz), 133.7 (CH), 134.5 (C, d, JC-C-C-C-F 3.4 Hz), 
136.4 (C), 145.5 (C), 157.0 (C, d, JC-F 247.3 Hz), 159.8 (C), 160.6 (C), 165.2 (C), 170.4 





































2H-phthalazin-1-one (224) was synthesised as described above for 4-{4’’-fluoro-3’’-[4’’’-
(3’’’’-methoxybenzoyl)piperazine-1’’’-carbonyl]benzyl}-2H-phthalazin-1-one (223) using 
3-methoxyphenylacetic acid (0.023 g, 0.14 mmol), N,N’-diisopropylethylamine (46.7 µL, 
0.273 mmol), O-benzotriazole-N,N,N’,N’-tetramethyluroniumhexafluorophosphate (0.052 
g, 0.14 mmol) and 4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-1-
one (199) (0.050 g, 0.14 mmol) in N,N’-dimethylformamide (5 mL).  Purification using 
flash column chromatography (methanol/dichloromethane, 4:96) gave 4-(4’’-fluoro-3’’-
{4’’’-[(3’’’’’-methoxyphenyl)acetyl]piperazine-1’’’-carbonyl}benzyl)-2H-phthalazin-1-
one (224) (0.045 g, 64%) as an off-white solid.  NMR spectra showed a 60:40 mixture of 
rotamers, of which only the signals for the major rotamer is recorded. Mp 108–110 °C; 
,max/cm
–1 (neat) 3192 (NH), 2915 (CH), 1638 (CO), 1491, 1431, 1258, 1150, 1013, 843; 
*H (400 MHz, CDCl3) 3.00–3.82 (13H, m, 4 + NCH2, 2’’’’-H2 and OCH3), 4.27 (2H, s, 1’-
H2), 6.75–6.85 (3H, m, 3 + ArH), 6.97–7.08 (1H, m, ArH), 7.19–7.25 (1H, m, ArH), 7.27–
7.35 (2H, m, 2 + ArH), 7.67–7.72 (1H, m, ArH), 7.74–7.79 (2H, m, 2 + ArH), 8.43–8.49 
(1H, m, ArH), 9.88 (1H, s, NH); *C (101 MHz, CDCl3) 37.7 (CH2), 41.2 (CH2), 42.0 (2 + 
CH2), 45.8 (CH2), 46.7 (CH2), 55.2 (CH3), 112.4 (CH), 114.3 (CH), 116.2 (CH, d, JC-C-F 
22.1 Hz), 120.8 (CH), 123.6 (C, d, JC-C-F 18.1 Hz), 125.0 (CH), 127.2 (CH), 128.3 (C), 
129.2 (CH, d, JC-C-C-F 2.6 Hz), 129.5 (C), 129.9 (CH), 131.6 (CH), 131.7 (CH, d, JC-C-C-F 
7.3 Hz), 133.7 (CH), 134.5 (C, d, JC-C-C-C-F 3.5 Hz), 136.1 (C), 145.5 (C), 157.0 (C, d, JC-F 
246.5 Hz), 160.0 (C), 160.8 (C), 165.2 (C), 169.7 (C); m/z (ESI) 537.1903 (MNa+. 












To a solution of 4-methoxyphenylacetic acid (226) (0.500 g, 3.01 mmol) in toluene (25 
mL) was added thionyl chloride (2.19 mL, 30.1 mmol), and the resultant solution stirred 
vigorously under reflux for 48 h.  On cooling to ambient temperature, the toluene was 
removed in vacuo and excess thionyl chloride removed by azeotroping with additional 
aliquots of toluene (3 + 25 mL).  The resultant reside was washed with hexane (3 + 25 mL) 
and the organic layer concentrated in vacuo to afford (4-methoxyphenyl)acetyl chloride 
(227) (0.502 g, 90%) as a yellow oil, which was used without further purification. ,max/cm
–
1 (neat) 2938 (CH), 1692 (CO), 1613, 1514, 1406, 1238, 1179, 1024, 816; *H (500 MHz, 
CDCl3) 3.81 (3H, s, OCH3), 4.08 (2H, s, CH2), 6.88–6.91 (2H, m, 2 + ArH), 7.17–7.21 
(2H, m, 2 + ArH); *C (126 MHz, CDCl3) 52.3 (CH2), 55.3 (CH3), 114.4 (2 + CH), 123.3 

































To a solution of 4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-1-one 
(199) (0.050 g, 0.14 mol) in dichloromethane (5 mL) was added (4-methoxyphenyl)acetyl 
chloride (227) (0.030 g, 0.16 mmol) followed by N,N’-diisopropylethylamine (47.5 µL, 
0.273 mmol) dropwise.  The resultant solution was stirred at ambient temperature for 24 h, 
and then diluted by the addition of water (5 mL).  The organic layer was then washed with 
water (2 + 5 mL), dried (MgSO4), filtered and concentrated in vacuo.  Purification using 
flash column chromatrography (methanol/dichloromethane, 1:99) afforded 4-(4’’-fluoro-
3’’-{4’’’-[(4’’’’’-methoxyphenyl)acetyl]piperazine-1’’’-carbonyl}benzyl)-2H-phthalazin-
! #+#!
1-one (225) (0.037 g, 53%) as a white solid.  NMR spectra showed a 53:47 mixture of 
rotamers, of which only the signals for one rotamer is recorded. Mp decomp >280 °C; 
,max/cm
–1 (neat) 3188 (NH), 2918 (CH), 1634 (CO), 1611 (C=C), 1512, 1429, 1244, 1175, 
1011; *H (400 MHz, CDCl3) 3.00–3.83 (13H, m, 4 + NCH2, 2’’’’-H2 and OCH3), 4.27 (2H, 
s, 1’-H2), 6.87 (2H, d, J 8.6 Hz, 2 + ArH), 6.97–7.08 (1H, m, ArH), 7.16 (2H, d, J 8.6 Hz, 
2 + ArH), 7.27–7.35 (2H, m, 2 + ArH), 7.67–7.79 (3H, m, 3 + ArH), 8.43–8.49 (1H, m, 
ArH), 10.33 (1H, s, NH); *C (101 MHz, CDCl3) 37.7 (CH2), 40.2 (CH2), 41.9 (CH2), 42.0 
(CH2), 45.7 (CH2), 46.7 (CH2), 55.3 (CH3), 114.4 (2 + CH), 116.2 (CH, d, JC-C-F 22.2 Hz), 
123.6 (C, d, JC-C-F 17.9 Hz), 125.0 (CH), 126.5 (C), 127.2 (CH), 128.3 (C), 129.2 (CH, d, 
JC-C-C-F 3.7 Hz), 129.6 (2 + CH and C), 131.6 (CH), 131.7 (CH, d, JC-C-C-F 7.9 Hz), 133.7 
(CH), 134.4 (C, d, JC-C-C-C-F 3.3 Hz), 145.5 (C), 157.0 (C, d, JC-F 248.0 Hz), 158.6 (C), 
160.7 (C), 165.2 (C), 170.1 (C); m/z (ESI) 537.1892 (MNa+. C29H27FN4NaO4 requires 
537.1909). 
 











To a solution of 3-fluoropropan-1-ol (229) (96.2 µL, 1.28 mmol) in dichloromethane (5 
mL) was added triethylamine (0.357 mL, 2.56 mmol) dropwise.  The solution was cooled 
to 0 °C and p-toluenesulfonyl chloride (0.269 g, 1.41 mmol) added in small portions.  The 
resultant mixture was allowed to warm to ambient temperature and stirred for 48 h.  Water 
(15 mL) was added to quench the reaction and the crude product extracted using 
dichloromethane (3 + 20 mL).  The organic layer was dried (MgSO4), filtered and 
concentrated in vacuo.  Purification using flash column chromatography (ethyl 
acetate/hexane, 15:85) gave 3-fluoropropyl-4’-methylbenzenesulfonate (230) (0.244 g, 
82%) as a colourless oil.  ,max/cm
–1 (neat) 3213, 2907 (CH), 1635 (C=C), 1496, 1429, 
1255, 1159 (SO2), 1004, 772; *H (400 MHz, CDCl3) 2.04 (2H, dquint, J 26.1, 5.6 Hz, 2-
H2), 2.46 (3H, s, CH3), 4.16 (2H, t, J 6.1 Hz, 1-H2), 4.48 (2H, dt, J 46.9, 5.6 Hz, 3-H2), 
7.33–7.38 (2H, m, 2 + ArH), 7.78–7.82 (2H, m, 2 + ArH); *C (101 MHz, CDCl3) 21.7 
(CH3), 30.0 (CH2, d, JC-C-F 20.1 Hz), 66.1 (CH2, d, JC-C-C-F 4.8 Hz), 79.5 (CH2, JC-F 166.0 
Hz), 127.9 (2 + CH), 129.9 (2 + CH), 132.8 (C), 145.0 (C); m/z (EI) 232.0565 (M+. 
C10H13FO3S requires 232.0569), 173 (39%), 155 (100), 84 (68), 65 (21).     
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To a solution of 3,4-dimethoxybenzaldehyde (249) (1.00 g, 6.02 mmol) in toluene (30 mL) 
was added nitromethane (1.63 mL, 30.1 mmol) and ammonium acetate (0.464 g, 6.02 
mmol).  The resultant solution was stirred under reflux for 18 h.  After cooling to ambient 
temperature, the reaction mixture was washed with water (2 + 30 mL) followed by brine (2 
+ 30 mL).  The organic layer was dried (MgSO4), filtered and concentrated in vacuo to 
give (1’E)-1,2-dimethoxy-4-(2’-nitrovinyl)benzene (248) (1.25 g, 100%) as a yellow solid, 
which was used without further purification. Mp 140–141 °C (lit.,224 Mp 140–141 °C); 
,max/cm
–1 (neat) 3127, 2999 (CH), 1627 (C=C), 1598 (NO), 1488, 1336 (NO), 1260, 1140, 
1033; *H (400 MHz, CDCl3) 3.93 (3H, s, OCH3), 3.95 (3H, s, OCH3), 6.92 (1H, d, J 8.4 
Hz, ArH), 7.01 (1H, d, J 2.0 Hz, ArH), 7.18 (1H, dd, J 8.4, 2.0 Hz, ArH), 7.53 (1H, d, J 
13.6 Hz, 2’-H), 7.97 (1H, d, J 13.6 Hz, 1’-H); *C (101 MHz, CDCl3) 56.0 (CH3), 56.1 
(CH3), 110.3 (CH), 111.4 (CH), 122.8 (C), 124.6 (CH), 135.2 (CH), 139.3 (CH), 149.6 (C), 
152.8 (C); m/z (CI) 210.0763 (MH+. C10H12NO4 requires 210.0766), 180 (15%), 167 (21), 
151 (7). 
 









To a suspension of (1E)-1,2-dimethoxy-4-(2’-nitrovinyl)benzene (248) (4.54 g, 21.7 
mmol) in methanol (100 mL) was added a commercially prepared solution of 25% sodium 
methoxide in methanol (10 mL) dropwise.  The resultant reaction mixture was stirred at 
ambient temperature for 3.5 h, after which acetic acid (5 mL) was added dropwise.  The 
mixture was stirred for a further 1.5 h and then concentrated in vacuo.  The residue was 
reconstituted in toluene (100 mL) and washed with water (3 + 100 mL), and the organic 
layer dried (MgSO4), filtered and concentrated in vacuo.  Purification using flash column 
! #+%!
chromatography (ethyl acetate/petroleum ether, 1:1) afforded 
(±)-1,2-dimethoxy-4-(1’-methoxy-2’-nitroethyl)benzene (247) (2.62 g, 50%) as a yellow 
solid. Mp 97–98 °C (lit.,224 Mp 104–106 °C); ,max/cm
–1 (neat) 2999 (CH), 1683, 1597 
(C=C), 1587 (NO), 1571, 1424, 1260, 1137, 1017; *H (400 MHz, CDCl3) 3.26 (3H, s, 
OCH3), 3.89 (3H, s, OCH3), 3.90 (3H, s, OCH3), 4.38 (1H, dd, J 12.4, 3.2 Hz, 2’-HH), 4.61 
(1H, dd, J 12.4, 10.0 Hz, 2’-HH), 4.89 (1H, dd, J 10.0, 3.2 Hz, 1’-H), 6.85–6.93 (3H, m, 3 
+ ArH); *C (101 MHz, CDCl3) 56.0 (CH3), 56.0 (CH3), 57.0 (CH3), 79.9 (CH), 80.6 (CH2), 
109.1 (CH), 111.3 (CH), 119.6 (CH), 128.3 (C), 149.6 (2 + C); m/z (CI) 242.1029 (MH+. 
C11H16NO5 requires 242.1028), 228 (67%), 210 (100), 181 (51), 167 (24), 128 (6).  
 










To a stirred 2 M sodium hydroxide solution (15.0 mL, 30.0 mmol) was added 
"-aminobutyric acid (251) (3.00 g, 29.1 mmol). To this was added a further aliquot of 2 M 
sodium hydroxide solution (15.0 mL, 30.0 mmol) and benzyl chloroformate (4.40 mL, 
30.8 mmol) simultaneously.  The reaction mixture was vigorously stirred at 0–5 °C for 1 h, 
and then at ambient temperature for a further 1 h. The reaction mixture was extracted into 
diethyl ether (3 + 50 mL), and the aqueous layer acidified by the addition of concentrated 
hydrochloric acid solution (pH 3). After cooling in an ice bath, the resultant crystals were 
removed by filtration and air dried to yield the desired product (250) (4.82 g, 70%) as a 
white solid, which was used without further purification. Spectroscopic data in accordance 
with the literature.229 Mp 61–62 °C (lit.,229 mp 64–65 °C); *H (500 MHz, CDCl3) 1.84 (2H, 
quint, J 7.0 Hz, 3-H2), 2.40 (2H, t, J 7.0 Hz, 2-H2), 3.26 (2H, q, J 7.0 Hz, 4-H2), 4.92 (1H, 
br s, NH), 5.09 (2H, s, CH2Ph), 5.80 (1H, br s, OH), 7.30–7.36 (5H, m, 5 + ArH); *C (125 
MHz, CDCl3) 25.0 (CH2), 31.1 (CH2), 40.2 (CH2), 66.8 (CH2), 128.1 (CH), 128.2 (2 + 
CH), 128.6 (2 + CH), 136.4 (C), 156.6 (C), 178.2 (C); m/z (EI) 237.0997 (M+. C12H15NO4 





























To a solution of (±)-1,2-dimethoxy-4-(1’-methoxy-2’-nitroethyl)benzene (247) (0.295 g, 
1.22 mmol) in diethyl ether (10 mL) was added dropwise, a lithium aluminium hydride 
suspension (1.0 M in diethyl ether) (3.69 mL, 3.67 mmol).  The resultant solution was 
stirred vigorously under reflux for 2 h, and then cooled to ambient temperature.  Excess 
lithium aluminium hydride was carefully quenched by the dropwise addition of water (2.5 
mL).  The organic layer was separated and concentrated in vacuo to afford the (±)-
2-(3’,4’-dimethoxyphenyl)-2-methoxyethanamine (246) (0.078 g, 30%) as a light green oil, 
which was used immediately in the next step without further purification.  A solution of 
(±)-2-(3’,4’-dimethoxyphenyl)-2-methoxyethanamine (246) (0.078 g, 0.37 mmol) in 
dichloromethane (10 mL) was cooled to 0 °C, and to this was added 
4-(benzyloxycarbonylamino)butanoic acid (250) (0.092 g, 0.39 mmol), 
4-(dimethylamino)pyridine (0.005 g, 0.041 mmol) and ethyl 
3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.071 g, 0.37 mmol).  The 
resultant reaction mixture was stirred at 0 °C for 2 h, and then allowed to gradually warm 
to ambient temperature and stirred for 15 h.  After concentration in vacuo, the crude 
reaction mixture was reconstituted in ethyl acetate (20 mL) and washed with water (3 + 20 
mL).  The organic layer was dried (MgSO4), filtered and concentrated in vacuo.  
Purification using flash column chromatography (methanol/dichloromethane, 1:9) afforded 
(±)- N-[2-(3’,4’-dimethoxyphenyl)-2-methoxyethyl]-4’’-(benzyloxycarbonylamino) 
butanamide (245) (0.127 g, 79%) as a colourless oil. ,max/cm
–1 (neat) 3325 (NH), 2940 
(CH), 1705 (CO), 1512, 1451, 1250, 1134, 1026, 741; *H (400 MHz, CDCl3) 1.83 (2H, 
quint, J 6.8 Hz, 3’’-H2), 2.23 (2H, t, J 6.8 Hz, 2’’-H2), 3.15–3.28 (6H, m, OCH3, 4’’-H2 
and 1-HH), 3.60–3.70 (1H, m, 1-HH), 3.86 (6H, s, 2 + OCH3), 4.19 (1H, dd, J 8.8, 4.0 Hz, 
2-H), 5.09 (2H, s, OCH2Ph), 5.14 (1H, br s, NH), 6.21 (1H, br s, NH), 6.80–6.85 (3H, m, 3 
+ ArH), 7.28–7.37 (5H, m, 5 + ArH); *C (101 MHz, CDCl3) 26.0 (CH2), 33.7 (CH2), 40.4 
(CH2), 45.7 (CH2), 55.9 (2 + CH3), 56.7 (CH3), 66.7 (CH2), 82.1 (CH), 109.3 (CH), 111.0 
(CH), 119.3 (CH), 128.1 (2 + CH), 128.5 (3 + CH), 131.5 (C), 136.6 (C), 148.9 (C), 149.2 
! #+'!
(C), 156.8 (C), 172.6 (C); m/z (FAB) 431.2171 (MH+. C23H31N2O6 requires 431.2182), 270 











To a solution of 3,4-dimethoxybenzaldehyde (249) (1.50 g, 9.03 mmol) in dimethyl 
sulfoxide (10 mL) was added nitromethane (4.89 mL, 90.3 mmol) and 4Å molecular 
sieves.  The reaction mixture was stirred at ambient temperature for 48 h then diluted by 
the addition of water (50 mL) and extracted with ethyl acetate (200 mL).  The organic 
layer was stringently washed with water (5 + 100 mL), dried (MgSO4), filtered and 
concentrated in vacuo.  Purification using flash column chromatography (ethyl 
acetate/hexane, 1:4) afforded (±)-1-(3’,4’-dimethoxyphenyl)-2-nitroethanol (256) (1.74 g, 
85%) as a yellow solid.  Spectroscopic data in accordance with the literature.236 Mp 89–91 
°C (lit.,236 mp 91–92 °C); ,max/cm
–1 (neat) 3497 (OH), 2840 (CH), 1680, 1541, 1512, 1423, 
1374, 1256, 1232; *H (500 MHz, CDCl3) 2.76 (1H, d, J 3.2 Hz, OH), 3.88 (3H, s, OCH3), 
3.90 (3H, s, OCH3), 4.49 (1H, dd, J 13.5, 3.2 Hz, 2-HH), 4.61 (1H, dd, J 13.5, 10.0 Hz, 2-
HH), 5.42 (1H, dt, J 10.0, 3.2 Hz, 1-H), 6.86–6.89 (1H, m, ArH), 6.91–6.94 (2H, m, 2 + 
ArH); *C (126 MHz, CDCl3) 56.0 (CH3), 56.0 (CH3), 70.9 (CH), 81.3 (CH2), 108.9 (CH), 
111.4 (CH), 118.4 (CH), 130.7 (2 + C), 149.5 (C); m/z (CI) 228.0875 (MH+. C10H14NO5 











A solution of (±)-1-(3’,4’-dimethoxyphenyl)-2-nitroethanol (256) (1.22 g, 5.37 mmol) in 
methanol (10 mL) was added dropwise to a suspension of 10% palladium on activated 
carbon (0.25 g) in methanol (10 mL) with constant stirring.  The resultant reaction mixture 
was stirred under an atmosphere of H2 at ambient temperature for 24 h.  After filtering 
through a pad of Celite( and washing with methanol (150 mL), the solution was 
! #+(!
concentrated in vacuo to afford (±)-1-(3’,4’-dimethoxyphenyl)-2-aminoethanol (255) (1.06 
g, 100%) as a pale yellow oil which was used without further purification. ,max/cm
–1 (neat) 
3356 (NH/OH), 2940 (CH), 2839, 1589 (C=C), 1512, 1458, 1258, 1234, 1134; *H (400 
MHz, CDCl3) 2.79 (1H, dd, J 12.4, 7.6 Hz, 2-HH), 2.95 (1H, dd, J 12.4, 3.2 Hz, 2-HH), 
3.45 (1H, br s, OH), 3.86 (3H, s, OCH3), 3.87 (3H, s, OCH3), 4.56–4.60 (1H, m, 1-H), 
6.80–6.87 (2H, m, 2 + ArH), 6.90 (1H, br s, ArH); *C (101 MHz, CDCl3) 49.3 (CH2), 55.9 
(2 + CH3), 74.2 (CH), 109.0 (CH), 111.0 (CH), 118.1 (CH), 135.2 (C), 148.4 (C), 149.0 
























A solution of 4-(benzyloxycarbonylamino)butanoic acid (250) (0.518 g, 2.18 mmol) and 
ethyl 3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.399 g, 2.08 mmol) in 
dichloromethane (10 mL) was stirred at 0 °C for 0.2 h.  4-(Dimethylamino)pyridine (0.025 
g, 0.20 mmol) was added and the solution stirred for a further 0.2 h.  A solution of (±)-
1-(3’,4’-dimethoxyphenyl)-2-aminoethanol (255) (0.410 g, 2.08 mmol) in dichloromethane 
(10 mL) was then added dropwise to the reaction mixture and stirred for 2 h at 0 °C.  The 
reaction mixture was then allowed to gradually warm to ambient temperature and stirred 
for a further 16 h.  The mixture was diluted with dichloromethane (50 mL) and washed 
with water (3 + 50 mL).  The organic layer was dried (MgSO4), filtered and concentrated 
in vacuo.  Purification using flash column chromatography (methanol/dichloromethane, 
1:99) afforded (±)-N-[2-(3’,4’-dimethoxyphenyl)-2-hydroxyethyl]-4’’-
(benzyloxycarbonylamino) butanamide (257) (0.680 g, 79%) as a brown oil. ,max/cm
–1 
(neat) 3308 (OH/NH), 2938 (CH), 1699 (CO), 1645 (C=C), 1514, 1256, 1234, 1138, 1024; 
*H (400 MHz, CDCl3) 1.70–1.86 (2H, m, 3’’-H2), 2.18 (2H, t, J 6.8 Hz, 2’’-H2), 3.10–3.29 
(3H, m, 4’’-H2 and 1-HH), 3.56–3.65 (1H, m, 1-HH), 3.82 (3H, s, OCH3), 3.83 (3H, s, 
OCH3), 4.74 (1H, dd, J 8.4, 2.8 Hz, 2-H), 5.04 (2H, s, OCH2Ph), 5.31 (1H, t, J 6.0 Hz, 
NH), 6.60 (1H, t, J 5.6 Hz, NH), 6.77–6.92 (3H, m, 3 + ArH), 7.27–7.32 (5H, m, 5 + ArH); 
*C (101 MHz, CDCl3) 26.2 (CH2), 33.3 (CH2), 40.1 (CH2), 47.7 (CH2), 55.9 (CH3), 55.9 
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(CH3), 66.8 (CH2), 73.0 (CH), 109.1 (CH), 111.1 (CH), 118.1 (CH), 128.1 (2 + CH), 128.5 
(3 + CH), 134.6 (C), 136.4 (C), 148.5 (C), 149.0 (C), 157.1 (C), 173.8 (C); m/z (FAB) 
417.2023 (MH+. C22H29N2O6 requires 417.2026), 389 (20%), 249 (20), 179 (33), 150 (12), 
91 (100), 84 (75), 57 (28).   
 










A neat mixture of "-aminobutyric acid (251) (1.00 g, 9.70 mmol) and phthalic anhydride 
(258) (1.44 g, 9.70 mmol) were stirred at 170 °C for 5 h.  After cooling to ambient 
temperature, the resulting solid was dissolved in dichloromethane (50 mL) and washed 
with 0.1 M hydrochloric acid (3 + 20 mL).  The organic layer was dried (MgSO4), filtered 
and concentrated under reduced pressure to yield 4-(1’,3’-dioxo-1’,3’-dihydro-2’H-
isoindolin-2’-yl)butanoic acid (259) (2.11 g, 93%) as a white solid.  Spectroscopic data in 
accordance with the literature.237 Mp 111–113 °C (lit.,237 mp 117 °C); ,max/cm
–1 (neat) 
2940 (OH), 1766 (CO), 1696 (CO), 1469, 1436, 1312, 1284, 1120, 893; *H (400 MHz, 
CDCl3) 2.03 (2H, quint, J 7.0 Hz, 3-H2), 2.43 (2H, t, J 7.0 Hz, 2-H2), 3.77 (2H, t, J 7.0 Hz, 
4-H2), 7.70–7.75 (2H, m, 2 + ArH), 7.83–7.88 (2H, m, 2 + ArH); *C (101 MHz, CDCl3) 
23.7 (CH2), 31.0 (CH2), 37.1 (CH2), 123.3 (2 + CH), 132.0 (2 + C), 134.0 (2 + CH), 168.4 
(2 + C), 177.0 (C); m/z (EI) 233.0691 (M+. C12H11NO4 requires 233.0688), 215 (40%), 187 






















A solution of 4-(1’,3’-dioxo-1’,3’-dihydro-2’H-isoindolin-2’-yl)butanoic acid (259) (0.406 
g, 1.74 mmol) and ethyl 3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.318 g, 
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1.66 mmol) in dichloromethane (10 mL) was stirred at 0 °C for 0.25 h.  
4-(Dimethylamino)pyridine (0.020 g, 0.16 mmol) was added and the solution stirred for a 
further 0.25 h.  A solution of (±)-1-(3’,4’-dimethoxyphenyl)-2-aminoethanol (255) (0.327 
g, 1.66 mmol) in dichloromethane (10 mL) was then added dropwise to the reaction 
mixture and stirred for 2 h at 0 °C.  After gradually warming to ambient temperature, the 
mixture was stirred for a further 16 h before being diluted with dichloromethane (100 mL) 
and washed with water (3 + 100 mL).  The organic layer was dried (MgSO4), filtered and 
concentrated in vacuo. Purification using flash column chromatography 
(methanol/dichloromethane, 1:99) followed by trituration with diethyl ether afforded (±)-
N-[2-(3’,4’-dimethoxyphenyl)-2-hydroxyethyl]-4’’-(1’’’,3’’’-dioxo-1’’’,3’’’-dihydro-
2’’’H-isoindolin-2’’’-yl)butanamide (260) (0.512 g, 75%) as an off-white solid. Mp 120–
123 °C; ,max/cm
–1 (neat) 3366 (NH/OH), 2938 (CH), 1769 (CO), 1703 (CO), 1515, 1396, 
1259, 1232, 1023; *H (400 MHz, CDCl3) 2.01–2.10 (2H, m, 3’-H2), 2.16–2.33 (2H, m, 2’-
H2), 3.31 (1H, ddd, J 13.6, 8.4, 5.2 Hz, 1-HH), 3.54 (1H, br s, OH), 3.66–3.74 (3H, m, 4’-
H2 and 1-HH), 3.87 (3H, s, OCH3), 3.89 (3H, s, OCH3), 4.85 (1H, dd, J 8.4, 2.4 Hz, 2-H), 
6.34 (1H, t, J 5.2 Hz, NH), 6.84–6.86 (1H, m, ArH), 6.89–6.96 (2H, m, 2 + ArH), 7.71–
7.76 (2H, m, 2 + ArH), 7.83–7.87 (2H, m, 2 + ArH); *C (101 MHz, CDCl3) 24.9 (CH2), 
33.5 (CH2), 37.1 (CH2), 47.8 (CH2), 55.9 (CH3), 56.0 (CH3), 73.3 (CH), 109.0 (CH), 111.1 
(CH), 118.0 (CH), 123.4 (2 + CH), 132.0 (2 + C), 134.2 (2 + CH), 134.4 (C), 148.6 (C), 
149.1 (C), 168.8 (2 + C), 173.1 (C); m/z (FAB) 413.1711 (MH+. C22H25N2O6 requires 















A solution of N-[2-(3’,4’-dimethoxyphenyl)-2-hydroxyethyl]-4’’-(1’’’,3’’’-dioxo-1’’’,3’’’-
dihydro-2’’’H-isoindolin-2’’’-yl)butanamide (260) (2.05 g, 4.97 mmol) in toluene (15 mL) 
was stirred vigorously under reflux, and to this was added freshly distilled phosphorus 
oxychloride (1.16 mL, 12.4 mmol) dropwise.  The reaction mixture was stirred for 18 h 
and then cooled to ambient temperature.  After concentration in vacuo, the crude reaction 
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mixture was purified using flash column chromatography (methanol/dichloromethane, 
1:99) to afford 1-[3’-(1’’,3’’-dioxo-1’’,3’’-dihydro-2’’H-isoindolin-2’’-yl)propyl]-6,7-
dimethoxyisoquinoline (261) (1.23 g, 66%) as a light brown solid. Mp 125–127 °C; 
,max/cm
–1 (neat) 3308, 2969 (CH), 2629, 1688 (CO), 1508, 1400, 1273, 1166, 1122; *H 
(500 MHz, CD3OD) 2.38 (2H, quint, J 7.0 Hz, 2’-H2), 3.52–3.57 (2H, m, 1’-H2), 3.90 (2H, 
t, J 7.0 Hz, 3’-H2), 4.05 (3H, s, OCH3), 4.08 (3H, s, OCH3), 7.47 (1H, s, ArH), 7.62 (1H, s, 
ArH), 7.77–7.79 (4H, m, 4 + ArH), 7.96 (1H, d, J 6.5 Hz, ArH), 8.17 (1H, d, J 6.5 Hz, 
ArH); *C (126 MHz, CD3OD) 28.8 (CH2), 29.9 (CH2), 38.3 (CH2), 57.1 (CH3), 57.4 (CH3), 
105.6 (CH), 107.5 (CH), 123.1 (CH), 123.6 (C), 124.1 (2 + CH), 130.4 (CH), 133.1 (2 + 
C), 135.5 (2 + CH), 138.5 (C), 154.5 (C), 156.5 (C), 159.2 (C), 169.7 (2 + C); m/z (CI) 


















To a solution of 1-[3’-(1’’,3’’-dioxo-1’’,3’’-dihydro-2’’H-isoindolin-2’’-yl)propyl]-6,7-
dimethoxyisoquinoline (261) (0.044 g, 0.12 mmol) in ethanol (10 mL) was added 
hydrazine monohydrate (12.9 µL, 0.266 mmol) and the resultant solution stirred under 
reflux for 20 h.  After cooling to ambient temperature, the mixture was concentrated in 
vacuo and the crude residue reconstituted in methanol (10 mL).  To this was added 
N,N’-bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine (0.25 g, 0.80 mmol) followed 
by 4-dimethylaminopyridine (0.001 g, 0.008 mmol) and the reaction mixture stirred at 
ambient temperature for further 24 h.  Concentration in vacuo, followed by purification 
using flash column chromatography (methanol/chloroform, 1:99) afforded 1-[3’-{N,N’-
bis(tert-butoxycarbonyl)guanidino}propyl]-6,7-dimethoxyisoquinoline (262) (0.05 g, 82%) 
as a pale yellow oil. ,max/cm
–1 (neat) 3361 (NH), 2479, 2247, 2216, 2070, 1122, 1092, 973; 
*H (400 MHz, CD3OD) 1.45 (9H, s, O
tBu), 1.52 (9H, s, OtBu), 2.11 (2H, quint, J 6.8 Hz, 
2’-H2), 3.27–3.29 (2H, m, 1’-H2), 3.51 (2H, q, J 6.8 Hz, 3’-H2), 4.00 (3H, s, OCH3), 4.01 
(3H, s, OCH3), 7.29 (1H, s, ArH), 7.47 (1H, s, ArH), 7.56 (1H, d, J 6.0 Hz, ArH), 8.15 
(1H, d, J 6.0 Hz, ArH); *C (126 MHz, CD3OD) 28.3 (3 + CH3), 28.6 (3 + CH3), 30.0 (CH2), 
! #""!
33.1 (CH2), 41.6 (CH2), 56.5 (CH3), 56.6 (CH3), 80.3 (C), 84.4 (C), 104.7 (CH), 106.7 
(CH), 120.2 (CH), 124.1 (C), 135.2 (C), 140.5 (CH), 152.0 (C), 154.8 (C), 157.6 (C), 159.8 
(C), 164.5 (C); m/z (FAB) 489.2715 (MH+. C25H37N4O6 requires 489.2713), 389 (4%), 289 
(27), 230 (12), 205 (8), 149 (3), 58 (10). 
 














To a stirred solution of 1-[3’-{N,N’-bis(tert-butoxycarbonyl)guanidino}propyl]-6,7-
dimethoxyisoquinoline (262) (0.050 g, 0.10 mmol) in dichloromethane (5 mL) was added 
trifluoroacetic acid (0.25 mL).  The reaction mixture was stirred at ambient temperature for 
2 h and then concentrated in vacuo.  The crude residue was reconstituted in methanol (3 
mL) and to this was added a few drops of concentrated hydrochloric acid.  After stirring at 
ambient temperature for 0.5 h, the mixture was concentrated in vacuo to yield a crude 
residue, which upon trituration with dichloromethane afforded 1-(3’-guanidinopropyl)-
6,7-dimethoxyisoquinoline (Crispine C) (243) (0.025 g, 73%) as a pale yellow solid. Mp 
203–204 °C (lit.,214 mp 208–210 °C); ,max/cm
–1 (neat) 3317 (NH), 3131, 1652, 1634, 1508, 
1409, 1280, 1232, 1167; *H (500 MHz, CD3OD) 2.18 (2H, quint, J 7.1 Hz, 2’-H2), 3.43 
(2H, t, J 7.1 Hz, 1’-H2), 3.59–3.62 (2H, m, 3’-H2), 4.12 (3H, s, OCH3), 4.12 (3H, s, OCH3), 
7.66 (1H, s, ArH), 7.70 (1H, s, ArH), 8.12 (1H, d, J 6.6 Hz, ArH), 8.24 (1H, d, J 6.6 Hz, 
ArH); *C (126 MHz, CD3OD) 29.5 (CH2), 29.7 (CH2), 41.8 (CH2), 57.4 (CH3), 57.5 (CH3), 
105.6 (CH), 107.6 (CH), 123.3 (CH), 123.8 (C), 130.4 (CH), 138.9 (C), 154.9 (C), 156.3 
(C), 158.8 (C), 159.6 (C); m/z (FAB) 289.1662 (MH+. C15H21N4O2 requires 289.1665), 242 
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